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Comparative genome analysis implied that a progressively more elaborate 
regulation of gene expression rather than invention of new genes is responsible for the 
organismal complexity, and that a constrained organization of metazoan enhancers is 
essential for the precise patterns of gene expression during development. This project was 
focused on studying of the transcriptional regulatory complex that directs tissue-specific 
gene expression and organ development in the prostate. 
Genetic manipulation of the rat probasin (Pbsn) gene promoter in transgenic mice 
uncovered a ~150 base pair core DNA fragment, which confers prostate-selectivity to the 
expression of this gene. Among a cluster of DNA sequence-specific transcription factors 
directly binding to this region, there are two cell-type limited proteins: the androgen 
receptor, a nuclear receptor, and Foxa1, a forkhead protein. Reporter assays indicated the 
forkhead response elements are crucial for AR-mediated transcriptional regulation. In 
vitro and in vivo binding assays established that the two proteins can bind adjacent DNA 
sequence concomitantly while the binding is not interdependent. A physical interaction 
occurs between Foxa1 and AR when the ligand for AR is present. This interaction is 
mediated through the forkhead domain and the AR DNA binding domain. Alignment of 
the forkhead and the androgen response elements resulted in the identification of a shared 
cis-regulatory code that is present in a variety of prostate-specific enhancers across 
species.  
The impact of Foxa1 loss-of-function and haploinsufficiency on mouse prostatic 
organogenesis was analyzed. Foxa1-/- prostates showed drastic morphologic alteration 
including a disorganized epithelial pattern resembling primitive epithelial cords, and an 
expansion in the mesenchymal smooth muscle layer. Cell type and ultrastructural studies 
demonstrated that Foxa1-/- epithelium is predominantly arrested as immature basal cells, 
consistent with a failure of luminal determination. Foxa1-/- basal cells actively express 
Sonic hedgehog (Shh), Ptc1 and Foxa2, proteins that are normally elevated during 
embryonic ductal budding in the UGS. Alteration of these signals correlates with the 
expansion of precursor cells and the modified epithelial-stromal pattern in Foxa1-/- 
prostates. In contrast, expression of the Nkx3.1 homeobox protein is absent in these 
Foxa1-/- cells. In addition a haploinsufficient phenotype was observed in heterozygous 
dorsal prostates showing a similar ductal morphologic defect. A novel Foxa1 target gene 
was identified. Upon examination of its promoter, critical forkhead response elements 
were identified to be immediately flanked by androgen response elements. We propose 
that Foxa1 regulates genes involved in prostatic ductal morphogenesis, and promotes 
epithelial cell maturation through balancing the effects of Shh, Foxa2, and Nkx3.1. 
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CHAPTER І 
 
GENERAL INTRODUCTION 
 
The prostate is a male accessory sex gland that is important for normal 
reproduction of the species. Diseases occurring in this gland remain a major health 
problem in the expanding population of elder men in the world. The lack of an effective 
way to prevent or treat prostatic disease is largely due to an incomplete understanding of 
the molecular events that underlie normal prostate cell growth and gene regulation.  It is 
now largely believed that normal organ development is dependent on a concerted 
organization and communication of various cell types, while the individual cell type is 
specified through a regulated interaction of diverse signaling pathways that activate 
unique subsets of genes, and make the cells become functionally specialized. Disruption 
of precisely controlled cellular processes or genetic pathways could affect organ 
development or function, leading to phenotypically abnormal organs having wrong 
identity, leading to disease, or loss of function. Like many insights that are being made in 
other organs, major progress in the prostate research field is greatly attributed to the 
studies involving in vitro tissue culture or transgenic animal models. Here, I will 
summarize some critical findings in this area and introduce some current knowledge 
about the prostate in terms of developmental biology, endocrinology, cell and molecular 
biology. 
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Prostatic Development and Hormone Regulation 
Male accessory sex organs include the prostate, bulbourethral gland, seminal 
vesicle, ductus deferens and the epididymis, all of which have served as ideal models for 
studying androgen-regulated cell growth and gene function (Cunha et al., 1987). 
However the prostate has been studied extensively since it is one of the most frequently 
disease-affected organs. Prostate cancer and benign prostatic hyperplasia are two major 
diseases in the prostate. Both diseases feature an abnormally high rate of cell proliferation, 
which results in an enlargement of the gland and/or disruption of the ductal-acinar 
structure. Until now, it is not clear why bulbourethral gland, seminal vesicle and 
epididymis have a substantially low incidence of disease compared to the prostate (Cunha 
et al., 1987). 
The prostate gland is an exocrine gland that can only be found in mammals. It is 
composed of highly branched ductal networks that produce major components of the 
seminal fluids. The prostate is located immediately below the bladder and closely 
associated with the urethra, therefore the prostatic secretions can be discharged from the 
prostatic ducts into the urethra by muscular contractions (Fig. 1-1). Many proteins 
produced by the prostate may be fundamentally important for sperm movement and 
liquification, which may assist in normal reproductive activity in male adult animals 
(Cunha et al., 1987).  
A. Prostatic Induction and Morphogenesis 
The prostate is derived from the embryonic urogenital sinus (UGS), a subdivision 
of the cloaca, which belongs to the endodermal hindgut. The UGS is a midline structure 
which is composed of an endodermally derived epithelial layer and a surrounding 
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mesodermally derived mesenchymal layer (Marker et al., 2003). In both male and female 
mice, the UGS, located just caudal to the neck of the developing bladder, can be first 
observed at embryonic day 13 (E13) (Staack et al., 2003). There is no morphologic 
difference between male and female UGS until E17.5, during which the prostatic 
induction occurs due to an increased level of serum androgens produced by the fetal 
testes. At E17.5 in the mouse (E18-E19 in the rat), the first sign of prostatic 
morphogenesis is observed as the urogenital sinus epithelium (UGE) invades into the 
surrounding urogenital sinus mesenchyme (UGM), forming the earliest prostatic buds 
(Marker et al., 2003). In the following a few days [E17.5-postnatal day 7 (P7)], the 
outgrowth of these prostatic buds gives rise to a number of solid epithelial cords in a 
precise spatial pattern which eventually establishes different lobe subdivisions of the 
prostate (Sugimura et al., 1986a). In the mouse, the ventral prostate (VP) lobes are 
derived from up to 3 main ducts that are emerged from each ventral side of the UGS; the 
dorsolateral prostate (DLP) lobes are derived from around 25 main ducts from each 
dorsolateral side of the UGS; and the anterior prostate (AP) lobes are derived from 2 
large buds, from each side of the UGS, which eventually grow into the mesenchyme of 
the seminal vesicles. Most of these main ducts are not branched at birth (Sugimura et al., 
1986a). 
Neonatally, as these main ducts continue to elongate into the surrounding 
mesenchyme as a result of intense proliferative activity at their tip, they start to send out 
side-branches. This process is called ductal branching morphogenesis, which takes place 
in the first 1-2 weeks after birth (Fig. 1-2). The patterns of branching morphogenesis are 
distinctive for each prostate lobe, and the results of branching morphogenesis are the 
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generation of three distinct bilaterally symmetrical prostatic lobes: AP, DLP and VP 
(Sugimura et al., 1986a). During branching morphogenesis, ductal canalization is 
initiated in the solid epithelial cords from the urethral terminus toward the distal ductal 
tips. Concomitantly with all these changes in ductal morphology, prostate epithelial and 
stromal cell differentiation occurs (Marker et al., 2003) (Fig. 1-2).  
The prostate branching morphogenesis is almost completely finished around P14 
in the mouse. At puberty (around P20), the prostate wet weight increases significantly 
due to an increased protein and DNA synthesis that are stimulated by the surging serum 
androgen levels. Due to lobe-specific differences in the patterns of branching 
morphogenesis, the final shape of each lobe is distinct. Furthermore, the different lobes 
have distinct histologic features. AP shows extensive epithelial cell infolding. DLP shows 
less extensive epithelial cell infolding and VP shows minimal epithelial cell infolding 
(Marker et al., 2003). 
B. Prostate Epithelial and Mesenchymal Cell Differentiation 
As prostate branching morphogenesis proceeds, prostatic cells differentiate 
simultaneously in the first 1-3 weeks after birth. The epithelial cells within the embryonic 
UGE or the early developing epithelial cords are immature epithelial cells, which are 
characterized by coexpression of a number of basal cytokeratins (Ck) such as Ck5, Ck14, 
and luminal Ck8, Ck18, and other markers such as basal nuclear protein p63 (Wang et al., 
2001). As the solid epithelial cords branch and canalize, these epithelial cells differentiate 
and reorganize into two distinct cell populations: the basal epithelial cells and the luminal 
epithelial cells. Each of these two cell populations can be identified according to their 
distinct cell distribution, morphology, and specific markers. Basal epithelial cells are 
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localized along the basement membrane, forming a discontinuous layer and expressing 
Ck5, Ck14 and p63. Luminal cells are tall columnar cells, lining the lumen and 
expressing Ck8 and Ck18 (Hayward et al., 1996a). In mature prostate gland, columnar 
luminal cells exhibit basally located rough endoplasmic reticulum, supranuclear Golgi 
complexes and apical vesicles that contain dense secretory materials, all of which are 
typical features of secretory function (Sahlen et al., 2002). At sexual maturity, the 
luminal cells undergo functional differentiation and produce prostate-specific secretory 
proteins, which demonstrate a lobe specific manner. For example, the prostate spermine 
binding protein (Sbp) is a VP enriched protein (Chang et al., 1987), while a range of 
dorsolateral proteins are the major secretory proteins in DLP (Donjacour et al., 1990). As 
the prostatic epithelium differentiates, the immature prostatic mesenchymal cells 
differentiate into a layer of smooth muscle that surrounds the prostatic ducts (Hayward et 
al., 1996b).  
Thus, the adult prostate glands contain three major cell types, luminal secretory 
cells, basal epithelial cells and stromal smooth muscle cells. In addition to these cell types, 
there are a few less common cell populations present in the epithelium and the stroma. 
The neuroendocrine cells are present as a very rare cell population in both developing and 
adult prostate ducts (Garabedian et al., 1998). Although it is widely accepted that luminal 
and basal cells are derived from the common epithelial precursor of the cloaca (Wang et 
al., 2001), the origin of the neuroendocrine cell is unclear. One study suggested that 
neuroendocrine cells are derived from neural crest and migrate into the UGE through the 
UGM during early prostate development (Aumuller et al., 1999); while another 
hypothesis holds that the neuroendocrine cells share a common progenitor with secretory 
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cells (Xue et al., 1998a; Xue et al., 1998b). The neuroendocrine cells can be identified as 
expressing specific markers such as the chromogranin A, serotonin, synaptophysin and 
neurophysin (Xue et al., 1997; Abrahamsson, 1999; Rodriguez et al., 2003). Recent 
research also suggested that in the prostate there is another very small population of cells 
which have the potential for regeneration. These cells are proposed to be stem cells and 
are located in the basal epithelial compartment (Xin et al., 2003; Collins et al., 2001). In 
the mouse, a very rare basal cell population has been shown to express a marker gene 
profile which is characteristic of immature/undifferentiated transient or intermediate cells 
(Wang et al., 2001). Although no prostate stem cell has yet been isolated, these studies 
collectively suggested that the prostate stem cells are present and concentrated in 
embryonic UGE but are sparse in mature glands, and they preferentially expresses Ck5, 
Ck14, p63 and high levels of α2β1-integrin (Collins et al., 2001; Wang et al., 2001).  
In addition to the smooth muscle cells, the prostate stromal layer also contains 
several less common cell types including the fibroblastic, lymphatic and vascular cells 
(Cunha et al., 1987).      
C. Steroid Hormones Regulate Prostatic Development 
Androgens have been shown to play a central role in organogenesis of the male 
reproductive tract (Thomson, 2001). The development of the prostate and other male 
internal accessory sexual structures is dependent on circulating androgens. The research 
performed by Jost and colleagues more than half century ago demonstrated that testicular 
factors are required for the formation of the male reproductive organs (Jost A, 1953). 
They showed that the development of the reproductive tract was independent of the 
genetic mechanism of sex determination but under the regulation of hormones. In their 
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experiments, administration of androgens to embryos in utero resulted in the 
development of male accessory sex organs such as the prostate in females. In vitro organ 
culture experiments confirmed that androgens are able to induce prostatic budding in 
embryonic female reproductive tracts (Price D., 1965; Cunha, 1973; Lasnitzki and 
Mizuno, 1977; Takeda et al., 1986). On the other side, ablation or surgical removal of 
fetal testes during the ambisexual period of sex differentiation inhibited the development 
of male sex glands including the prostate (Cunha et al., 1987). Likewise, administration 
of estrogens or antiandrogens blocked the development of the prostate and other male 
accessory sex glands (Neumann et al., 1970a; Neumann et al., 1970b; Steinbeck et al., 
1970; Elger et al., 1974). 
These observations demonstrated that androgens are critical in inducing prostatic 
organogenesis. Moreover, during postnatal period, prostatic development is also 
dependent on androgens. Castration of neonatal mice inhibited the continued growth and 
development of the prostate, while castration of adult mice induced a striking reduction in 
prostatic size (80-85%) and DNA content (Berry and Isaacs, 1984; Sugimura et al., 1986b; 
Donjacour and Cunha, 1988). On the other hand, administration of testosterone to 
immature male animals accelerated the prostatic development and maturation (Cunha et 
al., 1987). These observations suggested that androgens are required for the development, 
morphogenesis and maintenance of the prostate. 
 Androgen production by the developing fetal testes initiates before prostatic 
induction and continues throughout the entire periods of prostatic morphogenesis (Pointis 
et al., 1980). Testosterone is the primary androgen that is produced by the fetal testes, 
while dihydrotestosterone (DHT) is the active intracellular androgen responsible for 
 
prostatic growth (Cunha et al., 1987). DHT is produced within the UGS by enzymatic 
reduction of testosterone by 5α-reductase (Lasnitzki et al., 1974; Wilson and Lasnitzki, 
1971).  
Androgens act via the androgen receptor (AR), a member of the nuclear hormone 
receptor superfamily. AR is an important signal transducer which mediates the effect of 
the extracellular androgens and activates androgen-responsive target gene in the cellular 
nuclear. In the embryonic prostate, the expression of stromal AR coincides with prostatic 
budding while the expression of epithelial cell AR initiates at the end of the first postnatal 
week when the solid prostatic ducts begin to canalize (Shannon and Cunha, 1983). Males 
who lack AR or contain a defective AR do not develop male secondary sex organs even 
though their testes produce sufficient amount of androgens (Wilson et al., 1981; Griffin 
and Wilson, 1984). This syndrome, called testicular feminisation (Tfm), has been 
described in human, mouse and rat (Cunha et al., 1987).  
In addition to androgens, the prostate growth is also significantly affected by the 
stimulation of estrogens. Exposure of male fetuses to estrogen compounds at extremely 
low environmental levels caused an enlargement of the prostate (Nagel et al., 1999; vom 
Saal et al., 1997). However, developmental exposure of males to high levels estrogen 
compounds reduced the prostatic growth and induced altered glandular morphology 
(Prins et al., 2001; Prins, 1997; Prins, 1992). Estrogen receptors have also been detected 
in both epithelial and stromal compartments (Bruner-Lorand et al., 1984). A direct effect 
of estrogen is to induce squamous metaplasia which is mediated through estrogen 
receptors in both epithelium and stroma (Triche and Harkin, 1971; Mawhinney and 
Neubauer, 1979). An indirect mechanism of estrogen is to act via the hypothalamus and 
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pituitary by suppressing the secretion of gonadotropins which reduce testicular androgen 
production (Shearer et al., 1973). However, mice with inactivating mutation in estrogen 
receptor α or β or both have normal prostatic development (Jarred et al., 2002; Dupont et 
al., 2000). These data suggest that prostatic development is sensitive to the overall 
endocrine environment, including the estrogen levels. 
 
Epithelial-Mesenchymal Interactions 
The interactions between epithelial and mesenchymal cells are essential for 
directing the organogenesis of the prostate and almost all other organs. The 
differentiation and morphogenesis of either epithelium or stroma will not happen if the 
epithelium or stroma is grown separately. During prostatic induction, AR is first 
expressed in mesenchyme but is absent in epithelium. Epithelium starts to express AR at 
a relatively late stage during ductal canalization (Cunha et al., 1987). Androgen 
signalling in the mesenchyme has been shown to be both necessary and sufficient for 
prostatic organogenesis (Cunha and Lung, 1978; Cunha et al., 1980a; Cunha et al., 1981; 
Lasnitzki and Mizuno, 1980). These observations led to the hypothesis that androgens 
regulate prostatic epithelial development through eliciting the activity of paracrine factors 
produced by the mesenchyme.  
When prostatic organogenesis is initiated in the embryonic stage, prostatic 
epithelium buds into the great mass of surrounding urogenital sinus mesenchyme, and 
these small embryonic rudiments eventually generates a complete adult organ. This is an 
observation not unique to the prostate, since other organs such as the mammalian salivary, 
mammary glands, lung, seminal vesicle and bulbourethral also undergo a similar early 
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stage of organogenesis during which the epithelial component is a tiny bulbous or tubular 
rudiment surrounded by a vast mass of mesenchyme (Lung and Cunha, 1981; Cunha, 
1972; Alescio and Cassini, 1962; Kratochwil, 1969; Sakakura et al., 1976). During 
prostatic development, the epithelial ducts elongate and branch within the mesenchyme, 
and the mesenchymal mass becomes progressively organized into the smooth muscle 
sheaths and connective tissues that wrap the epithelial ducts. Thus, during prostatic 
development, the rodent prostate transforms from a predominantly mesenchymal to a 
predominantly epithelial organ.  
The in vivo interactions between UGE and UGM were modeled in a series of 
classical tissue recombination experiments, which were pioneered by Cunha and 
colleagues. Their comprehensive research demonstrated that UGM can act both as a 
permissive and an instructive inductor. Permissive inductions are those in which 
mesenchyme permits the epithelium to adopt its normal developmental program, while 
instructive inductions are those in which mesenchyme induces and specifies the 
epithelium to adopt a new developmental fate. An example of permissive induction is the 
interaction between UGM and seminal vesicle epithelium. Recombinants derived from 
UGM plus seminal vesicle epithelium differentiate into seminal vesicle, since seminal 
vesicle epithelium is derived from the mesodermally derived Wolffian duct, whose 
developmental repertoire has been stably committed to the formation of epididimis, 
ductus deferens and seminal vesicle, but not the prostate (Cunha et al., 1987). In contrast, 
in instructive inductions, the epithelium retains the ability to respond to a heterologous 
inductor. For example, UGM can elicit prostatic development in epithelium of UGS 
derivatives such as urethra, bladder, and vagina (Cunha et al., 1987). Extensive 
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observations from these tissue recombination analysis demonstrated that these epithelial 
ducts can be induced by UGM to give rise to prostate histology and ultrastructure, as well 
as to express androgen-dependent prostate-specific proteins. And most strikingly, in the 
presence of androgens, the female UGS can be induced to give rise to prostate (Cunha et 
al., 1987). However, the responsiveness to prostatic induction is not shared by the 
endodermal compartments that are out of the UGS. For example, the esophagus, a foregut 
endoderm derivative, cannot be induced by UGM to form prostate (Cunha et al., 1987). 
These data demonstrated that the embryonic derivation from hindgut endoderm is a 
prerequisite for epithelial cell responsiveness to inductive UGM. 
 In fact, the differential response of epithelium to distinct inductive mesenchymes 
is not unique to UGS organs. Studies in other animal models have shown that endodermal 
domains are usually patterned by interactions with overlying mesodermal tissue (Szuts et 
al., 1998). Classic tissue transplant studies using chick embryos showed that the 
cardiogenic mesoderm, which is transiently apposed to the prospective hepatic endoderm, 
provides a signal that is crucial for inducing liver progenitors in the endoderm (Zaret, 
2002). In mice, during tissue specification, signals from the cardiogenic mesoderm 
initiate the liver gene program in proximal endoderm and suppress the pancreatic 
program (Deutsch et al., 2001). Ventral endoderm cells sufficiently distal to the 
cardiogenic mesoderm escape the latter inhibitory effect and initiate the pancreatic gene 
program. Ventral foregut explants, when exposed to cardiogenic mesoderm, initiate liver 
gene expression, otherwise they initiate pancreatic gene expression in the absence of such 
inductor (Deutsch et al., 2001).  
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Tissue recombination experiments have demonstrated that in addition to the 
paracrine signaling from mesenchymal cells to epithelial cells, epithelium can also 
pattern or permit the development of smooth muscle cells in the stroma (Cunha et al., 
1996). Rat UGM has been recombined with either mouse or human prostate epithelium. 
Grafts of UGM paired with mouse epithelium formed a thin smooth muscle layer 
identical with the mouse stromal architecture; while grafts of UGM paired with human 
epithelium formed a thick smooth muscle layer identical to the human stromal 
architecture (Hayward et al., 1998). These experiments suggested that prostatic 
epithelium is able to pattern and induce the surrounding smooth muscle cells by 
producing instructive paracrine signals. Similarly, such reciprocal signaling is also 
supported in other modeling system for non-prostatic organs. For example, at an early 
developmental stage of the embryonic chick, the hepatic endoderm is also important to 
induce the cardiogenic mesoderm in a reciprocal manner (Schultheiss et al., 1995; Sugi 
and Lough, 1995; Gannon and Bader, 1995). Thus, such reciprocal signaling seems a 
common and crucial mechanism for coordinating the organ development in the embryo.  
At present, several mesenchymal paracrine regulators have been described such as 
FGF7, FGF10 and IGF1 (Baker et al., 1996; Ruan et al., 1999; Sugimura et al., 1996; 
Thomson and Cunha, 1999). Recently, growing evidence indicated that a few crucial and 
well-conserved signaling pathways may play key roles in regulating prostatic epithelial-
mesenchymal interactions. 
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Conserved Signaling Pathways  in Regulating Prostatic Development 
Embryonic organ induction is one of the general principles that has to be 
determined in order to further study the organ development. One of the first 
demonstrations showing that cells can communicate with adjacent cells was the 
observation of two-headed salamanders in a tissue transplantation experiment (Pires-
daSilva and Sommer, 2003). The transplanted tissue was able to induce the fate of the 
neighbor cells in the host embryo, suggesting that cells might talk with each other 
through some kind of signals. In the past two decades, extensive research in embryonic 
and developmental biology has demonstrated a strikingly simplified principle in the 
generation of the organism complexity. That is, despite the huge number of cell types and 
patterns found in the diverse animals, only a few conserved signaling pathways are 
required to generate them (Pires-daSilva and Sommer, 2003). Surprisingly, although after 
a million years of evolution, signaling pathways have evolved into complex networks, 
recent studies revealed that most cell-cell interactions during embryonic development 
involve Hedgehog (Hh) (Ingham and McMahon, 2001), Wingless (Wnt) (Cadigan and 
Nusse, 1997), Notch (Mumm and Kopan, 2000), transforming growth factor-β (Tgf-β) 
(Massague and Chen, 2000), receptor tyrosine kinase (Schlessinger, 2000) and nuclear 
hormone pathways (McKenna and O'Malley, 2002). It is now thought that the organ 
specificity is controlled by the intensity of these signals, the cross-modulation and 
interaction within different signaling cascades, and the competence or originality of the 
cells that are receiving these signals (Zaret, 2002). Recently it has been suggested that 
molecules that are involved in these pathways also play crucial roles in various 
developmental aspects of the prostate (Marker et al., 2003). 
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A. Hedgehog Signaling – Prostatic Ductal Morphogenesis 
 Members of the Hh family were isolated in the early 1990s (Lee et al., 1992; 
Mohler and Vani, 1992; Tabata et al., 1992). Since then, they have been recognized as 
key regulators of many crucial processes during embryonic development. Now Hedgehog 
signaling is thought to be pivotal in controlling the growth, patterning and morphogenesis 
of almost every organ in the bodies of vertebrates (Ingham and McMahon, 2001). 
Depending on different contexts, Hedgehog signals can act as either morphogens 
inducing distinct cell fates within its target field, or mitogens regulating cell proliferation 
(Ingham and McMahon, 2001).  
 The Sonic hedgehog (Shh) gene is the vertebrate homolog of the Drosophila gene 
hedgehog (Echelard et al., 1993b). Both hedgehog and Shh encode secreted 
glycopeptides that bind to a membrane-bound receptor, Patched (Ptc), and activate a 
cascade event of intracellular signal transduction, which finally leads to transcriptional 
activation or repression of specific genes (Marigo and Tabin, 1996; Stone et al., 1996; 
Fuse et al., 1999). In Drosophila, Ci is the transcriptional regulator that functions as an 
activator while the protein is intact, and acts as a suppressor while the protein is cleaved 
(Aza-Blanc et al., 1997). Although both forms are present in Hedgehog-responsive cells, 
Hedgehog signaling strongly inhibits the cleavage event thus promoting transcriptional 
activity (Motzny and Holmgren, 1995; Wang and Holmgren, 1999). Gli1, Gli2 and Gli3 
proteins are vertebrate homologs of Ci with a highly conserved zinc finger DNA-binding 
domain (Walterhouse et al., 1999; Matise and Joyner, 1999). Although three Gli proteins 
may have overlapping or redundant functions, Gli1 is a clear transcriptional activator 
(Sasaki et al., 1997; Yoon et al., 1998). Interestingly, the receptor Ptc itself is a 
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downstream target of Shh signaling, and functions to attenuate Shh activity (Ingham, 
1991; Capdevila and Guerrero, 1994; Gailani et al., 1996; Dahmane et al., 1997).  
In the urogenital tract, Podlasek et al. first showed that Shh is expressed in the 
UGE in an androgen-dependent manner, and the temporal expression of Shh coincides 
with the formation of the main prostatic ducts and the following ductal morphogenesis 
(Podlasek et al., 1999a). Examination of the spatial expression in UGS suggested that the 
most abundant expression level was in the lumen of the UGS as well as in the adjacent 
proximal duct areas. During prostatic budding, focused expression of Shh was observed 
in the nascent prostatic epithelial buds as well as in the growing ductal tips (Lamm et al., 
2002; Freestone et al., 2003). Expression of Ptc1, Gli1 and Gli2 is localized primarily to 
mesenchyme surrounding the newly developed prostatic buds, while Gli3 is expressed 
throughout UGM in a diffused pattern (Lamm et al., 2002; Berman et al., 2004). 
Expression of Ptc1 and Gli1 is highly dependent on the Shh signaling, since treatment of 
UGM with Shh peptide upregulated expression of both genes in cultured tissue or in 
intact organ (Lamm et al., 2002). Blockage of Shh signaling with a neutralizing antibody, 
or with the chemical inhibitor cyclopamine, in organ culture experiments, inhibited the 
Shh signaling and abrogated the growth and ductal morphogenesis in transplanted tissues 
(Podlasek et al., 1999a; Lamm et al., 2002). This inhibitory effect is mediated through the 
inhibition of Gli protein expression (Lamm et al., 2002). 
In vitro organ culture as well as renal capsule rescue of Shh mutant UGS 
suggested that Shh is not required for prostatic induction (Berman et al., 2004; Freestone 
et al., 2003). However, the developed Shh-null prostates demonstrated aberrant branching 
morphogenesis as well as cytodifferentiation, confirming the role of Shh signaling in 
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prostatic ductal morphogenesis (Berman et al., 2004; Freestone et al., 2003). In addition, 
in vitro treatment of postnatal VP with recombinant Shh caused a decrease in the number 
of ductal tips as well as an expansion in mesenchyme (Freestone et al., 2003). The 
negative effect of Shh signaling on ductal branching was supported by another report 
which further suggested that this is an indirect effect through the surrounding stromal 
cells, since Shh treatment caused upregulated expression of activin A and transforming 
growth factor-β1, both of which have been shown to inhibit epithelial cell branching 
(Wang et al., 2003). Collectively, these studies indicate that Shh signaling plays a role in 
early prostatic branching morphogenesis and epithelial/stromal pattern formation, but not 
in prostatic induction. 
B. Wnt Signaling – A Crosstalk with AR Pathway 
Wnt proteins are another family of secreted glycoproteins that are 
developmentally important. Wnt provides crucial signals for embryonic induction, 
generation of cell polarity, and the specification of cell lineages (Cadigan and Nusse, 
1997). Mutations in several components of Wnt signaling have been implicated in the 
genesis of various human cancers (van Es et al., 2003). Wnt-1 in the mouse is the first 
Wnt member, while others share significant sequence homology to Wnt-1 (Nusse and 
Varmus, 1982; van Ooyen and Nusse, 1984). All Wnt proteins encode secreted 
glycoproteins, just as Hedgehog proteins (Nusse, 2003). In Drosophila, Wnt proteins act 
on its receptor Frizzled, which is a cell-surface transmembrane protein with an amino-
terminus positioned outside of the cell (Bhanot et al., 1996; Rocheleau et al., 1997a). 
Frizzled, upon ligand binding, activates Disheveled, which is a cytoplasmic G-protein 
regulator (Klingensmith et al., 1994; Theisen et al., 1994). Activated Disheveled in turn 
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inhibits zw3 (or vertebrate counterpart GSk-3) kinase (Dominguez et al., 1995; He et al., 
1995), which directly binds to and phosphorylates β-catenin, destabilizing the latter by 
promoting its entry into the ubiquitin-proteasome degradation pathway (Aberle et al., 
1997). β-catenin is the essential mediator of Wnt signaling. Mutations in β-catenin 
resulted in phenotypes similar to that observed in Wnt inactivation (Heasman et al., 1994; 
Wieschaus and Riggleman, 1987), while increased levels of β-catenin in cells caused 
activation of Wnt signaling (Schneider et al., 1996; Larabell et al., 1997). Wnt signals 
positively regulate β-catenin post-transcriptionally, leading to the accumulation of 
cytoplasmic and nuclear β-catenin (Larabell et al., 1997; Riggleman et al., 1990). 
Nuclear-accumulated β-catenin can bind to HMG box transcription factors, Tcf-LEF-1 
proteins, which by themselves are weak transcriptional activators. Complexes between 
Tcf and β-catenin act as potent transcriptional activators (Molenaar et al., 1996; Korinek 
et al., 1997; Morin et al., 1997). Thus β-catenin is a key component in classical Wnt 
pathways since it provides a link between Wnt signaling and transcriptional regulation. 
Furthermore, β-catenin also binds to E-cadherin and links cell adhesion complexes to the 
cytoskeleton (McCrea et al., 1991). 
In the normal prostate epithelium, nuclear translocation of β-catenin was found to 
occur concomitantly with androgen-induced regrowth of the prostate (Chesire et al., 
2002). Remarkably, β-catenin can interact with AR but not with other steroid hormone 
receptors such as estrogen receptor-α, progesterone receptor-β, or glucocorticoid receptor 
(Yang et al., 2002). This interaction requires the ligand binding domain and the amino-
terminus of AR, and the first six armadillo repeats of β-catenin. Through this specific 
interaction, β-catenin promotes AR activity in a ligand-dependent manner in prostate 
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cancer cells (Yang et al., 2002). Consistently, upregulation of E-cadherin in prostate 
cancer cells leads to redistribution of the cytoplasmic β-catenin to the cell membrane and 
reduction of AR-mediated transcription (Yang et al., 2002). More evidence suggested that 
AR can promote nuclear translocation of β-catenin in prostate cancer cell lines 
(Mulholland et al., 2002). By performing a time course cell fractionation, AR has been 
shown to be capable of shuttling β-catenin into the nucleus when exposed to exogenous 
androgen. In this experiment, cells exposed to androgen demonstrated nuclear co-
localization of AR and β-catenin (Mulholland et al., 2002). Furthermore, β-catenin has 
been shown to indirectly bind Pbsn promoter in an AR-dependent manner (Mulholland et 
al., 2002). These results supported β-catenin as a co-activator for AR, at the same time 
established a novel mechanism of nuclear accumulation of β-catenin by AR-mediated 
import. A recent study reported that in addition to an interaction with β-catenin, AR can 
also interact with T cell factor 4, the transcriptional mediator of Wnt signaling, through 
AR DNA binding domain (Amir et al., 2003). Tcf4 was found to coimmunoprecipitate 
with β-catenin and AR (Amir et al., 2003; Mulholland et al., 2003). Collectively, these 
data provided important insight into the intracellular cross talk between Wnt signaling 
and AR pathway in normal and prostate cancer cells. The direct AR-Tcf4 interaction, in 
conjunction with AR-β-catenin and Tcf4-β-catenin interactions, provides a mechanism 
for cooperative and selective gene regulation by AR nuclear hormone receptor pathway 
and Wnt/β-catenin/Tcf pathway that may contribute significantly to normal and 
neoplastic prostate growth (Amir et al., 2003). Moreover, β-catenin nuclear activation is 
thought to be correlated with abnormal cell growth in the prostate (Bierie et al., 2003; 
Cheshire and Isaacs, 2003). 
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C. Notch Signaling – A Correlation with Prostatic Progenitor Cell 
 Notch genes encode large Type I transmembrane receptors that have been 
conserved during evolution (Schweisguth, 2004). Notch receptors are activated by Type I 
transmembrane DSL ligands, known as Delta, Serrate and Lag2, to receive short-range 
signals between immediate adjacent cells (Mumm and Kopan, 2000). Ligand binding to 
Notch receptor induces a proteolytic cascade which results in release of the Notch 
intracellular domain (Schweisguth, 2004). Notch intracellular domain binds to multiple 
transcription repressors (CBF1, Su and Lag) and converts them into transcription 
activators (Lai, 2004). Activated Notch signaling eventually leads to the up-regulation of 
immediate downstream targets (Lai, 2004).  
 In the prostate, in situ hybridization showed Notch1 was selectively expressed in 
the epithelial cell but not in the stromal cell compartment of developing mouse prostates 
(Shou et al., 2001). Using quantitative RT-PCR and Notch1-GFP transgenic mice, Shou 
et al. demonstrated that strong Notch1 expression coincides with the prostatic branching 
morphogenesis with peak levels around P3-P10, while its expression is significantly 
downregulated in adult prostates (Shou et al., 2001). Interestingly, Notch1-expressing 
cells appeared to correlate with prostatic basal epithelial cells during development (Wang 
et al., 2004). Consistent with this finding, Notch1 expression following castration and 
hormone replacement is tightly associated with basal marker-expressing cells (Wang et 
al., 2004). Although Notch1 was found to be upregulated in prostate cancer cell lines as 
well as prostate cancer mouse models (Shou et al., 2001; Greenberg et al., 1995), 
activation of Notch signaling by transfecting cells with a constitutive active form of 
Notch1 inhibited the proliferation of prostate cancer cells (Shou et al., 2001).  
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 Since the temporal and spatial expression pattern of Notch1 in the prostate highly 
suggested a correlation of Notch1 with prostatic progenitor cells, Wang et al. generated a 
transgenic mouse line in which Notch1-expressing cells can be ablated in an inducible 
manner (Wang et al., 2004). In both organ culture of early postnatal prostates and 
prostatic regeneration after castration, ablation of Notch-expressing cells inhibited the 
branching morphogenesis, growth and differentiation in early postnatal prostates, as well 
as affected the regrowth of post-castration prostates with androgen replacement (Wang et 
al., 2004). These data provided preliminary evidence showing that Notch1-expressing 
cells define the progenitor cells in the prostatic epithelium, and that they are 
indispensable for normal development as well as regrowth of the prostate. 
D. Tgf-β Signaling – Epithelial-Stromal Communication 
 A distinct and attractive feature of the transforming growth factor-β (Tgf-β) 
superfamily is that this signaling pathway employs a large group of agonists but a very 
simplified intracellular signaling engine (Massague and Chen, 2000). Among the Tgf-β 
ligands, the bone morphogenetic proteins (BMPs) form the largest subgroup within the 
Tgf-β family and include various BMP factors and growth and differentiation factors. 
The BMPs have been well-documented for their remarkable roles as instructive signals in 
embyogenesis and maintenance of bone and other tissue in the adult (Balemans and Van 
Hul, 2002). The various forms of Tgf-β and Activin are structurally different from the 
BMPs and are well known for their roles in late stages of embryogenesis and the mature 
organism (Massague and Chen, 2000). The Tgf-βs have dual biological roles: they are 
crucial inhibitors of epithelial cell growth, immune and hematopoietic function; on the 
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other hand, they serve as strong promoters for the growth of connective tissues 
(Massague and Chen, 2000).  
Although Tgf-β signaling pathways employ a huge group of ligands and elicit 
very diverse physiological responses, the core of the signaling machinery is surprisingly 
simple across all the species of vertebrates, insects and nematodes. The basic signaling 
machinery is composed of type I and type II receptors, both of which are receptor 
serine/threonine protein kinases, as well as a family of receptor substrates, the Smad 
proteins, which move into the nucleus (Massague and Chen, 2000). Typically, the ligand 
binds and assembles the receptor complex, in which the type II receptor phosphorylates a 
“GS” region in type I receptor, resulting in the activation of the receptor I kinase. This 
kinase in turn phosphorylates Smad proteins, the only direct substrates mediating Tgf-β 
signaling to date, and Smads assemble multisubunit protein complexes that regulate the 
transcription of target genes (Massague, 1998). In vertebrates, the type I receptors for 
Tgf-β, Activin and Nodal, recognize Smad2 and Smad3, while the receptors for BMPs 
and growth and differentiation factors recognize Smad1, Smad5 and Smad8 (Massague 
and Chen, 2000). Receptor-mediated phosphorylation of these related Smads (R-Smads) 
allows the association of R-Smads with co-Smads (Smad4 and 4β in vertebrates), as well 
as the subsequent nuclear accumulation of the complexes (Howell et al., 1999). Although 
the selection of Smad by a given Tgf-β receptor provides the first level of target gene 
specificity, a given Smad can elicit different cellular responses depending on the cell 
types. The selectivity of target genes by activated Smad complexes is largely controlled 
by the DNA-binding cofactors, with which Smads form complexes (Massague and 
Wotton, 2000). A number of such Smad-binding partners have been identified including 
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p300/CBP, AP-1, AR etc (Derynck et al., 1998). Although Smads by themselves have 
DNA binding capacity with low affinity, such binding is not selective for gene activation 
(Shi et al., 1998). Hence the associated DNA-binding cofactors must provide a tight and 
highly specific recognition of DNA elements (Massague and Chen, 2000)  
a) BMPs in the Prostate 
 The expression of BMP2, BMP3, BMP4, BMP6 and BMP7 has been reported in 
either normal prostate or prostate cancer cells (Harris et al., 1994), with BMP6 and 
BMP7 implicated in potentially mediating osteoblastic metastases in prostate cancer 
(Bentley et al., 1992), while BMP2 is frequently lost during prostate cancer progression 
(Horvath et al., 2004). An essential role played by BMP in normal prostate development 
was demonstrated by a functional study of BMP4 (Lamm et al., 2001). The BMP4 gene 
was observed to be highly expressed in the male UGS from E14 through birth, a period 
marked by the formation of main prostatic ducts and initiation of ductal morphogenesis 
(Lamm et al., 2001). Thts expression was significantly decreased around P5-P10, and 
reduced to an even lower level in adult prostate. In situ hybridization revealed that BMP4 
message is initially localized to a broad and uniform domain of the E15 male UGS. As 
prostatic main buds appeared, expression of BMP4 remained highly concentrated around 
the newly formed ducts.  Postnatal expression of BMP4 at P1-P10 is most abundant in the 
mesenchyme immediately surrounding the epithelial buds. This expression is 
significantly downregulated in adult prostates (Lamm et al., 2001). Throughout the entire 
developmental stages, no expression was detected in the epithelium. BMP4 signal is 
mediated by its receptor BMPR. Expression of BMP4, BMPR-IA and BMPR-IB were 
detected in both UGM and UGE (Lamm et al., 2001).  
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In an in vitro organ culture system, treatment of UGS with exogenous BMP4 
inhibited epithelial cell proliferation and exhibited a dose-dependent suppression of 
ductal budding in these tissues. Consistent with this finding, adult BMP4 
haploinsufficient mice exhibited an increase in the number of duct tips in both VP and 
AP (Lamm et al., 2001). Taken together, these observations indicated that BMP4 is a 
UGM factor that negatively regulates prostate ductal budding and branching 
morphogenesis. 
b) Tgf-β in the Prostate 
In the normal prostate, Tgf-β1 is expressed in smooth muscle cells, which are 
closely adjacent to the epithelial compartment, while Tgf-β receptors are predominantly 
expressed in epithelial cells (Timme et al., 1994; Itoh et al., 1998). This pattern of 
distribution of ligand and receptor indicated a paracrine mode of action. The action of 
Tgf-β on the normal prostate is centrally focused at the interaction between the smooth 
muscle cells and epithelial cells (Lee et al., 1999). Tgf-β produced in prostatic smooth 
muscle cells acts as both a potent inhibitor of prostatic epithelial cells and a promoter of 
epithelial apoptosis (Sutkowski et al., 1992; Story et al., 1993; Ilio et al., 1995). In normal 
prostate glands, multiple layers of smooth muscle cells in the proximal region induce 
extensive apoptosis in the epithelium; however, in the distal region, extensive epithlial 
cell proliferation is observed concomitantly with a very thin and discontinuous smooth 
muscle cell layer (Lee et al., 1999). A recent study demonstrated that a layer of smooth 
muscle, which differentiates between the ventral mesenchymal pad and the urethral 
epithelium in E20.5 female mice but not in males, negatively regulates the prostatic 
induction (Thomson et al., 2002). These observations support the concept that smooth 
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muscle cells play a negative growth-regulatory role in epithelial cells through the 
production of Tgf-β1. However, other studies have reported that low concentrations of 
Tgf-β1 can increase the proliferation of prostatic cells, suggesting that Tgf-β1 may play a 
differential role in the regulation of prostatic cells (Zhou et al., 2003; Robson et al., 1999) 
(Collins et al., 1996). Furthermore, a recent organ culture study demonstrated that Tgf-β1 
stimulates cellular proliferation at the periphery of the organs while inhibiting cellular 
proliferation in the center of the organs (Tomlinson et al., 2004).  
In androgen-ablated prostate, Tgf-β signaling has also been proposed to be one of 
the most important pathways activated during castration-induced regression. Tgf-β 
expression increases following castration and reaches a peak at post-castration day eight. 
Expression of Tgf-β receptors also increases simultaneously. Such an increase in Tgf-β 
signaling is correlated with an elevated apoptotic status in epithelial cells during 
androgen deprivation. A newly formed layer of smooth muscle cells surrounding the 
distal prostatic ducts was observed, and these smooth muscle cells express Tgf-β1. At the 
same time, stromal cells surrounding the proximal prostatic ducts show reduced 
expression of both smooth muscle a-actin and Tgf-β1. This reduced Tgf-β1 expression in 
the proximal region is consistent with the observation that epithelial cells are viable in 
this region during castration-induced prostatic regression (Lee et al., 1999).  
Although prostatic stromal cells are also responsive to Tgf-β1, the action of Tgf-
β1 on stromal cells is different from the action on epithelial cells. It has been shown that a 
continuous exposure of prostatic stromal cells to Tgf-β1 resulted in an aggregation of 
smooth muscle cells, a condition in which the fibroblastic lineage is converted into 
muscular lineage (Peehl and Sellers, 1997). Also, examination of the three dimensional 
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distribution of smooth muscle in prostatic organs after treatment with Tgf-β1 showed that 
the smooth muscle distribution was affected by Tgf-β1, causing well-defined smooth 
muscle adjacent to epithelial ducts (Tomlinson et al., 2004),  The action of Tgf-β1 on 
stromal cell differentiation may play an important role during the development of benign 
prostatic hyperplasia. A recent study has further highlighted the essential role of stromal 
Tgf-β1 action in prostate cancer progression, by showing that ablation of Tgf-β1 
signaling in prostatic stromal cells leads to prostatic neoplasia (Bhowmick et al., 2004). 
Overall, these results demonstrated that Tgf-βs can have diverse activities in the prostate, 
c) Smads Link Tgf-β Pathway to AR 
 Androgen promotes cell growth and inhibits cell apoptosis through AR, while the 
Tgf-β pathway controls prostate cell proliferation, differentiation, and apoptosis. By 
using transient transfection systems, Hayes et al. first demonstrated the molecular 
mechanism by which Tgf-β inhibits AR-mediated transcriptional activation (Hayes SA et 
al., 2001). They showed that the Tgf-β signaling downstream mediator, Smad3 can 
specifically repress the androgen-responsive activation of the MMTV and the prostate 
specific antigen (PSA) gene promoters, both of which are natural androgen-regulated 
promoters. This inhibitory effect is transmitted through Tgf-β signaling and can be 
regulated by other Smad proteins (Hayes SA et al., 2001). Importantly, Smad3 directly 
interacts with AR via its MH2 domain and the transactivation domain of AR. The 
repressive effect of Smad3 is solely mediated through the MH2 domain (Hayes SA et al., 
2001). These results provided the first insight into the mechanism by which Tgf-β 
regulates the androgen-signaling pathway in normal prostate and cancer cells. 
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 A second study demonstrated a mutual regulation between androgen and Tgf-β 
signaling pathways (Chipuk et al., 2002). Androgens negatively regulate the expression 
of Tgf-β ligands and receptors. In addition androgen inhibits the activation of Smad 
through the direct interaction between ligand-bound AR and Smad3. This interaction is 
specific for Smad3 but not other Smad proteins. AR ligand binding domain directly 
blocks the binding of Smad3 to Smad-binding element, resulting in suppression in Smad3 
transactivation (Chipuk et al., 2002). Collectively, these data illustrate from a different 
view that ligand-activated AR inhibits Tgf-β transcriptional responses. 
 Along these lines, Kang et al. further demonstrated that Smad4 can interact with 
the DNA-binding and ligand-binding domains of AR, when Smad3 is present (Kang et al., 
2002). Surprisingly, addition of Smad3 enhanced AR transactivation in the prostate 
cancer PC3 and LNCaP cells, while addition of both Smad3 and Smad4 repressed AR 
transactivation in various androgen responsive promoters, including the PSA genes 
(Kang et al., 2002). However, in a Smad4-null cell line, the influence of Smad3 on AR 
transactivation is differentially dependent on the specific androgen responsive promoters. 
The effect of Smad3/Smad4 on AR transactivation was further proposed to involve 
acetylation events (Kang et al., 2002). Taken together, these results suggest that the 
cross-modulation between androgen and Tgf-β signaling is at least in part mediated by 
the interactions between AR, Smad3, and Smad4, and such a mutual regulatory 
mechanism may play a balancing role facilitating normal prostate development. 
Disregulation of either pathway may result in abnormal cell growth and unexpected gene 
activation or inactivation, which are associated with cancer progression. 
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E. Receptor Tyrosine Kinase Pathways 
 Receptor tyrosine kinase is a large family of cell surface receptors that contain 
intrinsic protein tyrosine kinase activity. These receptors catalyze the transfer of the 
gamma phosphate of ATP to the tyrosine of target proteins. Receptor tyrosine kinase 
signaling pathways play an important role in the control of many fundamental cellular 
processes including cell cycle, survival, proliferation, differentiation and metabolism 
(Schlessinger, 2000).  
All receptor tyrosine kinases contain an extracellular ligand binding domain that 
is usually glycosylated. This ligand binding domain is connected with a cytoplasmic 
domain by a transmembrane helix. The cytoplasmic domain has a conserved protein 
tyrosine kinase core and supplementary regulatory sequences which are subjected to 
phosphorylation and regulation by heterologous protein kinases (Hunter, 2000; Hubbard 
et al., 1998). All known receptor tyrosine kinases (e.g. EGF receptor, FGF receptor, IGF 
receptor) are monomers on the cell membrane, except the insulin receptor which is a 
heterodimer. Ligand binding induces receptor dimerization, resulting in the 
autophosphorylation of their cytoplasmic domains (Lemmon et al., 1994; Jiang and 
Hunter, 1999). Although all receptor tyrosine kinases are activated by dimerization, 
different ligands employ different mechanisms for inducing the active state of the 
receptors. Structural studies of the catalytic core of several receptor tyrosine kinases, as 
well as the biochemical studies of receptor phosphorylation and activation suggest that 
receptor oligomerization can increase the local concentration of the protein tyrosine 
kinase, leading to efficient transphosphorylation of tyrosine residues (Schlessinger, 2000).  
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In addition to its role in controlling protein kinase activity, autophosphorylation of 
receptor tyrosine kinases is essential for the recruitment of a variety of signaling proteins, 
since most tyrosine autophosphorylation sites function as binding sites for various 
signaling proteins or docking proteins, which contain Src homology 2 or phosphotyrosine 
binding domains. Docking proteins contain specific domains such as binding domains 
that are responsible for complex formation with cell surface receptors, hence functioning 
as platforms for the recruitment of signaling proteins in response to receptor stimulation. 
For example, upon FGF stimulation, most of the activated signaling proteins are recruited 
via docking proteins but not by their direct binding to FGF receptor. A total number of 
activated signaling proteins is the sum of those recruited by receptor itself and those 
recruited by docking proteins that are phosphorylated by the same receptor (Schlessinger, 
2000). The diverse downstream effector proteins involve a variety of signaling pathways 
including Ras/MAP, JNK, and PI-3 pathways (Schlessinger, 2000). These pathways 
regulate the activity of transcriptional factors by phosphorylation and by other 
mechanisms, leading to an overall physical or pathological response to the activation of 
the specific receptor.  
a) EGF Signaling – Prostate Cell Proliferation 
 The epidermal growth factor receptor (EGFR) was the first identified receptor 
tyrosine kinase. Many mechanisms for activation and recruitment of intracellular 
signaling pathways after growth factor stimulation were discovered through the studies of 
EGF signaling. The EGFR family has four members: EGFR (ErbB1), ErbB2, ErbB3, and 
ErbB4. EGFR has numerous ligands including EGF, Tgf-α, HB-EGF. Activating 
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mutations and overexpression of this receptor family were found in a variety of cancers 
and other diseases (Schlessinger, 2000). 
 In normal prostate, EGF is produced in stromal cells, while EGFR is primarily 
expressed in basal epithelial cells (Sherwood and Lee, 1995). Expression of EGF was 
observed to be elevated in prostate cancer cells. In contrast, Tgf-α is prominently 
expressed in prostate cancer cells but not in normal prostate (Byrne et al., 1996). EGF 
and Tgf-α function as strong promoters for cell proliferation in both stroma and 
epithelium (Culig et al., 1996). Blocking antibody against EGFR inhibited prostate cell 
proliferation and downregulated MAP kinase signaling pathway (Prewett et al., 1996). It 
has been shown that castration of adult mice reduced the production of EGF in prostate, 
and androgen restoration also restored the EGF levels (Hiramatsu et al., 1988). Since 
androgen regulates the growth of the stromal cells from which EGF is produced, this 
androgen-dependent effect on EGF expression may be due to an indirect mechanism. On 
the other hand, EGF signaling also increases coactivation of the AR in prostate cells, 
suggesting a mutual regulatory mechanism (Gregory et al., 2004).  
 In prostate cancer, EGF and Tgf-α stimulate cancer cell proliferation. High levels 
of Tgf-α expression has been observed in high-grade prostate cancers (Sherwood and Lee, 
1995). Overexpression of Tgf-α in transgenic mice causes prostatic hyperplasia, 
suggesting that activation of EGFR signaling plays a key role in prostate cancer 
progression (Wong et al., 1998). Several studies also suggested that EGF signaling as 
least in part account for the progression of androgen-independent prostate cancer 
(Djakiew, 2000). 
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b) FGF Signaling – Paracrine Regulator for Prostatic Organogenesis 
 The fibroblast growth factor (FGF) family contains at least 23 related growth 
factors; while there are four known receptors (FGFR1, FGFR2, FGFR3 and FGFR4) 
mediating FGF signals (Naski and Ornitz, 1998). FGFs activate FGF receptors (FGFR) 
with the cooperation of the accessory molecule heparin sulfate proteoglycan (Yayon et al., 
1991), which is essential for stabilizing FGF-FGFR complex. The dual ligand-dependent 
activation of FGFR provides a mechanism for localized activation of FGFR and cell 
proliferation or differentiation (Spivak-Kroizman et al., 1994). The heparin is synthesized 
in limited areas in extracellular matrix and provides a scaffold where FGFR-expressing 
cells migrate toward and hence survive, proliferate and differentiate.  
 FGFs are key regulators of early organogenesis and play important roles in the 
development of almost every organ in the body. For example, FGF signaling is essential 
for limb induction and maintenance (Ohuchi et al., 1997; Xu et al., 1998), as well as for 
lung branching morphogenesis (Bellusci et al., 1997b; Park et al., 1998). In the prostate, 
two well characterized FGFs are FGF7 and FGF10. FGF7 is also called keratinocyte 
growth factor. Both FGF7 and FGF10 play important roles in prostate growth (Sugimura 
et al., 1996) (Thomson and Cunha, 1999; Donjacour et al., 2003).  
FGF7 is expressed in prostate mesenchymal cells and acts as a paracrine regulator 
on the growth of epithelial cells, since the receptor for FGF7 is expressed in epithelial 
cells. It has been shown that FGF7 regulates the growth of the VP (Sugimura et al., 1996) 
and seminal vesicle (Alarid et al., 1994). Similar to the effects of EGF and Tgf-α, FGF7 
is also mitogenic to epithelial cells, since treatment of VP and seminal vesicle with FGF7 
stimulated tissue growth in organ culture system; while addition of FGF7 antibody 
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partially blocked organ growth (Sugimura et al., 1996). Consistent with this biological 
role, FGF7 mRNA is abundant during the active development of VP and seminal vesicle 
in vivo (Thomson et al., 1997). However, unexpectedly, transgenic mice with targeted 
gene deletion in FGF7 did not show a phenotype in the male reproductive organ 
including the prostate (Guo et al., 1996), suggesting that FGFs may work in a redundant 
manner and other FGFs may compensate for the loss of FGF7 in the prostate.   
 FGF7 has long been suggested as an androgen-regulated mesenchymal paracrine 
factor (Peehl and Rubin, 1995). Although in vitro cultured prostatic stromal cells 
responded to androgens by upregulating FGF7 (Yan et al., 1992), in vivo studies showed 
an opposite result that FGF7 mRNA was decreased rather than increased upon androgen 
treatment (Nishi et al., 1996; Thomson et al., 1997). Also, FGF7 mRNA was observed to 
be inversely proportional to androgen activity in an in vitro organ culture system 
(Thomson et al., 1997). These results indicated that FGF7 is not directly regulated by 
androgen in vivo. This was further supported by studies of the protein distribution of 
FGF7 in the prostate, where the distribution of FGF7 is not affected by androgen 
manipulation (Nemeth et al., 1998). 
Since FGF10 shares a very high sequence homology with FGF7, it has been 
hypothesized as another candidate for paracrine regulator which may play key roles in 
mesenchymal-to-epithelial cell signaling. FGF10 mRNA was highly expressed in VP and 
seminal vesicle (Thomson and Cunha, 1999), and it was also found in tissues that do not 
belong to male reproductive organs such as the lung and skin. However, the tissue 
distribution of FGF10 is much more tissue restrictive as compared with the distribution of 
FGF7, which is widely expressed (Thomson and Cunha, 1999).  
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In the prostate, FGF10 is expressed during the earliest stages of prostatic 
development. The highest FGF10 mRNA levels were found to be in the time window 
during which prenatal and neonatal prostatic organogenesis occurs. In adult prostate 
tissues, FGF10 levels were significantly decreased to a very low or even undetectable 
level. Spatially, FGF10 mRNA was only detected in a small population of mesenchymal 
cells in both VP and seminal vesicle by in situ hybridization. In neonatal prostate, FGF10 
mRNA was found to be in the mesenchymal cells of peri-urethral area as well as around 
the growing tips of prostatic buds; while in later stages, FGF10 mRNA was found in 
mesenchyme surrounding epithelial buds which undergo branching morphogenesis 
(Thomson and Cunha, 1999). 
Addition of FGF10 to in vitro cultured prostate organ stimulated the development 
of prostatic rudiments. Recombinant FGF10 also can stimulate the growth of prostate 
epithelial cells but not stromal cells, suggesting a mitogenic effect as EGF, Tgf-α and 
FGF7 (Thomson and Cunha, 1999). However, FGF10 does not appear to be acting 
synergistically with androgen on protatic growth. Similar to FGF7, in an in vitro cell 
culture study, prostatic fibroblasts produced more FGF10 in response to androgen (Lu et 
al., 1999), while in vivo examination of FGF10 levels suggested an opposite correlation 
of FGF10 and androgen stimulation (Thomson and Cunha, 1999). Organ culture 
experiments also did not support the idea that FGF10 is regulated by androgen (Thomson 
and Cunha, 1999). Moreover, the growth stimulating effect of FGF10 could not be 
completely inhibited by anti-androgens, further suggesting that FGF10 action was 
independent of the androgen signaling pathway (Thomson and Cunha, 1999). These data 
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supported FGF10 as a paracrine regulator that functions directly to regulate prostatic 
growth.  
Recently, the male reproductive tracts of FGF10 knockout mice were analyzed. 
Interestingly, although the testis of FGF10 knockout mice produces sufficient androgens, 
most of the male secondary sex organs, including the prostate and the seminal vesicle, 
were absent (Donjacour et al., 2003). Addition of FGF10 to in vitro cultured FGF10 
knockout UGS partially reversed the phenotype by inducing prostatic budding and 
differentiation in the presence of androgens (Donjacour et al., 2003). These in vivo 
functional studies demonstrated that FGF-10 is the first identified mesenchymal factor 
required for prostatic organogenesis.  
 
AR Protein Biology and Transcriptional Regulation 
AR is the mediator of the biological action of androgens. AR belongs to the 
nuclear receptor superfamily. Androgen-bound AR translocates from cytoplasm to the 
nucleus and acts as a transcription factor to regulate gene expression. AR-regulated genes 
participate in a variety of biological and physiological activities including two most 
important functions: the differentiation of male reproductive organs and the maintenance 
of spermatogenesis (Gelmann, 2002). AR regulates gene transcription through 
recognition and binding to the specific androgen response element (ARE) within the 
promoter or enhancer sequences of its target genes. AR transcriptional activity is 
frequently influenced by numerous co-activators or co-repressors that affect different 
aspects of AR functionality, encompassing ligand binding and DNA binding. The 
fascinating and complicated AR biology stems largely from these AR coregulators which 
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modulate AR activity either by direct or indirect modification of histones or by 
recruitment of basal transcription machinery (Heinlein and Chang, 2002). Abnormal AR 
biology due to aberrant coregulator activity contributes to the progression of 
androgen/AR-related diseases, including prostate cancer (Suzuki et al., 2003). Although 
AR shares many similarities with other nuclear receptor family members (e.g. ER, GR), 
in terms of structure and biology, it displays distinct features including functional 
interaction with coregulators (Heinlein and Chang, 2002). 
A. The Protein Structure of AR 
Nuclear receptor members function as ligand-inducible transcription factors, 
which can be divided into three types. Type 1 receptors typically form ligand-induced 
homodimer and bind to inverted repeat DNA cis-elements. AR, estrogen receptor (ER), 
progesterone receptor, glucocorticoid receptor (GR) and mineralocorticoid receptor 
belong to type 1 receptor.  The type 2 receptors frequently form heterodimer with retinoic 
acid receptors and bind to direct repeat DNA cis-elements. Vitamin D3 receptor, 
peroxisome proliferator-activated receptor, thyroid hormone receptor and all-trans-
retinoic acid receptor belong to type 2 receptor. Type 3 receptors are orphan receptors 
whose ligands are unknown (Heinlein and Chang, 2002).  
The protein structure of AR can be divided into four functional domains: the NH2-
terminal domain (NTD), DNA binding domain (DBD), hinge region, and ligand-binding 
domain (LBD).  Both NTD and LBD contain transactivation function individually. The 
transcriptional activation function of NTD is contained in a region called AF-1, which 
functions in a ligand-independent manner (Jenster et al., 1995), while the transactivation 
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activity in LBD is located in AF-2, which functions in a ligand-dependent manner 
(Danielian et al., 1992; He et al., 1999).  
There are two functional regions in the NTD: a polyglutamine repeat and the AF-
1 transactivation region. The polyglutamine repeat is required for full receptor activity 
and interacts with different coregulators (Simental et al., 1991; Jenster et al., 1991); while 
the AF-1 contains a WXXLF motif, which has been shown to serve as an interface for 
protein interaction with AR LBD (He et al., 2000). Interaction between NTD and LBD 
can be faciliatated by a variety of coregulators, and this interaction has been shown to be 
important for stabilizing the ligand-bound status of the receptor (Ikonen et al., 1997)  
As with other members of nuclear receptor family, AR DBD consists of two zinc 
fingers that recognize a specific DNA consensus sequence, GGTACAnnnTGTTCT. AR  
always binds as a dimer to classical AREs, as well as to various complex DNA response 
elements (Kasper et al., 1994; Verrijdt et al., 1999; Zhou et al., 1997; Claessens et al., 
2001). Some proteins modulate AR transcriptional activity by affecting the binding 
capacity of AR to its cis-elements. For example, receptor accessory factor binds AR NTD 
and enhances AR DNA binding (Kupfer et al., 1993), while calreticulin prevents AR 
DNA binding by interacting with AR DBD (Dedhar et al., 1994). Most recently, the 3D 
crystal structure of AR DBD bound to a naturally occurring selective AREs has been 
solved. The study revealed an unexpected head-to-head arrangement of the two 
monomers rather than a head-to-tail arrangement seen in nuclear receptors bound to the 
response elements with similar geometry (Shaffer et al., 2004). Compared with GR, the 
AR DBD dimerization interface contains additional interactions that stabilize the dimer 
and increase the affinity for nonconsensus response elements (Shaffer et al., 2004). These 
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results provided a definitive answer to the mechanism which underlies the selective 
binding of AR to its specific response elements. Although AR is normally thought to 
function as a homodimer, it can also form heterodimers with other nuclear receptor 
members such as GR and ERα (Panet-Raymond et al., 2000; Chen et al., 1997).  
The hinge region of AR links the DBD and LBD, and contains a ligand-dependent 
nuclear localization signal, which may interact with nuclear trafficking protein importin 
(Jenster et al., 1993; Zhou et al., 1994).  
AR LBD forms a ligand-binding pocket with 11-13 alpha-helices. By comparing 
the receptor structure in ligand absent status and in ligand-bound status, crystallographic 
studies demonstrated that ligand binding induces a conformational change in LBD, in 
which helix 12 and the AF-2 domain folds across the ligand-binding pocket (Williams 
and Sigler, 1998; Brzozowski et al., 1997). In addition to binding ligand, LBD also 
mediates AR interaction with heat shock proteins (Fang et al., 1996), as well as the 
interaction with AR NTD. The interaction between the AR NTD and LBD creates a 
coregulator interaction interface that is different from that of ER (Heinlein and Chang, 
2002). This observation supported the functional analysis of full-length receptors which 
suggested distinct differences between AR and ER. However, until now, no 3D structure 
has yet been determined for any full-length nuclear receptor. 
B. AR-Mediated Transcriptional Activation through the Basal Machinary 
 Transcriptional activation of genes by AR requires the final recruitment of RNA 
polymerase II onto the target genes’ promoter. The recruitment of RNA polymerase II is 
initiated with the binding of TATA Binding Protein (TBP) near the transcriptional 
initiation site and mediated through the assembly of general transcription factors. TBP is 
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part of a complex called transcription factor IID (TFIID). The binding of TBP at TATA 
element causes bending in DNA and brings TATA upstream elements close to the 
general transcription machinery, leading to important interactions between general 
transcription factors and AR-coregulator complex. After TBP binding, TFIIB binds 
directly to TBP and recruits the TFIIF-polymerase II complex, which in turn recruits the 
ATPase/kinase, TFIIE, and the helicase, TFIIH, then transcription is initiated (Heinlein 
and Chang, 2002).  
AR has been shown to be directly or indirectly interacting with various general 
transcription factors. For example, AR NTD has been shown to directly recruit TFIIF 
(McEwan and Gustafsson, 1997), and bind TFIIH (Lee et al., 2000). Also, it has been 
demonstrated that AR interacts with some of the transcription elongation factor (Lee et al., 
2001). These data suggest that AR may regulate transcriptional activity by interacting 
with TFIIF and TFIIH, as well as by facilitating the recruitment of elongation factors to 
androgen-regulated promoters. In addition, AR also indirectly influences transcription 
through coregulators which have an effect on basal transcription machinery. For example, 
ligand-dependent transactivation of AR by ARA160 is through the modification of the 
DNA binding capacity of TBP (Hsiao and Chang, 1999).  
C. AR Coregulators Modulate the Receptor Activity  
AR coregulators are generally considered as proteins that can interact with AR but 
do not possess DNA binding activity. Based on their different functional mechanisms, 
AR coregulators are subdivided into two categories. Type I coregulators function 
primarily with the AR at the target gene’s promoter to facilitate DNA occupancy, 
chromatin remodeling, or the recruitment of general transcription factors that are 
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associated with the RNA polymerase II. Type II coregulators function primarily to 
modulate the appropriate protein conformation of AR, facilitate the interaction between 
AR NTD and LBD, or influence AR protein stability and subcellular distribution AR. 
The overall effect of type II coregulators on AR can result in a changed transcriptional 
activity (Heinlein and Chang, 2002).  
Several important type I coregulators include CBP/p300, SRC-1, and SWI/SNF. 
Both CBP/p300 and SRC-1 have histone acetyltransferase activity and interact with the 
basal transcriptional machinery (Ogryzko et al., 1996; Spencer et al., 1997). CBP has 
been found to interact with a number of AR coactivators (Chakravarti et al., 1996). These 
proteins and CBP may therefore bridge AR function to the basal transcriptional 
machinery. SRC-1 was isolated by a yeast two-hybrid screen as a steroid receptor 
coactivator and has been shown to be able to promote the ligand-dependent transcription 
of a number of steroid receptors including AR (Onate et al., 1995; Spencer et al., 1997). 
The mechanism of SRC-1 action may be through the recruitment of additional 
coregulators including CBP (Yao et al., 1996), and through the interactions with TBP and 
TFIIB (Takeshita et al., 1996). In addition, CBP/p300 and SRC-1 have both been 
demonstrated to have histone acetyltransferase activities, which are associated with 
reduced nucleosome-nucleosome contacts and active genes (Spencer et al., 1997; 
Ogryzko et al., 1996).  
SWI/SNF complex have been shown to interact with ER and GR (Ichinose et al., 
1997; Yoshinaga et al., 1992). It is thought that the recruitment of the SWI/SNF complex 
to the nuclear receptor is facilitated by other coactivators (Heinlein and Chang, 2002). 
SWI/SNF complex contains a DNA-dependent ATPase and modifies the conformation of 
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nucleosome in an ATP dependent manner, resulting in a decreased histone-DNA 
association and an increased gene transcriptional activity (Workman and Kingston, 1998). 
Several important type II coregulators include ARA70 and the f-actin binding 
protein filamin. Wild type ARA70 is localized to the cytoplasm, while ARA70 N-
terminal truncate protein can translocate with ligand-bound AR into nucleus and function 
as a strong transcriptional co-activator. ARA70 has also been shown to interact with other 
AR coactivors and may therefore act as a molecular platform for the transcriptional 
activity (Yeh and Chang, 1996). Mutation of filamin has been shown to prevent AR 
nuclear translocation even in the presence of androgen, suggesting that filamin facilitates 
the cytoplasmic to nuclear translocation of the ligand-bound receptor (Ozanne et al., 
2000). 
D. Cross-Modulation between AR and Other Signaling Pathways 
 In addition to the basal transcriptional machinery and the various coregulators, 
AR has also been shown to interact with other DNA-binding transcription factors. These 
AR-interacting proteins could be important mediators or effectors of a number of 
intracellular signaling transduction pathways. The transcriptional activity of AR has been 
found to be frequently influenced by a mechanism called cross-modulation, in which 
androgen signaling interplays with different signal cascades induced by either growth 
factors or cytokines (Heinlein and Chang, 2002). AP-1 and NFκB are two of the best 
characterized AR-interacting transcription factors which play key roles in affecting AR 
transcriptional activity (Sato et al., 1997; Palvimo et al., 1996). In addition, AR interacts 
with STAT3 and Smad3, both of which are signal transduction mediators (Matsuda et al., 
2001; Chipuk et al., 2002). AR can also interact with tissue specific transcription factors 
 39
such as SRY and Prostate Derived Ets Factor (PDEF) (Yuan et al., 2001; Oettgen et al., 
2000).   
a) AP-1 and AR Interaction 
The proto-oncoprotein c-Jun heterodimerizes with c-Fos to form the transcription 
factor AP-1. AP-1 regulates transcription through binding to a consensus AP-1 cis-DNA 
sequence. In a search for interacting partners, AR was found to inhibit the protein DNA 
interaction between c-Jun and AP-1 site; however AR itself cannot interact with AP-1 
DNA element. This mechanism was proposed for AR transcriptional inhibition of 
neurotrophin receptor promoter (Kallio et al., 1995).  
Bubulya et al. reported an indirect mechanism by which c-Jun can stimulate 
transcription via AR. In this process, c-Jun was found to support AR-mediated 
transactivation in the absence of its interaction with c-Fos or with AP-1 DNA element 
(Bubulya et al., 1996). They further showed that this positive effect of c-Jun on AR 
transactivation is dose-dependent and maybe through a direct interaction with AR DNA 
binding domain/hinge region. However, c-Jun loses its ability of enhancing AR-mediated 
transactivation when heterodimerized with c-Fos (Bubulya et al., 1996). Thus c-Jun was 
proposed as a mediator for AR-induced transactivation.  
However, in another experiment, the transcription of androgen-regulated PSA 
gene was measured when the AP-1 level in LNCaP cells was elevated by either 12-O-
tetradecanoylphorbol 13-acetate treatment or c-Jun expression vector transfection (Sato et 
al., 1997). It was found that androgen-induced PSA gene expression was inhibited by 
tetradecanoylphorbol 13-acetate without altering nuclear levels of AR protein. Transient 
overexpression of c-Jun and c-Fos also inhibited androgen-induced PSA promoter 
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activity. These observations were proposed to be related with the disruption of AR 
interaction with ARE, which was demonstrated in electrophoretic mobility shift assays 
(EMSA). Such repression was also found to be mutual, since AR-glutathione S-
transferase (GST) proteins inhibited the formation of c-Jun/AP-1 complexes. Co-
immunoprecipitation experiments suggested such mutual repression of DNA binding is 
due to a direct interaction between AR and c-Jun, while the degree of repression may be 
controlled by the ratio of AR to c-Jun (Sato et al., 1997). Using a series of mutant 
proteins, the interaction domains were tracked to the DBD and LBD of AR and the 
leucine zipper region of c-Jun (Sato et al., 1997). However, by using mutated AR proteins 
and transcription assays, Lobaccaro et al. demonstrated that several segments of the AR, 
including the first 188 amino acids of the NTD and the intact LBD of AR are necessary 
to obtain a full transrepression with the AP-1 pathway, while mutations within the DBD 
of AR highly impair this cross talk (Lobaccaro et al., 1999). 
Fronsdal et al. proposed an alternative mechanism, which may explain the mutual 
regulation of AR and AP-1. In this experiment, ectopically expressed CBP can largely 
relieve AP-1-mediated repression of AR activity. CBP can physically interact with both 
NTD and LBD of AR. These results suggested that the transcriptional interference 
between AR and AP-1 could be a result of competition for limiting amounts of CBP in 
the cell (Fronsdal et al., 1998). 
b) NFκB and AR Interaction 
Cross-modulation between AR and NFκB/Rel proteins is another well-
documented model in which distinct signaling pathways affect each other to provide 
opportunities for cell- or tissue-specific responses (Palvimo et al., 1996). Using various 
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androgen-regulated and NFκB-regulated reporter genes in transient transfection assays, 
RelA (p65), a major NFκB member, repressed AR-mediated transactivation in a dose-
dependent manner. However NFκB1 (p50), another major member of the NFκB family, 
did not affect the transactivation. This transcriptional interference between RelA and AR 
is mutual since cotransfected AR also inhibited RelA-mediated transactivation. A weak 
protein-protein interaction was detected between AR and RelA; however this interaction 
did not affect the DNA-binding activities of either protein (Palvimo et al., 1996).  
As mentioned above, CBP is capable of relieving AP-1 mediated transrepression 
of AR activity. A similar mechanism applies to NFκB (Aarnisalo et al., 1998). 
Exogenously transfected CBP was also capable of diminishing the mutual transcriptional 
repression between AR and RelA (Aarnisalo et al., 1998). These observations implied 
that transcriptional interference between AR and AP-1 or NFκB is mediated, at least 
partially, through competition for intracellular CBP protein. CBP may serve as an 
integrator or modulator between AR and other signaling pathways. 
c) STAT3 and AR Interaction 
Signal Transducer and Activator of Transcription 3 (STAT3), combined with 
upstream Janus Kinase (JAK) and downstream Mitogen-Activated Protein Kinase 
(MAPK), is important mediator of cytokine signaling such as the Interleukin 6 (IL-6). IL-
6 is also able to induce AR-mediated gene activation in prostate cancer, and this 
activation requires activated STAT3, which associates with AR in an androgen-
independent but IL-6-dependent manner (Chen et al., 2000). Inhibition of STAT3 results 
in inhibition of AR-mediated gene activation in response to IL-6. These findings revealed 
the importance of activated STAT3 in prostate cancer progression (Lou et al., 2000).  
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Matsuda et al. provided evidence for a direct physical interaction between AR and 
STAT3 (Matsuda et al., 2001). They found that IL-6-induced activation of STAT3 was 
augmented in the presence of dihydrotestosterone (DHT). Reciprocally, phosphorylation 
of STAT3 in response to IL-6 allows STAT3 to interact with AR and enhanced AR 
transcription (Matsuda et al., 2001). These data suggested a model of cross-stimulation 
between two pathways. Later, by using immunoprecipitation and transactivation studies 
in LNCaP cells, Ueda et al. showed a direct interaction between amino acids 234-558 of 
the AR NTD and STAT3, following IL-6 treatment (Ueda et al., 2002). 
However, in another study, IL-6 was found to inhibit DHT-mediated expression 
of PSA gene (Jia et al., 2004). In this study, IL-6 prevented the promoter recruitment an 
AR coactivator, p300, resulting a partially inhibited histone H3 acetylation at the same 
element. Interestingly, the inhibitory effect by IL-6 was partially abrogated by knocking 
down STAT3, suggesting that this inhibition is mediated through STAT3 (Jia et al., 2004). 
These results argue that the resulting effects of the crosstalk between these two pathways 
may be dependent on specific cellular context. 
d) Smad3 and AR Interaction 
As introduced earlier, Tgf-β-induced phosphorylation of Smad3 also results in 
interaction between Smad3 and AR (Kang et al., ; Hayes SA et al., 2001; Chipuk et al., 
2002). The overall effect of AR and Smad3 interaction is cell type-dependent, possibly 
due to the differential availability of other AR and/or Smad3 interacting proteins. For 
example, in prostate cancer cells DU145 and PC3, Smad3 enhances AR transcriptional 
activity, while in CV-1 cells, Smad3 inhibited AR transcriptional activity (Kang et al., 
2002). 
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e) SRY and AR Interaction 
The Sex-determining Region on the Y chromosome (SRY) encodes a testis-
expressed protein essential for male sex determination. Coexpression of AR and SRY 
caused a significant repression in AR transcriptional activity on a number of androgen-
responsive genes, including the human PSA gene (Yuan et al., 2001). Although no SRY-
promoter interaction was identified in this study, mammalian two-hybrid experiments 
demonstrated an AR-SRY interaction, which is mediated through the AR DBD. In vitro 
binding experiments confirmed this interaction as direct protein-protein interaction, and 
further mapped the AR-interacting domain to the SRY high mobility group box DNA 
binding domain (Yuan et al., 2001).  In vivo stable SRY expression inhibited the 
endogenous PSA gene in LNCaP cells. These findings regarding AR-SRY interaction 
suggested a combinatory regulation role of AR and SRY in determining normal male 
reproductive organ development and function.  
f) Ets Factor and AR Interaction 
The Ets transcription factor family comprises more than 20 members that are 
involved in normal development and oncogenesis. Ets factors have conserved DBD of 
around 85 amino acids, named the ETS domain. Schneikert et al. first demonstrated that 
AR negatively regulates matrix metalloproteinase-1 expression not through AP-1 but 
rather through a family of Ets factors (Schneikert et al., 1996). This negative regulation is 
AR-specific and requires AR NTD but not the DNA binding activity of AR (Schneikert et 
al., 1996). However, in a GST pull-down assay, AR interacts physically with a 
representative Ets factor, ERM, and this interaction was not mediated through AR NTD 
but through AR DBD-LBD (Schneikert et al., 1996). This result indicated that the 
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interaction of AR with ERM may allow the apposition of the two proteins to enable AR 
NTD to interfere with ERM transcriptional activity. These results identified a novel 
regulatory pathway in which steroid hormone receptor such as AR negatively regulates 
the expression of matrix metalloproteinases through interacting with Ets factors. 
In addition, AR negatively regulates the expression of maspin gene, a tumor 
suppressor frequently lost in prostate cancer cells. Ets positively regulates maspin gene 
(Zhang et al., 1997). During the progression of cells from normal to cancer status, loss of 
maspin expression is a result from both the absence of positive regulation by the Ets 
element and the presence of negative regulation by AR. This observation provided a 
balancing mechanism between AR and Ets transcriptional regulation (Zhang et al., 1997). 
Recently, Oettgen et al. isolated a novel, prostate epithelium-specific Ets 
transcription factor, named PDEF (Oettgen et al., 2000). Reporter assay demonstrated 
that PDEF acts as an androgen-independent transcriptional activator on the PSA promoter. 
PDEF also directly interacts with the AR DBD and enhances androgen-mediated 
activation of the PSA promoter (Oettgen et al., 2000). It is interesting that Nkx3.1, a 
prostate specific homeobox protein, interacts with PDEF and attenuates PDEF-mediated 
transactivation of PSA promoter (Chen et al., 2002b). These data depicted a multiprotein 
nuclear complex involving several cell-type specific proteins (AR, PDEF and Nkx3.1) 
that participate in transcriptional regulation in prostate cells. Although PDEF was 
identified as a prostate-enriched transcription factor, follow-up studies showed it is also 
overexpressed in human breast cancer cells (Feldman et al., 2003). 
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The Transcriptional Synergy 
 Transcriptional regulation of gene expression involves a synergistic effect from 
the basal transcriptional machinery, proximal sequence-specific activators, cofactors,  
long-range enhancer-promoter interactions, chromatin remodeling complexes, as well as 
the signal transduction cascades. Transcriptional synergy has long been proposed as an 
important mechanism to achieve organism diversity, in addition to two other mechanisms: 
alternative splicing and DNA rearrangement (Levine and Tjian, 2003). Whole-genome 
sequence assemblies have been available for seven different animals, including nematode 
worms, fruitflies, mosquitoes, sea squirts, pufferfish, mice and humans. Computer-
assisted comparative genome analyses indicated that increases in gene number, during 
animal evolution, cannot account for the increased morphological and behavioural 
complexity. Instead, the organism complexity arises from a progressively more elaborate 
regulation of gene expression (Levine and Tjian, 2003).  
Levine et al. has recently pointed out the following: 1) vertebrate genomes have 
only about twice the number of genes that invertebrate genomes have, and the increase is 
primarily due to the duplication of existing genes rather than the invention of new ones; 2) 
the simple nematode worm, Caenorhabditis elegans, contains around 20,000 genes but 
does not have the complex cell types and tissues seen in the fruitfly Drosophila, which 
contains less than 14,000 genes; most strikingly, the human genome contains only around 
30,000 protein-coding genes (Levine and Tjian, 2003). They proposed that a greater 
elaboration of cis-regulatory DNA sequences, and an increased complexity in the 
multiprotein transcription complexes, could be two pervasive mechanisms that lead to the 
observed correlation between gene number and physiological/behavioral complexity 
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(Levine and Tjian, 2003). Thus, genome analysis provided definitive evidence for the 
progressively complicated transcriptional synergy. 
In a complex eukaryote in particular, an organism differentially transcribes 
30,000-50,000 genes in precise spatial and temporal patterns to maintain cell specificity 
as well as to respond dynamically to its environment. The generally accepted concept is 
that cell accomplishes this by employing combinatorily subsets of basal transcription 
factors, ubiquitous DNA binding factors or cofactors, signal-responsive or tissue-specific 
activators or coactivators. A small grouping of these factors could lead to an 
exponentially larger number of regulatory decisions (Brivanlou and Darnell, Jr., 2002).  
For instance, Carey pointed out earlier that a given RNA polymerase II enhancer 
responds to various signal cascades by organizing a unique array of activators in a tightly 
clustered fashion which produces great opportunities for their interaction with the DNA 
and the basal machinery. On the other hand, a given RNA polymerase II transcriptional 
machinery is also designed to respond in a synergistic fashion to multiple activators 
(Carey, 1998). 
The basis for the transcriptional synergy stems from the highly sophisticated cis-
regulatory DNA seen in higher and complex eukaryotes. However, the rapidly expanding 
cofactor and chromatin remodelling complexes might be critical for the integration of 
such complex cis-regulatory information. For example, different enhancers recognize 
different cofactor complexes, while distinct core promoters interact with various TFIID 
complexes. The overall diversification comes from the mixing and matching of these 
complexes, resulting in a huge variety of gene expression patterns (Levine and Tjian, 
2003). 
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The nuclear receptor is a special class of transcription factors. Transcriptional 
synergy applies to the action of members of this family. Combinatorial control of gene 
expression by nuclear receptors was well exemplified by their differential recruitment of 
functionally diverse coregulator complexes as well as their differential interaction with 
various pathways (Fig. 1-3). Indeed, the functional flexibility seen in nuclear receptors is 
largely due to this principle of cooperativity (McKenna and O'Malley, 2002). 
 
Probasin (Pbsn): A Gene Ideal for Studying Prostate-Specific Gene Regulation 
 The rat Probasin gene encodes a prostate basic protein, which is expressed as a 
prostate epithelium-specific and androgen-regulated gene (Kasper and Matusik, 2000).  
The expression of Pbsn was first described in the rat prostate, where the Pbsn protein was 
localized to the nuclei of luminal epithelial cells as well as in the luminal secretions 
(Matuo et al., 1985). Although all the rat prostate lobes express Pbsn, the expression level 
is highest in LP, followed by DP, AP and VP. Analysis of the Pbsn cDNA revealed a 
signal peptide that may account for the secretory nature of this protein. Amino acid 
sequence analysis of Pbsn indicated that this protein belongs to the lipocalin family 
(Spence et al., 1989). The tertiary protein structure of Pbsn suggested it may function as a 
ligand carrier protein (Kasper and Matusik, 2000).  
 Pbsn expression is tightly limited to the prostate epithelium; hence it is one of the 
best markers for prostatic differentiated response. The high prostate specificity of the 
Pbsn promoter has been confirmed in various in vitro and in vivo studies, and has been 
applied to numerous gene targeting and gene therapy studies (Greenberg et al., 1994; Yan 
et al., 1997; Kasper et al., 1998; Zhang ZF et al., 2000; Greenberg et al., 1995; Barrios et 
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al., 1996; Green et al., 1998). The proximal Pbsn promoter encompassing the element of 
−426/+28 bp has been shown to target a reporter gene specifically in prostate cell lines, 
with very low levels of reporter gene expression observed in the non-prostate cell lines 
(Yan et al., 1997). In vivo, either a 12-kb large Pbsn promoter or a 500 bp small promoter 
have been successfully used to target reporter genes or oncogenes into the transgenic 
mouse prostate (Kasper et al., 1998; Greenberg et al., 1995).  
 The Pbsn gene is androgen-regulated. Expression of the Pbsn gene is initiated 
around the third postnatal week, during which the serum androgen levels increase. 
Castration of adult animals led to a drastic reduction in Pbsn mRNA to nearly 
undetectable levels, while androgen replacement restored Pbsn expression (Kasper and 
Matusik, 2000).  
DNase I protection assays identified two AREs located in the proximal Pbsn 
promoter (Rennie et al., 1993). The first ARE at -236/-223 bp was named as androgen 
receptor binding site-1 (ARBS-1). The second ARE at -140/-117 bp was named as 
ARBS-2. In vitro binding assay determined that ARBS-2 is a strong ARE with higher 
affinity to AR than ARBS-1. However, both sites are occupied even when AR is at very 
low levels, and both sites are required for the full androgen-responsive promoter activity. 
Mutation of either ARE significantly reduced androgen inductivity >95% of Pbsn 
promoter, further suggesting that two ARE function in a cooperative fashion (Rennie et 
al., 1993). Thus, the region (-244/-96 bp) that encompasses the two ARBSs and is 
required for full androgen-induction of Pbsn expression was designated as androgen 
responsive region (ARR) (Kasper et al., 1999). Later, improved dimethyl sulfate (DMS) 
methylation protection assays revealed two additional AR binding sites (G1 and G2) with  
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atypical half-site sequences located at ( 209/ 196 bp) and ( 107/ 93 bp) (Reid et al., 
2001). Reid et al. further illustrated that ARBS-1 and ARBS-2 belongs to class-1 ARE 
which displays conventional guanine contacts; G1 and G2 belong to class-2 ARE which 
shows atypical sequence features. The binding of AR to class-2 ARE can dramatically 
alter the allosteric interactions between the receptor and adjacent DNA, stabilizing AR 
binding to adjacent class-1 sites and resulting in synergistic transcriptional activity and 
increased hormone sensitivity (Reid et al., 2001). 
Recently, by testing a series of truncated Pbsn promoter fragments, Zhang et al 
identified two more nonconventional ARBSs, named ARBS-3 and ARBS-4, within -
705/-426 bp of Pbsn (Zhang ZF et al., 2004a). Functional analysis of these individual 
ARE supported use of the Pbsn promoter as a model, in which six ARBSs function in a 
cooperative manner for maximum androgen-regulated prostate-specific gene transcription 
(Zhang ZF et al., 2004a).  
 An artificial Pbsn promoter ARR2PB, which contains an extra copy of ARR (-
244/-96 bp) fused in front of the -286/+28 bp proximal promoter, targeted high levels of 
reporter genes into both prostate cell lines and transgenic mouse prostate. Interestingly, 
this artificial Pbsn promoter has striking similarity in the organization of the AREs as the 
natural Pbsn promoter. This version of Pbsn construct has been widely used by many 
research groups for in vitro or in vivo prostatic targeting (Zhang ZF et al., 2004b). Further 
analysis using transgenic mice delimited the prostate specific control region to ARR, a 
147 bp DNA fragment, which contains sufficient cis-regulatory information for directing 
prostate expression (Zhang ZF et al., 2004b). 
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Hypothesis 
Androgen signaling is essential but not sufficient for prostate-specific gene (e.g. 
Pbsn, PSA) expression, since AR is expressed in other tissues (e.g. seminal vesicle, 
muscle, mammary gland), and AREs are also contained in non-prostatic gene promoters. 
When the Pbsn promoter sequences between the two ABRSs were replaced with a 
random DNA element with the same size, all promoter activity was abolished although 
AR still bound to ARBSs. This observation suggested that non-AR transcription factors 
play crucial roles in Pbsn gene regulation (Kasper et al., 1999). Thus, additional cis-
regulatory information as well as other key signaling pathways is required to direct this 
prostatic differentiated function. Five key cis-acting elements were identified within -
286/+28 bp using linker scan mutagenesis and reporter assays in cell culture. Two of 
these elements, named as tissue specific-1 (TS-1) and tissue specific-2 (TS-2), when 
mutated, reduced promoter bioactivity only in prostatic cell lines but not in non-prostatic 
cell lines. In contrast, the other three elements, when mutated, reduced bioactivity in all 
the cell lines (Zhang et al unpublished). TS-1 and TS-2 are tightly adjacent to an 
individual ARBS site and the core region of each is almost identical. In transgenic mice, 
mutation of TS1 reduced expression of a linked reporter gene, but the expression was still 
prostate specific; mutation of TS2 abolished all reporter activity in all transgenic lines 
(Zhang ZF et al., 2004b). The hypothesis is that the transcription factors bound to these 
key cis-acting elements are essential for prostatic differentiated response, and therefore 
may be relevant for prostatic organogenesis; a cluster of nuclear proteins bound within 
this region involves prostate-specific regulation via transcriptional synergy by responding 
to various signaling pathways and integrating diverse cellular information.   
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Figure 1-1. Perinatal urethra and associated reproductive organs. (A) P0 male rat 
urogenital tract: DP, dorsal prostate; DLP, dorsolateral prostate; AP, anterior prostate; VP, 
ventral prostate; UR, urethra; VD, vas deferens; BL, bladder. (B) Diagram of A. (C) P0 
female urogenital tract: VMP, ventral mesenchymal pad; Vg, vagina; Cx, cervix; Ut, 
uterus. (D) Diagram of C. Scale bar: 1 mm. Adapted from (Thomson et al., 2002) 
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Figure  1-2. Molecular aspects of prostatic branching morphogenesis. The diagram 
shows that reciprocal signaling between prostatic epithelium and mesenchyme is essential 
for the development and morphogenesis of the gland. Ductal canalization occurs from 
proximal to distal in the solid epithelial cords. This process is accompanied by epithelial 
and mesenchymal cell differentiation. This complex genetic network involves androgen 
signaling pathway, Shh signaling and mesenchymal paracrine signaling molecules such 
as the FGFs and the BMPs. Adapted from (Marker et al., 2003). 
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Figure 1-3. Cross talk of androgen-AR signaling with various signal transduction 
pathways. The combinatorial control of gene expression by AR and coregulators involve 
interactions among diverse signaling cues (Tgf-β/Smad3, Wnt/β-catenin, STAT3 and 
MAPK) at different molecular levels. The overall effect may lead to a dynamic and 
context-dependent expression of specific genes (see text for details). Diagram is adapted 
from (Heinlein and Chang, 2002). 
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CHAPTER II 
 
MATERIALS AND METHEDS 
 
Reporter Plasmids and Expression Vectors 
A. Luciferase Reporter Plasmids 
ARR2PBLuc reporter (where ARR is the androgen response region) contains an 
additional androgen response region (-244 to -96 bp) fused upstream of the -286/+28bp 
Pbsn promoter to enhance the androgen response (Zhang ZF et al., 2000).  
A 621-bp fragment of PSA minimal promoter (-610 to +11 nt) was amplified by 
PCR and cloned at the SmaI and XhoI sites of pGL3-basic luciferase vector (Promega), 
then an 823-bp upstream enhancer fragment (-4758 to -3935 bp) containing the -4.1/-3.9 
kb PSA core enhancer region was obtained by PCR and inserted upstream of the PSA 
promoter at SacI and SmaI sites, resulting in PSA-EPLuc reporter construct (EP stands 
for enhancer/promoter).  
For promoter mutagenesis studies, three mutant Pbsn promoter fragments and two 
mutant PSA enhancer fragments were generated using PCR-based site-directed 
mutagenesis. All mutant and wild type fragments were cloned into pGL3-basic vector. 
The primers used for PCR are listed in Table 2-1.  
B. Expression Vectors 
Mammalian HNF-3α expression vector pRB-HNF-3α (Jackson et al., 1993) was 
kindly provided by Dr. Kenneth S. Zaret (Fox Chase Cancer Center, Philadelphia, PA). 
Full-length wild type HNF-3α cDNA and eight cDNAs encoding differently truncated 
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HNF-3α fragments were PCR amplified and directionally cloned into 
pcDNA3.1D/V5/His-TOPO expression vector (Invitrogen, K4900) in frame with the 
carboxy-terminal V5 epitope and 6×His tag. The resulting expression vectors are pHNF-
3α-WT1-466, pHNF-3α-∆NT141-466, pHNF-3α-FH141-294, pHNF-3α-∆CT1-294, pHNF-3α-
∆231-385, pHNF-3α-∆31-420, pHNF-3α-NT1-180, pHNF-3α-CT295-466, and pHNF-3α-DN59-
345. The pcDNA3.1D/V5/His/lacZ is an expression control vector included in the 
pcDNA3.1 Directional TOPO Expression Kit.  
The rat AR expression vector (Zhang ZF et al., 2000), GST-ARNT/DBD, GST-
ARDBD and GST-ARDBD/LBD vectors (Snoek et al., 1996) have been described previously. 
GST-ARNT was amplified by PCR and cloned into pRC/CMV (Invitrogen) as a BamHI 
fragment and subcloned into the BamH1 site of pGEX-3X vector (Pharmacia) in frame 
with the GST fusion. GST-AR LBD was cloned using pCMV/AR6 as the template (Snoek 
et al., 1996), and the PCR product was digested with BamHI and cloned into the BamHI 
site of pGEX-3X vector. All reporter and expression constructs were confirmed by 
sequencing. 
For synthesis of specific Foxa1 and Foxa2 in situ probes, specific fragments for 
Foxa1 (270bp) and Foxa2 (200bp) were RT-PCR amplified, using primer sets: Foxa1-f, 
GGCCTGGGCTCTATGAACTC and Foxa1-r, GCCGTTCATGGAGGTGAC; Foxa2-f, 
CCCATTCCAGCGCTTCTC and Foxa2-r, GTAATGGTGCTCGGGCTTC. PCR 
fragments were cloned into pCR2.1-TOPO vector (Invitrogen). 
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Cell Culture and Transfection Assays 
The human prostate carcinoma cell lines DU145, LNCaP and PC-3; the human 
cervical adenocarcinoma cell line Hela; the human hepatocellular carcinoma cell line 
HepG2 were obtained from American Type Culture Collection (Manassas, VA). All cell 
lines were cultured as recommended by American Type Culture Collection, except for 
PC-3 cells which were maintained in RPMI medium, 10% FBS and 250 nM 
dexamethasone. The AR-Hela cells expressing stably integrated flag-tagged full-length 
AR were acquired from Dr. Michael Carey (UCLA School of Medicine, Los Angeles, 
CA) (Huang et al., 1999).  
Transient transfection assays were performed using lipofectin reagent (4µl/well) 
for LNCaP cells and lipofectamine 2000 for other cell lines. The pRL-CMV containing 
the Renilla luciferase reportor gene (Promega, Madison, WI) was used to optimize 
transfection efficiencies for each cell line. Optimal volumes of liposome and transfection 
durations were obtained and used to get highest transfection efficiencies. Briefly, cells 
were seeded at an initial density of 8-10 × 104 /well in 24-well plates one day before 
transfection. The following morning, cells were transfected with plasmid DNA and 
lipofectin or lipofectamine 2000 in Opti-MEM I Reduced Serum Medium (Gibco, 31985). 
In transfection experiments where AR expression was required, 0.2 µg of rat AR 
expression vector was transfected for each well. The total amount of plasmid DNA was 
normalized to 0.8-1 µg /well by the addition of pVZ-1 plasmid. In addition, all samples 
received 12.5 ng /well of pRL-CMV reporter plasmid. After 4-6 h of transfection, the 
medium was replaced by Minimum Essential Medium (Gibco, 11090) with 5% 
Charcoal/Dextran Treated Fetal Bovine Serum (HyClone, Logan, Utah) in the presence 
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or absence of 10-8 M of R1881 or DHT. Cells were harvested and lysed with 80-µl 
passive lysis buffers after 24 h of incubation.  
 
Luciferase Reporter Assay 
The luciferase activity was determined using the dual luciferase reporter assay 
system (Promega, E1960) and LUMIstar (BMG lab Technologies, INC., Durham, NC).  
Background activity of the cell lysate with no DNA transfecton was subtracted from the 
activities obtained from experimental group. All values were normalized by Renilla 
activity to correct for the transfection efficiency. Results are presented as relative 
luciferase activities. Each experiment was at least repeated three separate times in 
triplicate. In promoter mutagenesis experiments, mean normalized values from samples 
showing the highest inhibition of promoter activity were compared with those from 
samples transfected with the wild type promoter by using Student’s paired t test.  
 
Nuclear Extract Preparation 
  A minimum of 109 cells was used for a single nuclear extraction experiment. Cell 
pellet volume (CPV) was measured, and pellet was washed with 5×CPV volume of cold 
PBS, and centrifuged for 5 min at 2000 rpm (HS-4 rotor) at 4 C. Cells were resuspended 
in 2×CPV volume of Buffer A [10mM HEPES (pH 7.9), 1.5mM MgCl2, 10mM NaCl, 
1mM DTT, Protease Inhibitor]. Cells were broken with 10 strokes using pestle “A” 
(loose), spin 15 min at 3000 rpm (HB-6 rotor). Supernant was decanted and spun 20 min 
at 25,000 g (HB-6 rotor at 12,500 rpm). Pellets were resuspended with Buffer C [20mM 
HEPES (pH 7.9), 1.5mM MgCl2, 420mM NaCl, 25% (v/v) glycerol, 0.2mM EDTA, 
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1mM PMSF, 1mM DTT, Protease Inhibitor) in 2×CPV volume/109 cell. Nuclei was 
broken with 10 strokes using pestle B (tight), and mixed end-over-end on a rotator for 30 
min at 4 C. Spin 30 min at 25,000 g. Supernatant was then collected. Dialysis tube 
(6,000-8,000D, cut-off) was heated in H2O until boiling. Supernatant was dialyzed in 50 
volume of Buffer D [20mM HEPES (pH 7.9), 100mM NaCl, 20% (v/v) glycerol, 0.2mM 
EDTA , 1mM PMSF, 1mM DTT, Protease Inhibitor] for 2 hours per change of buffer, 
with total of 3 changes. After last dialysis, samples were spun for 25,000 g for 15 min. 
Supernatant, the nuclear extract, was stored at -80 C. Pellets were discarded. 
 
Electrophoretic Mobility Shift Assays (EMSA) 
Nuclear extract for PC-3 cells was prepared as described above. Nuclear extract 
for LNCaP cells was purchased from Geneka Biotechnology Inc., Montreal, Canada. 
Recombinant wild type and truncated HNF-3α proteins were synthesized in vitro using 
the TnT T7 Quick Coupled Transcription/Translation System, (Promega, L1170). GST-
AR fusion proteins were purified as described previously (Snoek et al., 1996). All nuclear 
extracts and purified proteins were stored in buffers containing 1× concentration of 
Complete protease inhibitor cocktail (Roche Molecular Biochemicals). All 
oligonucleotides for EMSA were synthesized by Integrated DNA Technologies, Inc., 
Coralville, IA. After annealing the sense and antisense strands, the double-stranded DNA 
probes were end-labeled with T4 polynucleotide kinase (New England Biolab), [γ-32P] 
ATP and purified with a 15% Polyacrylamide Gel Electrophoresis (PAGE), eluted with 
elution buffer [10mM Tris.HCl (pH 7.5), 1mM EDTA (pH 8.0), 50mM NaCl, 0.3M 
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NaAc, 0.5% SDS], and sequentially washed with >3 volumes of 95% ethanol and 500 ul 
100% ethanol. Probes were dissolved in nuclease-free water and stored in -20 C  
A typical binding reaction involved a 10-min preincubation with 10 µg of nuclear 
extract, 1 µg of the non-specific competitor poly (dI-dC) and buffer D (20 mM Hepes-
NaOH, pH 7.9; 100 mM NaCl; 0.2 mM EDTA; 1.5 mM MgCl2; 1 mM dithiothreitol; 
20% glycerol; and 1 mM PMSF), followed by a 15 min incubation with 200,000 cpm of 
radiolabeled probe on ice in a total volume of 20 µl.  
In oligonucleotide competitions, 200-600 fold molar excess of cold, double-
stranded oligonucleotide was added to the preincubation mix. In experiments where in 
vitro synthesized HNF-3α proteins were used, 1-5 µl out of 50 µl products from the TnT 
reaction system were added to the preincubation mix.  
In supershift analyses, antibodies were added after the binding reaction and 
incubated for an additional 20 min on ice prior to electrophoresis. All supershift 
antibodies were purchased from Santa Cruz Biotechnology, Inc. (AR, C-19: sc-815X; AR, 
N-20: sc-816X; HNF-3α, C-20: sc-6553X; HNF-3β, M-20: sc-6554X; HNF3-γ, N-19: sc-
5361X; p-c-Jun: sc-822X; c-Fos: sc-447X; NF-1, H-300: sc-5567X; Oct-1: sc-8024X). 
The concentration of antibody in each EMSA reaction was 0.2 µg/µl.  
Complexes were resolved by electrophoresis for 2.5-h at 160 V on a 5% native 
polyacrylamide gel, which was later fixed in fixation buffer (10% methanol, 10% acetic 
acid) for 20 min, dried for 3.5-h, and processed for autoradiography. 
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SDS-PAGE Fractionation of Nuclear Extract Proteins for EMSA 
 Thirty µg of LNCaP nuclear extract was combined with appropriate volume of 
4×NuPAGE LDS sample buffer and denatured by incubating at 65 C for 10 min. 
Denatured samples were run on a 10% NuPAGE gel along with molecular marker. 
Proteins were transferred to PVDF membrane (Invitrogen) in a transfer buffer without 
methanol. Membrane lane with nuclear extract protein was cut into 2-3 mm slices and the 
migration distance of molecular marker was recorded for migration curve calculation. 
Each slice of membrane was placed into a 1.5 mL tube with 50 µL 1×EMSA binding 
buffer containing 1% Triton and 0.1 mg/mL BSA (final concentrations). Binding reaction 
was performed in tubes on a shaker at 4 C for 4 hr with shaking. Samples were stored at -
70 C for future usage. Use 10-20 µL of each of the eluted protein fractions for EMSA 
assay. 
 
Southwestern Analysis 
 An oligonucleotide containing two tandem copies of wild type –124/-109bp 
(2×R2: 5’-ACCTATTTGTATACTAACCTATTTGTATACTAGATGACA-3’), and 
another oligonucleotide containing two mutant sites (2×mR2: 5’-
ACCTAGAAGTATACTAACCTAGAAGTATACTAGATGACA-3’) were radiolabeled 
by extension of an annealed 10-bp primer, 5’-TGTCATCTAG-3’. (Underscored letters 
represent the nucleotide replacements in the wild type TATTTGTAT motif.) The primed 
oligonucleotide probes were radiolabeled with the Klenow fragment of Escherichia coli 
DNA polymerase, dNTPs, [α-32P] dATP, and [α-32P] dTTP. An oligonucleotide 
containing two copies of consensus androgen receptor binding site (see Table 2-1) was 
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radiolabeled in the same condition and used for a positive control. Nuclear extracts (30 
µg) of PC-3 and LNCaP cells were heated at 70 °C for 10 min in 1 × LDS loading buffer 
(Invitrogen), resolved on 4% stacking, 12% resolving SDS-polyacrylamide gel, and 
eletrophoretically transferred to nitrocellulose membranes (Bio-Rad). Membranes were 
soaked in PBS for 15 min, blocked for 4 hr at room temperature with buffer A (20 mM 
Hepes-NaOH, pH 7.8, 50 mM NaCl, 12.5 mg/ml skim milk, 2.5 mg/ml bovine serum 
albumin, 200 µg /ml native salmon sperm DNA, 5 µg /ml poly dI-dC, and 50 ng/ml single 
stranded DNA), and incubated overnight at room temperature in 2.5 ml of buffer A plus ≥ 
107 cpm of radiolabeled probe. Membranes were washed three times for 15 min each at 
room temperature in a washing buffer containing 20 mM Hepes-NaOH, 50 mM NaCl, 1 
mg/ml of skim milk, and 0.025% Nonidet P-40. Membranes were dried completely in air 
at room temperature, prior to autoradiography. 
 
Chromatin Immunoprecipitation (ChIP) 
The procedure and PCR primers used in ChIP assay have been reported 
previously (Shang et al., 2002). LNCaP cells were initially grown in RPMI-medium 1640 
with 5% Charcoal/Dextran Treated Fetal Bovine Serum (HyClone, Logan, Utah). After 3 
days of cultivation, cells were either treated with 10-8 M DHT or allowed to grow in the 
androgen-depleted medium. After 48 h of treatment, cells were washed with PBS and 
cross-linked with 1% formaldehyde at 37°C for 10 min. Cells were scraped into conical 
tube, pelleted for 4 min at 2000 rpm at 4°C, resuspended in SDS lysis buffer (1% SDS, 
10mM EDTA, 50mM Tris-HCl, pH 8.1, 1 × proteinase inhibitor cocktail) for 200 µl per 
106 cells, and sonicated with 4-5 sets of 10-second pulses at an 80% maximum power 
 62
(Fisher Sonic Dismembrator, Model 50). After centrifugation for 10 min, supernatants 
were collected and diluted 1:10 in chip dilution buffer (0.01% SDS, 1.1% Triton X-100, 
1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8.1, 167 mM NaCl), followed by pre-clearing for 
30 min with 3 µg of sonicated salmon sperm DNA with protein A agarose (80 µl. of 50% 
slurry in 10 mM Tris-HCl, 1 mM EDTA). Immunoprecipitation was performed overnight 
at 4°C with specific antibodies. Protein A agarose (60 µl) with salmon sperm DNA was 
added for 1 h with rotation to collect the complex. Beads were sequentially washed for 5 
min each with low salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM 
Tris-HCl, 150 mM NaCl), high salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM 
EDTA, 20 mM Tris-HCl, 500 mM NaCl), LiCl wash buffer (0.25 M LiCl, 1% NP40, 1% 
deoxycholate, 1 mM EDTA, 10 mM Tris-HCl) and twice with TE buffer (10 mM Tris-
HCl, 1 mM EDTA). Complex was eluted twice with 250 µl of elution buffer (1% SDS, 
0.1 M NaHCO3) and eluates were pooled. The formaldehyde crosslinking was reversed 
by adding 20 µl 5 M NaCl and incubating for 6-8 h at 65°C. Eluates were incubated for 
another 1 h at 45°C with 2 µl of 10 mg/ml Proteinase K. DNA was extracted by using 
QIAquick Spin Column (Qiagen) and 3-5 µl of DNA extraction was used in PCR 
amplification.  
 
Western Blot Analysis 
Cell pellets and freshly dissected mouse tissues were collected, sonicated and 
centrifuged in cold RIPA buffer (1×PBS, pH 7.4, 1% Nonidet P-40, 0.5% Sodium 
deoxycholate, 0.1% SDS, 1 mM PMSF and 1 × concentration of complete protease 
inhibitor cocktail). Following the transfer to polyvinylidene fluoride (PVDF) membrane 
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(Invitrogen), membranes were blocked in Tris-buffered saline containing 0.1% Tween-20 
(TBS-T) and 5% skim milk, and incubated with primary antibody (1:1000 dilution: anti-
HNF-3α, anti-HNF-3β, anti-HNF-3γ, anti-AR, anti-PSA and anti-flag) for 1 hr with 
shaking at room temperature. Anti-flag M2 monoclonal antibody was purchased from 
Sigma (F3165). In cases where anti-V5-HRP antibody (Invitrogen, R96125) was used to 
detect the recombinant V5-tagged HNF-3α proteins, a dilution of 1:5000 was used 
according to the protocol by manufacturer. The signal was visualized by enhanced 
chemiluminescence (ECL) assay (Amersham Pharmacia Biotech). 
 
Co-Immunoprecipitation (Co-IP) Analysis 
DHT-treated or untreated LNCaP cells (0.5-1×107) were washed 3 times with cold 
PBS and lysed with 1 ml of non-denaturing lysis buffer (50 mM Tris, 150 mM NaCl, 10 
mM EDTA, 0.02% NaN3, 50 mM NaF, 1 mM Na3VO4, 1% NP-40, 1 mM PMSF, 0.5 
mM DTT and 1× concentration of complete protease inhibitor cocktail). Following 
sonication and centrifugation, 1 mg of total cell lysate for each reaction was incubated at 
4 °C for 3 hr with 20 µl (dry volume) protein G-Sepharose beads (Amersham), which 
were conjugated with 1 µg experimental antibody or mock antibody. Bovine serum 
albumin (1 mg) was added to quench the non-specific binding. Immunoprecipitations 
were performed in the presence of ethidium bromide (0-100 µg/ml as indicated in the 
results) to disrupt DNA-protein interaction (Lai and Herr, 1992). Beads were washed four 
times with lysis buffer and once with PBS for 5 min each with rotation, which was 
followed by Western blot. The anti-AR (441) mouse monoclonal IgG (Santa Cruz, sc-
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7305) was used for immunoprecipitate AR, and the anti-HNF-3α (C-20) goat polyclonal 
IgG (Santa Cruz, sc-6553) was used to immunoprecipitate HNF-3α.  
For Co-IP experiments in AR-Hela cells, cells were maintained in medium with 
DHT and transfected with V5-tagged HNF-3α or LacZ expression vectors. Anti-Flag M2 
affinity gel (Sigma) was used to immunoprecipitate the flag-tagged AR, according to the 
protocol provided in the Flag Tagged Protein Immunoprecipitation Kit (Sigma, 
FLAGIPT-1). Complexes were washed with buffers and procedures described for LNCaP 
cells. Western blot was performed with anti-V5 HRP-conjugated antibody. 
 
In Vitro Transcription and Translation (TnT) of HNF-3α and Mutant Proteins 
Wild type HNF-3α and a series of truncated mutant HNF-3α expression vectors, 
with a T7 promoter, were transcribed and translated in vitro using the TnT T7 Quick 
Coupled Transcription/Translation System (Promega, L1170). A standard reaction 
involved a 90-min incubation at 30°C with 40 µl of TnT Quick Master, 2 µl of cold 
2 mM methionine, and 2 µg of plasmid DNA in a final volume of 50 µl. A LacZ 
expression vector was translated using the same conditions as a control. In vitro 
translated recombinant HNF-3α and LacZ proteins were labeled with a C-terminal V5-
epitope and were used immediately for in vitro binding reactions, or for EMSA. 
 
Purification of GST-AR Fusion Proteins 
GST-AR fusion proteins were purified as described previously (Snoek et al., 
1996). Five mLs of overnight cultures of pGEX-3X-AR plasmids in LB/ampicillin were 
added into 200 mLs LB/ampicillin in the next morning. Cultures were grown at 37°C 
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until OD600=0.6 (approximately 2 hrs), then protein expression was induced with 
0.1mM IPTG (20uL of 1M IPTG stock). Bacteria (JM109) were allowed to grow at 30°C 
with shaking for 2 hrs. Cultures were centrifuged at 8000 rpm for 10 min at 4°C. Cell 
were resuspended in 2mL Lysis buffer (PBS, protease inhibitors, 100 ug/mL lysozyme) 
and transfered to 15mL falcon tube. Cells were placed on ice for 30 min, and sonicated at 
maximum setting for 10 seconds then placed on ice for 10 seconds. Sonication was 
repeated for 5-6 times until solution turns clear. Solutions were aliquoted into 1.5mL 
tubes and centrifuged at 13,000rpm for 30 min at 4°C to pellet out the cellular debris. 
Supernatants were combined from each tube in a 15mL falcon tube that has preswelled 
glutathione-agarose beads. Incubation was performed with end-over-end rotation for 1hr 
at 4°C, and then tubes were centrifuged at 2000rpm for 15 seconds at 4°C. Beads were 
washed with ice cold PBS (with 1× protease inhibitor) for 4 times. Beads were then 
resuspended in 10mL PBS with protease inhibitors and stored at 4°C for 2 weeks.  
To elute the GST-proteins, beads were centrifuged at 2000rpm for 15sec at 4°C 
and supernatants were removed.  One mL of elution buffer (20mM HEPES, pH7.6, 
150mM KCl, 5mM MgCl2, 1mM EDTA, 0.05% NP-40, protease inhibitor, 0.046g 
glutathione) was added and incubation was performed at room temperature with rotation 
for 15 min. Elute was collected after centrifugation at 2000 rpm for 15 seconds (fraction 
#1). Elution was repeated for 2 times and fractions #2 and #3 were collected. After 
determination of protein concentration, proteins were resolved run a SDS-PAGE 
followed by Commassie Blue staining to check protein quality. 
To pre-swell the glutathione-agarose beads (Sigma #G-4501), 0.08g beads were 
measured out for each GST fusion protein. 14mL of ice cold PBS was added to the beads 
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and swelling was performed for at least 1 hr on ice. Beads were centrifuged at 2000rpm 
for 15 seconds and washed with PBS. Supernatant was removed before adding the GST-
protein lysate. 
 
GST-Pull Down Assays 
For GST-pull down assays, 50 µl swelled glutathione agarose beads (Sigma G-
4510) were incubated with 20 µg GST or GST-AR fusion proteins for each reaction. 
GST-bound beads were equilibrated with PBS-T binding buffer (1×PBS, pH 7.4, 1% 
Tween-20, and protease inhibitors) and incubated for 2 h at 4°C with 5-10 µl products 
from the TnT reactions. Complexes were washed four times with 1.5 ml of cold binding 
buffer, heated for 10 min at 70°C in 1×LDS loading buffer, and separated by SDS-PAGE. 
Then, V5-HRP antibody was used in a standard Western blot to detect proteins that 
interact with AR in vitro. 
 
Transgenic Mice, Genotyping and Renal Capsule Organ Rescue 
Foxa1 loss-of-function mutant mice were generated as previously described, and 
the mice were obtained from Dr. Markus Stoffel lab in Rockfeller University (Shih et al., 
1999). Newborn pups were sacrificed after birth. The entire prostatic rudiments with 
partial bladder, urethra and both seminal vesicles from 55 male mice were grafted 
underneath of the renal capsules of adult male nude mouse hosts. Meanwhile, PCR 
genotyping of the remained carcass was performed using primers specific for wild type 
allele: F, 5'-GGCCTGAGTCCCGGTGCTGTG-3' and R, 5'-
AGGCGGCTTGGCGTGAGGGTAG-3' (product size 250-bp); for mutant (3αa-Lacz) 
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allele: F, 5'-ATGACCACGAGCGGCAACATG-3' and R, 5'-
GGTTACGTTGGTGTAGATGGG-3' (product size 350-bp). PCR conditions were:  1) 
94°C 5min, 2) 94°C 30sec, 65°C 30sec, 72°C 30sec for 35cycles, 3) 72°C 10min. 
Prostate tissues were recovered from host kidneys after 4, 8 and 12 weeks, and 
genotypes were re-confirmed by using PCR, Foxa1 immunohistochemistry or β-
galactosidase staining.  
 
Tissue Recombination 
In tissue recombination experiments, E18 rat UGM was used as embryonic 
inductive mesenchyme and prepared as described (Cunha and Donjacour, 1987). Bladder 
epithelial (BLE) tissue fragments were separated from bladder stroma with the treatment 
of 20mM EDTA for ~30 min at 37°C (Cunha and Donjacour, 1987), pooled by genotype 
and recombined with rUGM. The bladder epithelial cells were separated from a total of 
89 newborn mice. The resulting recombinants (BLE+rUGM) were grafted underneath the 
renal capsules of male nude mice in triplicates for each time points (4 weeks and 12 
weeks) 
For tissue recombination using prostate epithelium (PrE), recombinants 
(PrE+rUGM) were grafted into adult male nude mouse hosts for 2, 4, or 12 weeks. For 
each time point, recombinants were grafted in triplicate for individual genotypes. 
 
Histology Analysis 
Hematoxylin and Eosin (H&E) staining was performed on 10% formalin-fixed 
paraffin-embedded 5 um sections as following: 1) Histoclear 5 min, 2) Histoclear 5 min, 
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3) 100% ethanol 3 min, 4) 95% ethanol 3 min 5) 95% ethanol 3 min, 6) 75% ethanol 10 
dips, 7) 70% ethanol 10 dips, 8) 50% ethanol 10 dips, 9) washing in running distilled 
water, 10) Hematoxylin 5 min, 11) washing in running distilled water, 12) 1% acid 
alcohol 2-3 dips, 13) washing in running distilled water, 14) 0.3% ammonia water 10 dips, 
15) wash in running distilled water, 16) 70% ethanol 10 dips, 17) Eosin 2 min, 18) 70% 
ethanol 20 dips, 19) 70% ethanol 20 dips, 20) 95% ethanol 10 dips, 21) 95% ethanol 10 
dips, 22) 100% ethanol 20 dips, 23) 100% ethanol 20 dips, 24) Histoclear 20 dips, 
25)Histoclear 20 dips, 26) Histoclear 20 dips, 27) mount. 
For PAS staining, paraffin-embedded sections were deparaffinized, oxidized in 
periodic acid solution for 5 min, rinsed in H2O, and placed in Schiff’s reagent for 15 min. 
Sections were then rinsed in running water for 10 min and counterstained with 
hematoxylin.  
 
β-Galactosidase Staining 
Fresh tissues were prefixed for 6 hr in 2% paraformaldehyde, 0.2% 
glutaraldehyde in PBS at 4°C, and embedded in OCT. Frozen sections were cut and 
immersed in the same paraformaldehyde/glutaraldehyde solution for 10 min at 4°C, then 
rinsed in water for 1 min. After one more rinse with PBS, β-galactosidase staining 
solution (Roche) was applied to sections and incubated at 37°C for 1-6 hr. Reactions 
were stopped, before non-specific staining was detected in wild type prostate tissues, with 
2 times of rinse in deionized water.   
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Electron Microscopy 
Upon dissection, fresh prostate tissues with different genotypes were fixed in 2% 
glutaraldehyde in 0.1M cacodylate buffer at 4°C overnight. The specimens were 
dehydrated in alcohol and polymerized. 1µm sections were cut and stained with toluidine 
blue. Seventy nanometer sections were then cut on a Leica Ultracut UCT ultramicrotome 
and ultrastructural analysis was performed on Phillips CM-12 Transmission Electron 
Microscope equipped with AMT digital camera system.  
 
Immunohischemical and Immunofluorescent Analysis 
 Urogenital sinus and individual prostatic lobes were dissected and fixed in 10% 
buffered formalin for 24 hr, processed and embedded in paraffin. Immunohistochemical 
and immunofluorescent staining was performed on 5 mm-thick sections, which were 
deparaffinized, rehydrated through a graded alcohol series, and washed in H2O for 5 min. 
Tissue sections were placed in antigen retrieval solution (Vector Laboratories, 
Burlingame) and antigen retrieval was performed by microwaving the sections for 20 min 
at boiling on 30% power in a 900 W microwave oven. Slides were cooled for 1 hr at 
room temperature in the antigen retrieval solution and then washed twice for 5 min in 
PBS, pH 7.4.  
For immunohistochemistry, all incubations were carried out at room temperature 
unless otherwise stated. Endogenous peroxidase activity was blocked with DAKO1 
Peroxidase Blocking Reagent (DAKO Corp., Carpinteria) for 15 min and sections were 
washed in PBS for 5 min. Immunohistochemistry was performed using the 
Vectastain1Elite ABC peroxidase kit (Vector Laboratories) according to the 
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manufacturer’s protocol. Briefly, non-specific antibody binding was minimized by 
incubating sections for 20 min in diluted normal blocking serum. Sections were incubated 
overnight at 48°C  in a humidified chamber with specific primary antibodies, diluted in 
PBS. Following overnight incubation, the slides were washed in PBS for 5 min. Sections 
were then incubated for 30 min with biotinylated secondary antibody solution diluted in 
PBS, followed by Vectastain Elite ABC Reagent diluted in PBS for 30 min. Between 
incubations, sections were washed for 5 min in PBS. Visualization of immunoreactivity 
was achieved by incubating sections in either DAKO Liquid DAB Substrate-Chromogen 
System (DAKO Corp.) for 2–4 min or the DAB peroxidase substrate kit (Vector 
Laboratories) for 10 min. The sections were washed in double distilled H2O, 
counterstained with hematoxylin, dehydrated, and coverslipped.  
Primary antibodies used in immunohistochemistry at the indicated concentrations 
were AR (rabbit, 1:1000; Santa Cruz, sc-816), CK5 (rabbit, 1:500; Covance Research 
Products, PRB-160P), CK14 [mouse, LL001, 1:10 (Wang et al., 2001); gift from Dr. E. 
Birgitte Lane, University of Dundee], CK8 [mouse, LE41, 1:10 (Wang et al., 2001); gift 
from Dr. E. Birgitte Lane], CK-Pan (rabbit, 1:1000; DAKO, Z0622), alpha-actin (mouse, 
1:1500; Sigma, 1A4), gamma-actin [mouse, B4, 1:10000 (Lessard, 1988); gift from Dr. 
James L Lessard], Foxa1 (goat, 1:1000; Santa Cruz, sc-6553), Foxa2 (goat, 1:1000; Santa 
Cruz, sc-9187), Nkx3.1 [rabbit, 1:3000 (Kim et al., 2002); gift from Dr. Cory Abate-Shen] 
and Probasin [rabbit, 1:1500 (Kasper and Matusik, 2000)] 
For immunofluorescence, all incubations were carried out at room temperature 
unless otherwise stated. Tissue sections were blocked with PBS containing 2% normal 
donkey serum (Vector Laboratories) and 2% BSA (Sigma, St. Louis) for 1 hr, and 
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incubated overnight at 4°C with primary antibodies diluted in PBS with 2% BSA and 2% 
donkey serum. After washing for 30 min in PBS, sections were incubated for 1 hr with 
fluorescent conjugated anti-goat, anti-rabbit and anti-mouse secondary antibodies, diluted 
in PBS with 2% BSA and 2% donkey serum. Sections were washed for 30 min in PBS 
and visualized by conventional fluorescent microscopy.  
Primary antibodies used in immunofluorescence at the indicated concentrations 
were AR (rabbit, 1:200), CK14 (mouse, 1:5), CK8 (mouse, 1:10), E-Cadherin (mouse, 
1:200; BD Transduction Laboratories), β-Catenin (mouse, 1:100; BD transduction 
laboratories), p63 (rabbit, 1:200; Santa Cruz, sc-8343), Sonic Hedgehog (rabbit, 1:100; 
Santa Cruz, sc-9024), Patch1 (goat, 1:100; Santa Cruz, sc-6149) and Ki67 (Rat, 1:15; 
DakoCytomation, M7249). Secondary antibodies were anti-mouse IgG TRITC (1:100; 
Sigma, T2402), anti-mouse IgG (Fab specific) TRITC (1:100; Sigma, T6528), anti-mouse 
(1:200; Molecular probes, A21203), anti-goat (1:200; Molecular probes, A11055), anti-
rabbit IgG (1:200; Molecular probes, A21206, A21207) and anti-rat IgG TRITC (1: 100; 
Sigma, T4280). In some experiments, DAPI staining was performed by using 
VECTASHIELD Mounting Medium (Vector, H-1200). 
 
In Situ Hybridization 
A. Preparation of Tissues for In Situ Hybridization 
 Freshly dissected pelvic organs were immediately placed into 5 volumes of cold 
RNAlater for at least 1 hr. Various lobes were dissected in the presence of RNAlater. 
After dissection, tissues were fixed in 4% paraformaldehyde in DEPC-treated PBS for 1 
hr at 4°C. 4% paraformaldehyde was made by heating 50mL of PBS in a 65°C water bath 
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and then adding 2g of paraformaldehyde, and cooling to 4°C on ice. After process the 
specimens, 4 um sections were cut and mounted onto slides and air dried overnight. 
B. Synthesis of RiboProbes 
 Specific gene fragments for Foxa1 and Foxa2 were amplified by PCR from mouse 
liver cDNA, then cloned into pCR2.1-TOPO vector and transformed into TOP10 cells. 
Sense or anti-sense orientations were identified by sequencing. Correct clones for each 
sense and anti-sense probes were amplified by minipreps (Qiagen). To prepare a template 
for production of “run off” transcripts derived from the insert sequence only, plasmids 
containing the required cDNAs were linearised with BamHI. One uL of undigested and 
digested plasmid DNA were electrophoresed on a 0.8% agarose gel to ensure the plasmid 
has been completely linearized. Entire digested sampleand 1 uL of undigested sample 
was electrophoresed and on a 1% low melt preparative grade agarose gel, and linearized 
plasmid was excised. DNA was purified by using Gel Extraction Kit (Qiagen), and eluted 
in 30uL of elution buffer. 
 The Digoxigenin (DIG) RNA labeling reaction is composed of 1 ug linearized 
DNA, 2uL DIG RNA Labeling Mix, 10×concentration, 2uL 10×transcription buffer, 2uL 
T7 RNA polymerase (20U/uL), 1uL of RNase inhibitor (20units/uL) in a 20uL reaction 
system [Roche #1175025, DIG RNA Labeling Kit (SP6/T7)]. Reaction was mixed and 
incubated in 37°C for 2 hrs. 2 uL RNase-free DNase I (10u/uL) was added to remove 
template DNA by incubating for 15 min at 37°C. Reaction was stopped by adding 2 uL 
0.2M EDTA solution, pH8. 
 After labeling reaction, probes were transfered to 0.5mL tubes and 2.5 uL (0.1 
volume) of 4M LiCl and 75uL (2.5 volume) 100% ethanol (-80°C) were added to the 
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standard reaction. Solution was mixed and stored at -70°C for 30 min or 2 hr at -20°C, 
followed by centrifugation at 13,000g at 4°C for 15 min. Pellet was carefully washed 
with 50 uL cold 70% ethanol (-20°C) and centrifuged at 13,000g for 5 min at 4°C and 
air-dried. Pellet was dissolved in 50uL sterile water with 1uL of RNase inhibitor and 
store at -70°C. 
 To determine the labeling efficiency, serial dilutions of DIG labeled transcripts 
were prepared in sterile water. One uL of each dilution was spotted onto Hybond-N+ 
membrane, air-dried and cross-linked with UV. Membrane was equilibrated in Buffer 1 
(Tris 100mM, NaCl 150mM, pH 7.5) for 1 min, and incubated in Buffer 2 [Buffer 1 with 
0.5% blocking reagent (Roche #1096176)] for 30 min at room temperature, followed by 
incubation of 30 min with anti-DIG alkaline phosphatase (AP)-conjugated antibody 
(Roche # 1093274) diluted 1:5000 in buffer 2. Membrane was then washed in Buffer 1 
for 10 min, 2 times, equilibrated in Buffer 3 (Tris 100mM, NaCl 100mM, MgCl2 50mM, 
pH9.5) for 2 min, and then incubated in Buffer 3 with 45uL NBT and 35uL BCIP per 
10mL, in dark at room temperature. Staining reaction was stopped with water and the 
membrane was air dried. Samples were semi-quantitated by comparing signals with 
standard DIG labeled control RNA of known concentration. 
 To determine the DIG RNA transcript quality, 2ug of each sample were heated at 
65 C for 10 min, stored on ice for 5 min, and dissolved on 2% agarose gel. 
C. Hybridization 
 Tissue sections were deparaffinized and hydrated through xylenes and ethanol 
series with gradient concentration (Xylene 1×10 min, 1×3 min, 100% ethanol 2×3 min, 
95% ethanol 2×3 min, 75% ethanol 1×3 min, 50% ethanol 1×3 min, DEPC-treated water 
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1×3 min, DEPC-treated PBS 1×3 min). Sections were postfixed for 10 min in 4% 
paraformaldehyde in DEPC-treated PBS (with 5 drops of 5M NaOH) followed by 
washing for 2×15 min in PBS with 0.1% active DEPC. After equilibration for 15 min in 
5×SSC, DEPC-treated, hybridization was performed immediately. Hybridization box was 
prepared and saturated with 5×SSC, 50% formamide solution. Prehybridization was 
performed for 2 hrs at 58°C in 5×SSC, 50% formamide solution, 40ug/mL salmon sperm 
DNA. Probes were denatured for 5 min at 80°C and added into the hybridization mixture 
(400 ng/mL of DIG-labeled probe, 5×SSC, 50% formamide, 40ug/mL salmon sperm 
DNA). Hybridization was performed for 4-40 hr at 58°C, and covered by rectangular 
cover slip.  
 Sections were washed for 30 min in 2×SSC at room temperature, followed by 1 hr 
wash in 2×SSC at 65°C and 1 hr wash in 0.1×SSC at 65°C. Sections were equilibrated for 
5 min in Buffer 1 at room temperature, followed by 2 hrs of incubation with anti-DIG 
antibody, AP-conjugated, diluted 1:5000 in Buffer 2 at room temperature. Sections were 
then washed with Buffer 1 twice for 15 min each, equilibrated for 5 min in Buffer 3, and 
stained in Buffer 3 with 45uL NBT and 35uL BCIP per 10mL of Buffer 3, in the dark. 
Reaction was stopped with TE buffer (Tris 10mM, EDTA 1mM, pH 8.0) for 10 min. 
Non-specific background was removed with 95% ethanol for ~1 hr and rinsed in water 
for 15 min to dissolve and remove potential crystals due to TE buffer. Slides were air-
dried and mounted with aqueous mounting solution (Biomeda #M01). 
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RNA Isolation and RT-PCR 
 Upon dissection, fresh tissues were immediately placed in 5 volumes of 
RNAlaterTM (Ambion, Austin). The prostates were dissected in RNAlaterTM, incubated 
at 4°C overnight and then stored at -20°C. Total RNA was extracted from pooled prostate 
tissues using the QiagenTM RNeasy extraction kit (Qiagen, Valencia) and treated with 
RNase-Free DNase (Qiagen). Two micrograms of total RNA was reverse transcribed 
using Superscript-IITM reverse transcriptase (Invitrogen) according to the manufacturer’s 
instructions. PCR was performed to produce gene specific fragments for Sbp (277bp), 
probasin (243bp), and Foxa2 (200bp). The PCR primers are: Sbp-f, 
CCCAGAATGTCCTGGGGAATG; Sbp-r, CCACACGCCCCTTGTTTGTAG; 
probasin-f, TGCACAGTATGAAGGGAGCA; probasin-r, 
TTGATCTTGCTTGGACAGTTG; Foxa2-f, CCCATTCCAGCGCTTCTC; Foxa2-r, 
GTAATGGTGCTCGGGCTTC. 
 
Matrix Assisted Laser Desorption Ionization Time-of-flight (MALDI-TOF) Mass 
Spectrometry (MS) 
 
The prostate tissues were dissected and then snap-frozen in liquid nitrogen.  Using a 
cryostat, 10 µm tissue sections were cut and mounted onto a conductive glass MALDI 
plate.  Three to four sections were obtained per specimen.  For histological information 
and to identify regions of interest for profiling, sections were stained with MALDI-
compatible cresyl violet as described previously (Chaurand et al., 2004). Areas of interest 
were then spotted with approximately 150nL of saturated sinapinic acid as matrix 
prepared in acetonitrile/H2O/TFA (50/50/0.1) by volume and allowed to dry.  Each 
section was then analyzed by MALDI-TOF MS in the linear mode using an Applied 
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Biosystems Voyager DE-STR mass spectrometer (Framingham, MA) in Mass 
Spectrometry Core Lab in Vanderbilt University. Acquired spectra were baseline 
subtracted and normalized by a costumer program. Spectra from each prostate sample 
were then averaged before comparison. 
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Table 2-1. Oligonucleotides used in CHAPTER II 
Name Sequence Purpose Restriction Site Added 
TTRs 5’-TGACTAAGTCAATAATCAGAATCAG-3’ EMSA, Competition  
PB-127/-102                 5’-AGAACCTATTTGTATACTAGATGACA-3’ EMSA  
PB-257/-232                 5’-CAGTTAAGAAAATATGATAGCATCTT-3’ EMSA  
ARBS2/R2 5’-GCCTAGTAAAGTACTCCAAGAACCTATTTGTATACTAGA-3’ EMSA  
ARBS2/R2-M1 5’-GCCTAGTAAAGTACTCCAAGAACCTAgaaGTATACTAGA-3’ EMSA  
ARBS2/R2-M2 5’-GCCTAGTAAAGTACTCCAAGAACCTATTTGatgACTAGA-3’ EMSA  
ARBS1/R1 5’- CAGTTAAGAAAATATGATAGCATCTTGTTCTTAGTCTTTTT-3’ EMSA  
ARBS1/R1-M3 5’- CAGTTAActAAATtaGAatGCATCTTGTTCTTAGTCTTTTT-3’ EMSA  
PB-127/-102-M1-F 5’-AGAACCTAgaaGTATACTAGATGACA-3’ EMSA, Mutagenesis  
PB-127/-102-M1-R 5’-TGTCATCTAGTATACttcTAGGTTCT-3’ EMSA, Mutagenesis  
PB-127/-102-M2-F 5’-AGAACCTATTTGatgACTAGATGACA-3’ EMSA, Mutagenesis  
PB-127/-102-M2-R 5’-TGTCATCTAGTcatCAAATAGGTTCT-3’ EMSA, Mutagenesis  
PB-257/-232M-F 5’- CAGTTAActAAATtaGAatGCATCTT-3’ Mutagenesis  
PB-257/-232M-R 5’-AAGATGCatTCtaATTTagTTAACTG-3’ Mutagenesis  
2×R2 5’-ACCTATTTGTATACTAACCTATTTGTATACTAGATGACA-3’ Southwestern  
2×mR2 5’-ACCTAgaaGTATACTAACCTAgaaGTATACTAGATGACA-3’ Southwestern  
PB-Primer 5’-TGTCATCTAG-3’ Southwestern  
2×AR-consensus 5’-GTCTGGTACAGGGTGTTCTTTTTGGTACAGGGTGTTCTTTTTG Southwestern  
AR-Primer 5’-CAAAAAGAAC-3’ Southwestern  
PSA1 
5’-
CCTACTCTGGAGGAACATATTGTATTGATTGTCCTTGACAGTAAA 
CAAATCTGTT-3’ 
EMSA  
PSA2 5’-GGATGCCTGCTTTACAAACATCCTTGAAAC-3’ EMSA  
mPSA1 
5’-
CCTACTCTGGAGGAACATATTGTATTGATTGTCCTTGACAGTAcA 
CAcATCTGTT-3’ 
EMSA  
mPSA2 5’-GGATGCCTGCTcTcCAcACATCCTTGAAAC-3’ EMSA  
hPAP 5’-TTCTTTTGTTTGTTTTTTGTTGTTGTTTGTTTGTTTTGCTG-3’ EMSA  
rPAP1 5’-TGGTTTTGTTTTCTTTTTAATGTTTGTTAT-3’ EMSA  
rPAP2 5’-GCCAATCTCTTGATTAAATAGGCACTTCCC-3’ EMSA  
rPAP3 5’-TCTTGACAGAACAGGAAGCCGAGAGTGAGC-3’ EMSA  
PBPC1-1 5’-ATTGACTGAATGTTTATTTAATTTCTCCTT-3’ EMSA  
PBPC1-2 5’-GAATTAGCAAATAATTTCTCTTATAAAAAT-3’ EMSA  
PSA-P-F 5’-CCCGGGTTGGATTTTGAAATGCTA-3’ PSA-EPLuc  SmaI 
PSA-P-R 5’-CTCGAGAAGCTTGGGGCTGG-3’ PSA-EPLuc XhoI 
PSA-E-F 5’-GAGCTCCTGCAGAGAAATTA-3’ PSA-EPLuc SacI 
PSA-E-R 5’-CCCGGGCCATGGTTCTGTCA-3’ PSA-EPLuc SmaI 
mPSA1-F 5’-TGACAGTAcACAcATCTGTTGTAAG-3’ Mutagenesis  
mPSA2-F 5’-TGCTcTcCAcACATCCTTGAAACAA-3’ Mutagenesis  
WT (1-466)-F 5’-CACCGAATTCATGTTAGGGACTGTGAAGAT-3’ WT construct EcoRI 
WT (1-466)-R 5’-AGCTCGAGCGGAAGTATTTAGCACGGGTCT-3’ WT construct XhoI 
NT (1-180)-R 5’-AGCTCGAGCGGTGATGAGCGAGATGTAGGA-3’ NT construct XhoI 
FH (141-294)-F 5’-CACCGAATTCATGGCGTACGCTCCGTCCAA-3’ FH construct EcoRI 
FH (141-294)-R 5’-AGCTCGAGCTGAGGGGTCTTTGCGGTTTTC-3’ FH construct XhoI 
CT (295-466)-F 5’-CACCGAATTCATGGGCCCGGTTAACCCCAGTGC-3’ CT construct EcoRI 
∆23 (1-385)-R 5’-AGCTCGAGCGGCCCCTTTCAGGTGCAGCTG-3’ ∆23 construct XhoI 
∆3 (1-420)-R 5’-AGCTCGAGCGTACTGCAGTGCCTGCTGATA-3’ ∆3 construct XhoI 
DN (59-345)-F 5’-CACCGAATTCATGACCCCGGCTTCCTTCAA-3’ DN construct EcoRI 
DN (59-345)-R 5’-AGCTCGAGCCAACTCCGAACCGCCCCCTGT-3’ DN construct XhoI 
AR-LBD-F 5-TCCGGATCCAAGGCTATGAATGTCAACCT-3’ GST-AR-LBD BamHI 
AR-LBD-R 5’-TCCGGATCCTCACTGTGTGTGGAAATAGAT-3’ GST-AR-LBD BamHI 
AR-NT-F 5’-TTTGGATCCCCATGGAGGTGCAGTTAGGGCTG-3’ GST-AR-NTD BamHI 
AR-NT-R 5’-TTTGGATCCTCACATGTCCCCATAAGGTCCGGA-3’ GST-AR-NTD BamHI 
For EMSA probes, only the sense strand sequences are shown here. Underscored sequences represent the binding sites for HNF-3 or AR. 
Sequences in bold lowercase characters are nucleotide replacements in mutagenesis study. 
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CHAPTER III 
 
ANDROGEN RECEPTOR-FOXA1 (HNF-3α) CIS-REGULATORY ELEMENTS 
ARE INVOLVED IN THE REGULATION OF PROSTATE DIFFERENTIATED 
FUNCTION 
 
Introduction 
 The prostate is a male accessory sex organ that is found exclusively in mammals. 
This organ produces various components found in the semen. Androgens are required to 
initiate prostatic development, to establish prostatic morphogenesis, and to begin 
secretory activities. In the mouse, the developing fetal testis begins to produce androgens 
at embryonic day 12.5-13 (E12.5–13) with peak production at E17-18, during which the 
earliest signs of prostatic formation are observed (Pointis et al., 1979; Pointis et al., 1980). 
Ablation or surgical removal of fetal testes during the ambisexual period inhibits the 
development of prostate and other male internal sex organs (Cunha et al., 1987). 
Androgens act directly through AR to elicit their effects (Gelmann, 2002). Testicular 
feminized (Tfm) mice, which express a non-functional AR, never develop a prostate, 
even though their testes produce adequate amounts of testosterone (Cunha et al., 1987; 
Quigley et al., 1995). In addition, prostatic epithelial cells that do not express functional 
AR, also do not express characteristic secretory markers (Donjacour and Cunha, 1993). 
These observations demonstrated the essential requirement of androgens and AR for 
prostate development and function. Interestingly, tissue recombination experiments 
showed that the urogenital epithelium (UGE) from Tfm mice develops normal prostate 
gland histology when combined with wild type urogenital mesenchyme (UGM), although 
these UGE contains a defective AR (Cunha and Chung, 1981). Also, it has been observed 
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that the induction of prostatic epithelial buds occurs prior to AR expression in wild type 
prostatic epithelial cells (Takeda et al., 1985; Cooke et al., 1991; Hayward et al., 1996a). 
These results argue that the epithelial AR is not required for prostatic determination, 
although it is essential for the production of androgen dependent secretory proteins at 
later stages (Donjacour and Cunha, 1993). 
Extensive tissue recombination studies have proven that mesenchymal-epithelial 
interactions play a key role in directing prostate development (Cunha et al., 1992; Cunha 
et al., 1987). Epithelial cells from other urogenital sinus derivatives (bladder, urethra and 
vagina) can be instructively induced by UGM to give rise to prostatic tissue (Cunha et al., 
1987; Cunha, 1975; Cunha et al., 1980b; Neubauer et al., 1983; Cunha et al., 1983). 
Similar results have been obtained using human bladder epithelial cells (Aboseif et al., 
1999). The ductal-acinar structures that form in such experiments histologically resemble 
prostatic epithelium and produce prostate specific antigen (PSA) (Aboseif et al., 1999). 
Nevertheless, the response of epithelia to inductive mesenchyme is limited by the 
developmental repertoire of the germ layer origin of the epithelium (Hayward, 2002). For 
example, mesodermally derived seminal vesicle epithelium responds to either urogenital 
sinus or seminal vesicle mesenchyme by generating seminal vesicle. In contrast, the 
endodermally derived epithelia of the prostate, bladder or urethra respond to the same 
inductive mesenchyme by generating prostatic tissue. Therefore, it is apparent that the 
cell developmental program is determined by both epithelial and mesenchymal factors. 
Although androgens and mesenchymal factors are critical to prostatic development, 
epithelial factors that directly participate in this process are still unknown. 
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Forkhead Box A (Foxa) transcription factors, Foxa1, Foxa2 and Foxa3, (formerly 
known as HNF-3α, HNF-3β and HNF-3γ) are a group of endoderm-related 
developmental factors that belong to the forkhead transcription factor family (Kaestner et 
al., 2000; Zaret, 1999; Kaufmann and Knochel, 1996). In mouse, Foxa2 (HNF-3β) is first 
expressed in the endoderm progenitor during gastrulation (E6.5), immediately followed 
by the expression of Foxa1 (HNF-3α) (before organogenesis, E7-8) and Foxa3 (HNF-3γ) 
(Sasaki and Hogan, 1993; Zaret, 1999). The targeted null mutation of Foxa2 gene results 
in embryonic lethality due to a lack of endodermal progenitors (Weinstein et al., 1994), 
while homozygous mutation of Foxa1 gene leads to perinatal death due to pancreatic 
defects (Kaestner et al., 1999). All three Foxa (HNF-3) genes are restrictively expressed 
in the endoderm-derived organs in the adult and are involved in endodermal 
differentiation (Zaret, 1999). In vivo footprinting using mouse embryo liver cells showed 
that Foxa factors, among a few earliest transcription factors, bind to the enhancer of liver-
specific albumin gene before this gene is activated (Zaret, 1999; Cirillo et al., 2002). This 
binding of Foxa is believed to provide developmental competence to the target gene, 
which becomes activated during hepatic induction when additional liver-enriched 
transcription factors are recruited (Zaret, 1999; Jackson et al., 1993; Zaret, 2002). 
Although Foxa proteins were first discovered in liver (Lai et al., 1990), the highest Foxa1 
mRNA level was detected in the prostate gland by comparison of 16 human tissues 
(Peterson et al., 1997). A novel expression pattern of Foxa1 in the epithelium of the 
bladder, urethra and prostate has also been reported (Peterson et al., 1997; Kopachik et al., 
1998). However, in the urogenital system, target genes that are regulated by Foxa1 have 
not been identified. The role of Foxa1 in the urogenital system remains to be defined. 
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In the adult prostate, fully differentiated luminal epithelial cells secrete androgen-
dependent prostate-specific proteins, such as Pbsn in the rat and PSA in the human. 
Activation of these characteristic genes in epithelium signifies that prostatic 
differentiation has occurred. The transcription factors that regulate these genes may also 
be involved in the process of prostate development. Therefore, a better understanding of 
the transcriptional regulation of these prostate specific genes is likely to provide insight 
into the organ development. In the present study, characterization of the Pbsn promoter 
has led to the identification of the binding of a cluster of ubiquitous transcription factors, 
and two forkhead response elements, which are immediately adjacent to functional AR 
binding sites. A similar organization of the AREs adjacent to forkhead response elements 
was observed in the PSA gene enhancer and the prostatic acid phosphatase (PAP) gene 
promoter/enhancer, suggesting that a common functional mechanism is involved. DNA 
mutation studies showed that these Foxa sites are essential for maximal androgen-
induction of both Pbsn and PSA gene. Chromatin immunoprecipitation assay confirmed 
that Foxa1 occupies the PSA enhancer in vivo. In addition, we detected a direct 
protein/protein interaction between Foxa1 and AR. These data suggest that an 
endodermal transcription factor Foxa1 and a steroid receptor AR may coordinately 
participate in the assembly of a nucleoprotein complex, which directs the prostatic 
differentiated function. The regulatory mechanism between Foxa1 and AR may also 
apply to the transcriptional control of other prostatic epithelial cell specific genes.  
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Results 
A. Octamer-binding transcription factor 1 (Oct1), Nuclear factor 1 (NF1) and c-jun 
Bind Pbsn Proximal promoter 
 
 The rat Pbsn is a prostate-specific and androgen-regulated gene, which has been 
extensively characterized (Rennie et al., 1993; Greenberg et al., 1994; Kasper et al., 1994; 
Yan et al., 1997; Kasper et al., 1999; Kasper et al., 1998; Zhang ZF et al., 2000; 
Masumori et al., 2001; Kasper and Matusik, 2000). It has been shown that a 12 kb 
fragment of the Pbsn 5’-flanking sequence, a –426/+28 base-pair (bp) fragment as well as 
an artificial Pbsn promoter ARR2PB, which contains an extra copy of –244/-96 bp fused 
in front of the –286/+28bp region, is able to specifically target genes to transgenic mouse 
prostate (Greenberg et al., 1994; Yan et al., 1997; Zhang ZF et al., 2000). Therefore, the 
minimal fragment that confers prostate specificity was mapped to the 315 bp region (–
286/+28) (Zhang ZF et al., 2000), which contains two functional AR binding sites 
(ARBS-1 at –236/–223 and ARBS-2 at –140/-117) (Rennie et al., 1993). Based on the 
hypothesis that additional key cis-acting elements remain to be uncovered, an extensive 
linker scan mutation analysis was performed by Zhang et al. Thirty one mutant Pbsn 
promoter fragments were generated by sequential replacing every ten base pair of Pbsn -
286/+28 sequence with a random ten base pair DNA sequence (Fig. 3-1).  
Luciferase reporter assay in cell culture experiments identified five key cis-
elements, mutation of which significantly affected Pbsn promoter activity (Zhang ZF et 
al., 2004b). Transcription factor data base search predicted a POU domain transcription 
factor Oct1 binding site, a NF1 binding site and a AP-1 binding site within three of these 
essential DNA elements. Mutation of these three cis-acting elements individually resulted 
in a reduction of promoter activity in all tested cell lines. In contrast, mutation of the 
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other two elements, named TS-1 and TS-2, led to a decrease in promoter activity only in 
prostatic cell lines, but not in non-prostatic cell lines (Zhang ZF et al., 2004b). 
 Using LNCaP nuclear extract, EMSA was performed to confirm the binding of 
these transcription factors to Pbsn promoter. Both competition and antibody supershift 
assays were performed for each of these elements. Fig. 3-2A shows that the complexes 
formed with Pbsn -226/-187 bp can be competed by an increasing amount of cold Oct1 
consensus binding sites (lane 3-5), and it was true reversely (lane 9-11). In addition, 
antibody to Oct1 produced a supershifted band in Pbsn bound complexes (lane 6). Lane 
12 shows a positive control for this supershift assay. These data indicated Oct1 binds 
directly to Pbsn -226/-187 bp.  
 Similar experiments were performed for the putative NF1 binding site at Pbsn -
96/-67 bp. Fig. 3-2B shows that using LNCaP nuclear extract, a specific complex was 
formed with Pbsn -96/-67 bp (lane 2). The formation of this complex was impaired by 
mutating the putative NF1 element (lane 3). Also this complex can be competed off by an 
increasing amount of cold Pbsn -96/-67 bp oligonucleotide (lane 4-5) or NF1 consensus 
binding sites (lane 6-7), but cannot be competed by control oligonucleotides (lane 8-11), 
suggesting binding specificity. In addition, supershift assay demonstrated a reduction in 
the binding of this complex to Pbsn -96/-67 bp when a NF1 antibody was added to the 
reaction (Fig. 3-2C, lane 3). Control antibodies had no effect (lane 5-7). Consensus NF1 
binding site was also radiolabeled and included in the supershift experiment as a positive 
control (lane 9). To rule out the possibility that the NF1 antibody may have artificial 
effect on the EMSA binding patterns, a negative control using radiolabeled consensus 
Oct1 binding site was included in the same experiment, and the same antibody had no 
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effect on the binding pattern of Oct1 probes (lane 12), suggesting the 
“immunoelimination” seen in Pbsn -96/-67 bp and NF1 consensus site are specific and 
not artificial effects. These data strongly indicated NF 1 binds to Pbsn -96/67 bp directly. 
 Similarly, a strong complex was formed at Pbsn -116/-87 bp when LNCaP 
nuclear extract was incubated with the radiolabeled probe (Fig. 3-2D, lane 2). Mutation 
of the putative AP-1 binding element led to a reduction in the complex formation (lane 3). 
Interestingly, this complex can be apparently competed off by an increasing amount of 
cold -116/-87 bp (lane 4-5), cold AP-1 consensus sites (lane 6-7) and cold C/EBPβ 
consensus sites (lane 8-9), but not by a control sequence (lane 10-11). The mutation and 
competition assays suggested the specificity of this complex bound at Pbsn -116/-87 bp. 
Supershift assay (Fig. 3-2E) demonstrated that antibodies to c-jun (lane 3) and C/EBPβ 
(lane 6), but not to c-fos (lane 4) or other control antibodies (lane 5), produced 
supershifted bands for the Pbsn -116/-87 complexes, supporting the finding that both c-
jun and C/EBPβ are involved in the complex formation at Pbsn -116/-87 bp. Furthermore, 
the same c-jun antibody cannot elicit supershift in the complexes formed with a mutant 
Pbsn -116/87 bp probe, which contains a disrupted AP-1 binding element (lane 12).  
Collectively, these data unambiguously demonstrated that at least four ubiquitous 
transcription factors participate in the assembly of the multiprotein complex on Pbsn 
promoter. These ubiquitous sequence-specific DNA-binding proteins, together with tissue 
restricted proteins (forkhead protein and AR) discussed later, may create the first level of 
transcriptional control that responds to various intracellular signaling pathways. 
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B. Molecular Weight Mapping of Tissue-Specific Binding Proteins 
 In contrast to these ubiquitous transcription factor binding sites, two tissue 
specific elements, TS-1 and TS-2, are more important due to several functional features: i) 
both TS-1 and TS-2 are tightly adjacent to a functional ARBS site and the core region of 
each is almost identical; ii) in transgenic mice, mutation of TS1 reduced expression of 
reporter gene, but the expression was still prostatic specific, while mutation of TS2 
abolished all reporter activity in all transgenic lines (Zhang ZF et al., 2004b). In EMSA 
using LNCaP nuclear extract, the binding patterns of TS-1 and TS-2 are almost identical, 
and both oligonucleotides can compete with each other for the binding of target proteins, 
suggesting that similar, if not identical, factors bind these elements (Zhang ZF et al., 
2004b).  
 In addition to transcription factor database search, which generated multiple hits, 
two strategies were used to try to map the molecular mass of the proteins that are directly 
bound with TS-1 and TS-2. Initially, LNCaP nuclear extract was fractionated with SDS-
PAGE according to standard molecular weight markers. Fractionated nuclear proteins 
were used to test the binding with TS-1 and TS-2 in EMSA (Materials and Methods). 
Active fractions containing the binding activity were identified. Fig. 3-3A is an EMSA 
demonstrating the binding activities of 9 fractions of LNCaP nuclear extract with TS-1 
(lane 11-20) or TS-2 (lane 1-10) probes. Notably, TS-1 and TS-2 showed a similar 
binding pattern. Using molecular weight markers and corresponding migration distances, 
a standard curve was generated (Fig. 3-3B), and the active binding fractions were 
calculated to be corresponding to molecular weight of 35-44 kDa, 45-52 kDa, 53-70 kDa 
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and 90-115 kDa. TS-2 showed higher affinity to both 35-44 kDa and 53-70 kDa fractions 
(Fig. 3-3A, lane 6 and 8) compared with TS-1 (lane 16 and 18).  
 Southwestern blotting was performed as a more precise mapping assay for the 
molecular weight. Two strong TS2-binding activities were detected at around 52 kDa and 
46 kDa, the details of which will be discussed. Importantly, these molecular mapping 
experiments, combined with database search, directly facilitated the identification of the 
binding of Foxa1.   
C. Two Foxa (HNF-3) Binding Sites Are Identified on the Pbsn Promoter  
In order to identify putative transcription factor binding sites in TS-1 and TS-2, 
two web-based search engines TESS (www.cbil.upenn.edu/tess) and TFSEARCH 
(www.cbrc.jp/research/db/TFSEARCH.html) were employed. The search was restricted 
to a maximum of 20% mismatch within an element length of 6 nucleotides or greater. 
Either a 9-nt sequence (-252/-244bp) located in R1 or a 9-nt sequence (-121/-113bp) 
located in R2 highly matched with the Foxa consensus binding sequence (5’-
TRTTTRYTY-3’) (Kaufmann and Knochel, 1996) (Fig. 3-4A). R1 and R2 are 
corresponding to the TS-1 and TS-2 element respectively. The first 7-nt 5’-
T(A/G)TT(T/G)(G/A)(T/C)-3’, extracted from various known Foxa-regulated gene 
promoters (Kaufmann and Knochel, 1996), perfectly matched with the TATTTGT motif 
in R2 (Fig. 3-4A). Fig. 3-4B shows an EMSA using nuclear extract prepared from 
LNCaP human prostate cancer cells, which express Foxa1 (Fig. 3-4C). TTRs is a strong 
Foxa binding unit on the liver transthyretin (TTR) gene promoter and was originally used 
to affinity-purify Foxa proteins (Lai et al., 1991; Lai et al., 1990; Costa et al., 1989). 
Strong complexes were formed when this TTR consensus Foxa binding site was used 
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(Fig. 3-4B, lane 2), and these complexes were reduced with addition of antibodies against 
Foxa1 or Foxa2 (lanes 3 and 4). RT-PCR using primers specific for Foxa2 failed to detect 
the expression of Foxa2 in LNCaP cells (data not shown), indicating the effect caused by 
Foxa2 (M20) antibody may due to the cross-reactivity of this antibody since Foxa1 and 
Foxa2 have highly homologous C-terminals. Four complexes, designated as a, b, c and d, 
were formed with radiolabeled Pbsn-127/-102, which overlaps R2 (Fig. 3-4B, lane7). 
Three complexes, designated as A, B and C, were formed with Pbsn-257/-232, which 
overlaps R1 (Fig. 3-4B, lane 20). Foxa1 antibody distinctly abolished the binding of two 
R2 complexes (lane 8, b and c) and R1 complex B (lane 21), while mock antibodies had 
no visible effect (lanes 10-16, and 23).  A 200-fold molar excess of cold TTRs 
oligonucleotide completely competed off the complexes b and c (lane 17), indicating 
binding specificity. An increasing competitor (400 to 600-fold) further affected complex 
a (lanes 18 and 19), suggesting that a higher-order Foxa1 complex might be contained in 
complex a. Since complex “a” was not affected by Foxa1 antibody (lane 8), it indicates 
that this complex may have higher stability and the epitope in this complex may not be 
accessible to Foxa1 antibody. Western blot in Fig. 3-4C shows that Foxa1 protein was 
strongly detected in LNCaP and PC3, but weakly detected in DU145 cells in comparison 
with the positive control HepG2 cells, and the negative control Hela or Cos-1 cells.  
Since ARBS-2 is tightly close to the Foxa1 motif in R2, it is necessary to 
determine: 1) whether Foxa1 still binds R2 when ARBS-2 site is occupied by AR, 2) 
whether the Foxa1/R2 interaction is dependent on adjacent AR binding. To address these 
questions in vitro, we used a radiolabeled probe (Table 2-1, ARBS2/R2) containing both 
ARBS-2 and R2. Fig. 3-4D shows that, among the multiple complexes formed with 
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LNCaP nuclear extract, two complexes were specifically reduced or removed by Foxa1 
antibody (lane 1 vs. 2), while both complexes were disrupted by mutating the HNF-3 
motif in ARBS2/R2 string (lane 3 vs. 7 and Table 2-1, ARBS2/R2-M1). Competition 
assay, using 100, 200 and 500-fold molar excess of cold ARBS-2 site (lane 3 vs. 4-6), 
showed that several complexes (indicated as asterisks) were sensitive to the competitor 
while none of the Foxa1 complexes were competed off. These results demonstrated in 
vitro that Foxa1/R2 binding can occur concomitantly with AR/ARBS-2 interaction, but 
Foxa1 binding is independent of AR/ARBS-2 interaction.  
In Fig. 3-4E, Southwestern blot was used to determine the relative molecular sizes 
of R2-interacting proteins. LNCaP and PC-3 cell nuclear extracts were resolved on SDS-
polyacrylamide gel and transferred to nitrocellulose membranes. The blots were probed 
with 32P-labeled oligonucleotides containing two tandem copies of wild type R2 (2×R2). 
For both LNCaP and PC-3 cells, two proteins with molecular weight around 52-kD and 
46-kD were detected (lanes 1 and 3). Similar blots probed with 2×mR2 (containing two 
copies of mutant R2, see Table 2-1 for sequence) showed that the binding of both 
proteins were distinctly reduced in LNCaP cells or completely blocked in PC-3 cells 
(lanes 2 and 4), indicating that the binding is sequence-specific. A radiolabeled 
oligonucleotide containing 2 tandem copies of AR consensus binding site (Table 2-1), 
serving as a positive control, was hybridized specifically to a 110-kD protein (the size of 
human AR), but not the low molecular weight proteins (lane 5). A parallel western blot 
using Foxa1 antibody showed a specific band around 52-kD (lanes 6 and 7), suggesting 
that the 52-kD protein detected by Southwestern was Foxa1. The 46-kD protein detected 
in both LNCaP and PC3 might be an Foxa1 minor degradation product, which escaped 
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antibody detection but still retained DNA binding activity. However, the presence of a 
higher-order protein complex on R2 (complex “a” in Fig. 3-4B, lane 7) suggests that 
additional DNA-binding protein on R2 may exist. 
D. In Vitro Synthesized Foxa1 Binds Pbsn Promoter 
Since crude nuclear extracts were used in EMSA and Southwestern experiments, 
it was necessary to confirm the results with Foxa1 synthesized by in vitro 
transcription/translation (TNT). Fig. 3-5A shows that synthesized Foxa1 specifically 
bound to the radiolabeled R2 in EMSA (lane 3), in contrast to the TNT blank control 
(lane 2), which only formed a non-specific band. Three Foxa1 mutants deleted in N-
terminal (∆N), C-terminal (∆C) or both terminal regions (FH) still showed binding 
activities (lanes 4-6), since all mutants still contain the forkhead (FH) DNA binding 
domain. The binding of Foxa1 was completely removed by an antibody against the Foxa1 
C-terminal (Fig. 3-5B, lane 2 vs. 3). The same antibody could not eliminate the complex 
formed by the mutant Foxa1 deleted in C-terminal (lane 5 vs. 6). In addition, a mutant 
probe (mPbsn-127/-102 bp) containing a mutated Foxa1 motif also affected the specific 
binding (lane 2 vs. 4). Similar results were observed when using R1 (Pbsn-257/-232 bp) 
sequence. As shown in Fig. 3-5C, Foxa1/R1 interaction is relative weaker in contrast to 
Foxa1/R2 (Fig. 3-5C, lane 2 vs. 4), since R1 has 1-bp mismatch with Foxa cognate 
binding site while R2 is a perfect match. The presence of multiple Foxa sites with 
different affinities has been proposed to be relevant for transcriptional modulation 
(Gaudet and Mango, 2002). These in vitro binding experiments confirmed the 
identification of two forkhead response elements immediately adjacent to the ARBSs in 
Pbsn proximal promoter. 
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E. Foxa1 is Expressed in Normal Prostate Epithelium 
Two previous studies have reported the mRNA expression profile of Foxa in the 
mouse and rat prostates by using in situ hybridization and Northern blot (Kopachik et al., 
1998; Peterson et al., 1997). We examined the Foxa protein expression pattern in the 
human and mouse prostate by immunohistochemical and Western blot analyses. In Fig. 
3-6, immunohistochemistry showed a clear nuclear staining of Foxa1 in both mouse 
(panels A and B) and human (panels C and D) prostate luminal epithelial cells. Foxa2 and 
Foxa3 were not detected (data not shown).  Consistently, Western blot showed that Foxa1 
is expressed in all mouse prostate lobes, with highest level of expression in ventral 
prostate (VP) (panel E). This pattern is consistent with the previous study showing that 
Foxa1 mRNA level in VP is 14 times more abundant than in liver (Peterson et al., 1997). 
Results from RT-PCR using primers specific for Foxa1, Foxa2 or Foxa3 are consistent 
with immunohistochemistry and Western blot (data not shown). The absence of Foxa2 
expression in adult mature prostate has been reported before (Kopachik et al., 1998) and 
this is different from the expression patterns in other organs where Foxa1 and Foxa2 are 
often co-expressed (Lai et al., 1991).  
F. Foxa1 Binding Sites are Essential for Maximum Androgenic Induction 
The mechanism of Foxa1 transcriptional regulation, in some part, involves 
nucleosome disruption (Cirillo et al., 1998; Cirillo et al., 2002). Although transiently 
transfected DNA cannot assemble the same higher-order chromatin structure as genomic 
DNA, certain levels of nucleosome-mediated regulation can be observed on transiently 
introduced DNA (Smith and Hager, 1997; Crowe et al., 1999). Studies using transient 
transfection have demonstrated that Foxa1 relieves nucleosome-mediated transcriptional 
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repression of a liver specific α-Fetoprotein gene (Crowe et al., 1999). In order to examine 
the biological role of the two Foxa1 binding motifs, we compared the activities of mutant 
Pbsn promoters with wild type promoter in transfection assay. PCR based site-directed 
mutagenesis was used to generate point mutations in Foxa1 binding sites (R1 and R2). As 
seen in Fig. 3-7A, three mutant promoters were generated. Two of them, M1 and M2, 
contain mutant forkhead motif in R2. The third one, M3, contains mutant forkhead motif 
in R1. EMSA in Fig. 3-7B demonstrated that M1 completely abolished Foxa1 complexes 
a, b and c. M2 slightly affected complexes b and c, but distinctly removed complex a. 
Addition of Foxa1 antibody further removed complex b and c, indicating that M2 affects 
the formation of a higher-order complex, which was competed by the Foxa consensus 
sequence (Fig. 3-4B, lanes 18 and 19). All mutant as well as a wild type Pbsn reporter 
constructs were transfected into LNCaP cells and luciferase activities were compared. 
Experiments were repeated at least six times. Fig. 3-7C is a representative experiment 
showing that the maximal androgen-induction of Pbsn promoter activity was significantly 
affected in either mutant R1 or mutant R2. In contrast to R1 motif, R2 may have a greater 
biological relevance since both M1 and M2 mutations almost completely ablated Pbsn 
activity (P<0.001). The significant decrease in M2 activity suggests that the complex a 
(Fig. 3-7B), which is in a higher-order, is biologically important. The reduction in M3 
activity is consistent with a previous study (Patrikainen et al., 1999) conducted by 
another group, who demonstrated a significant loss in Pbsn activity by deleting a region 
overlapping with R1. Similar results were obtained when these transfection experiments 
were performed in PC3 cells (data not shown). In addition, EMSA in Fig. 3-7D 
demonstrated in vitro that a purified GST-AR-DBD fusion protein bound to these mutant 
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ARBS-1/R1 or ARBS-2/R2 strings (Table 2-1 for sequences) with similar intensity as to 
the wild type sequence, indicating that these mutations generated in forkhead motifs do 
not directly abrogate the AR/ARBS interaction. Thus, the activity loss in Pbsn promoter 
(Fig. 3-7C) is not directly due to the loss of AR/ARBS binding. However, such mutations 
may destabilize the formation of a complete nucleoprotein complex in these regions, and 
this will be further discussed in this paper. These data strongly suggested that two 
forkhead motifs are required for the maximal androgenic induction in Pbsn gene. 
G. Dominant Negative Mutant Foxa1 Inhibits Pbsn Activity 
Both the N- and C-terminal regions of Foxa proteins have been suggested to have 
transactivation activities (Pani et al., 1992; Qian and Costa, 1995). Recent studies using 
in vitro nucleosome assembly showed that the transcriptional modulation by Foxa1 is 
mediated through its C-terminal region (Cirillo et al., 2002). We generated two 
recombinant Foxa1 mutants (∆N141-466, ∆C1-294) with deletions in either N- or C-
terminal region. These mutants as well as a wild type Foxa1 expression vector (0.2 
µg/well) was co-transfected into LNCaP cells with the ARR2PB-Luc reporter construct. 
Luciferase activities were measured and compared. As shown in Fig. 3-8A, over-
expression of wild type Foxa1 did not significantly increase the androgen-induction of 
Pbsn activity, indicating that the endogenous Foxa1 level is sufficient for the maximal 
promoter response. In contrast to wild type and ∆N141-466 proteins, over-expressing 
∆C1-294 significantly inhibited the total Pbsn activity (Fig. 3-8A, P<0.01), and this 
inhibition displayed a dose-responsive manner (Fig. 3-8B). In contrast, transfection of 
same amount of ∆C1-294 cannot significantly inhibit the activity of the mutant Pbsn 
promoter (Fig. 3-8C), which contains a non-functional Foxa site (M1 in Fig. 3-8C). 
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Western blot showed that transient expression of these Foxa1 proteins in LNCaP cells did 
not result in a detectable change in the endogenous AR protein level (Fig. 3-8D), 
suggesting that the reduction in Pbsn promoter activity was not due to a reduced AR level. 
These results strongly indicated a dominant negative mechanism for ∆C1-294, and 
further supported the regulatory role of Foxa1 C-terminal region in transcriptional 
modulation.  
H. Identification of Two Functional Foxa1 Binding Sites in PSA Core Enhancer 
The results obtained for rat Pbsn gene prompted the determination of whether 
Foxa1 is also required for the regulation of human PSA gene. It has been reported that the 
core enhancer region (–4.2/-3.8 kb) of PSA gene, but not the proximal promoter, is 
essential and sufficient for androgen regulation and prostate-specificity (Schuur ER et al., 
1996; Cleutjens et al., 1997; Farmer et al., 2001; Pang et al., 1997). Six ARE are located 
in this region (Huang et al., 1999). Among these AREs, ARE Ш (at –4154/-4132bp) 
shows the highest AR-affinity and biological activity, since mutations in ARE Ш 
significantly abolished PSA enhancer activity (Huang et al., 1999). Interestingly, we 
identified two strong Foxa binding motifs in this enhancer region (Fig. 3-9A). The first 
site, designated as PSA1, is located at -4122/-4109 bp, immediately downstream of the 
ARE Ш. The second site, PSA2, is located at –4028/-4005 bp, between ARE ШA and 
ARE ШB (Fig. 3-9A). In vitro synthesized Foxa1 bound to both elements (Fig. 3-9B, 
lane 2 vs. 3 and 3-9E, lane 3 vs. 4). Similar to the results for Pbsn, mutant Foxa1 proteins 
(∆N, ∆C and FH) containing the FH domain also showed binding activity (Fig. 3-9B 
lanes 4-6). In addition, the binding of Foxa1 was supershifted by Foxa1 antibody (lane 3 
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vs. 7). Therefore, both elements were confirmed to be authentic Foxa1 site by these in 
vitro experiments.  
Since PSA1 is closely adjacent to ARE Ш, it was intriguing to ask whether Foxa1 
and AR can bind to the DNA concomitantly. Thus, an oligonucleotide (Table 2-1) 
containing both ARE Ш and PSA1 was radiolabeled and incubated with constant amount 
of a purified GST-AR-DBD fusion protein. A specific AR-DBD/DNA complex was 
formed (Fig. 3-9C, lane 4). As increasing amount of Foxa1 proteins were added to the 
reaction, a specific Foxa1/DNA complex as well as a slow-migrating band 
(AR/Foxa1/DNA ternary complex) became stronger (lanes 5-8). Addition of Foxa1 
antibody disrupted the complex (lane 9). Similarly, in EMSA using LNCaP nuclear 
extract, Foxa1 antibody disrupted a strong complex that formed with this oligonucleotide 
(Table 2-1, PSA1) containing both Foxa1 and AR binding sites (Fig. 3-9D, lane 2 vs. 3). 
These data indicate that AR and Foxa1 can bind to respective DNA binding sites 
concomitantly. Thus, the binding of one protein does not negatively affect the adjacent 
binding of another protein. However, the dislocation of Foxa1 from target binding site 
(Fig. 3-9C, lane 9) may destabilize a higher-order protein complex associated with this 
entire regulatory region, which may include AR. 
A similar mutation assay was performed to determine the biologic relevance of 
these Foxa1 motifs in PSA enhancer. Fig. 3-10A shows two mutant PSA reporter 
constructs, mPSA1-EP and mPSA2-EP, which were generated by PCR and transfected 
into LNCaP cells. Luciferase activities were measured and compared with wild type 
construct. Fig. 3-10B shows that point mutations that abolish Foxa1 binding in either 
PSA1 (Fig. 3-10C, lane 2) or PSA2 (lane 4) significantly affected the maximal androgen-
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induced PSA activities (Fig. 3-10B, P<0.01). A reduction of 95% activity in PSA 
enhancer has been reported previously by deleting the region corresponding to PSA1 
(Farmer et al., 2001). Similarly, the direct interaction between AR and ARE Ш remained 
intact when mutant oligonucleotide (Table 2-1, mPSA1), containing both ARE Ш and 
mutant Foxa motif, was used in EMSA (Fig. 3-10D), indicating that the loss of PSA 
activity is not directly due to the loss of AR/ARE Ш binding. These results suggest that 
both Foxa1 motifs are essential for maximal PSA induction by androgen. 
I. Foxa1 Binds PSA Enhancer In Vivo 
Since LNCaP cells express endogenous PSA gene, chromatin 
immunoprecipitation (ChIP) was performed to investigate the in vivo association of 
Foxa1 with PSA enhancer. Fig. 3-11A is a schematic diagram of PSA regulatory region. 
Five previously described DNA fragments (Shang et al., 2002) corresponding to the distal 
region, ARE Ш, middle region, ARE Π and ARE І were tested in the experiment. The 
ARE Ш region (-4170/-3978 bp) is a 192-bp fragment that covers both Foxa1 motifs we 
identified in this study (Fig. 3-11A). To determine the occupancy of Foxa1 on active 
versus inactive PSA chromatin status, LNCaP cells were initially grown in RPMI-
medium 1640 supplemented with 5% charcoal/dextran treated fetal bovine serum. After 3 
days of cultivation, cells were either treated with 10-8 M DHT or retained in androgen-
depleted medium. Soluble chromatin was prepared after formaldehyde treatment of cells 
(Fig. 3-11C). Specific antibodies against Foxa1 or AR were used to immunoprecipitate 
antigen-bound genomic DNA fragments. The DNAs were amplified by PCR using 
specific primers (Shang et al., 2002) spanning the tested regions. After 48 h of DHT 
treatment, PSA expression was induced as compared to the undetectable level in 
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untreated cells (Fig. 3-11B). In contrast, the expression levels of Foxa1 protein were 
almost identical in androgen-treated and untreated cells. In agreement with previous 
study (Shang et al., 2002), DHT induced the recruitment of AR onto multiple AREs, but 
not control regions (Fig. 3-11D). In contrast to AR, Foxa1 constantly occupies the ARE 
Ш region independently of DHT treatment (Fig. 3-11D).  These ChIP assays 
demonstrated the in vivo association of Foxa1 with PSA enhancer, and also indicated that 
the occupancy of Foxa1 alone does not result in the transactivation of PSA gene.  
J. Foxa1 Binds Other Prostate-Specific Enhancers 
Foxa1 binding sites were further identified in other prostate specific gene 
regulatory regions. As shown in Fig. 3-12A, the proximal promoter of the rat prostatic 
acid phosphatase gene (rPAP) contains a Foxa1 binding sequence at –113/-103 bp. This 
sequence as well as an upstream ARE is well conserved in its human homologue hPAP 
gene promoter (Virkkunen et al., 1994). In the hPAP upstream enhancer (-1258/-779 bp), 
a G/T rich region (-1183/-1151 bp) contains two Foxa1 binding sites with a putative ARE 
in the middle. This region also exists in rPAP enhancer (Fig. 3-12A), except that only one 
Foxa1 binding site was found. Importantly, the hPAP enhancer (-1258/-779 bp) is related 
with the cell-specific expression of hPAP gene (Patrikainen et al., 1999). In addition, two 
Foxa1 motifs (at -184/-173 bp and -141/126 bp, Fig. 3-12A) were found in the rat 
prostatic steroid binding protein C1 (PBP C1) gene promoter (Claessens et al., 1989). All 
these Foxa1 sites were experimentally confirmed by EMSA. The sequences used in 
EMSA were shown in Table 2-1. Fig. 3-12B is a schematic diagram showing a striking 
similarity in the organization of binding motifs for Foxa1 and AR in these highly 
prostate-specific genes, suggesting a common functional mechanism may apply.  
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Figure 3-1. Key cis-regulatory elements in the prostate tissue-specific Pbsn promoter 
-286/+28 bp. Linker scan mutagenesis mapped five important cis-regulatory elements in 
addition to ARBS1 and ARBS2. Among these elements, there are potential binding sites 
for ubiquitous transcription factor Oct1, c-jun, C/EBP and NF1. In addition two tissue 
specific elements, namely TS1 and TS2, were revealed to be just immediately flanking 
the individual androgen response elements. 
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Figure 3-2. Ubiquitous transcription factors bind Pbsn -286/+28 bp. (A) Oct1 binds 
to Pbsn promoter. EMSA shows LNCaP nuclear extracts (N.E.) bind to radiolabeled 
Pbsn -226/-187 bp (lane 2), as compared to lane 1 where no nuclear extract was added. 
The binding was competed by 50×, 100× and 200× amount of cold Oct1 consensus 
oligonucleotides (lanes 3-5). Lane 5, binding was also supershifted by an antibody to 
Oct1. Competition assay was performed reversely by using Pbsn -226/-187 bp to compete 
the binding of Oct1 consensus probe (lanes 7-11). Lane 12, supershift assay shows Oct1 
antibody supershifted the complex formed by LNCaP N.E. and Oct1 consensus probe. (B) 
NF1 binds to Pbsn promoter. EMSA shows LNCaP N.E. bind to radiolabeled Pbsn -96/-
67 bp (lane 2). The binding intensity was reduced when a mutant Pbsn -96/-67 bp probe 
was used (lane 3). The complex was also competed off by cold Pbsn -96/-67 bp (lane 4-5) 
or by consensus NF1 binding site (lane 6-7). The binding was not competed by control 
oligonucleotides (lane 8-11). (C) The complex formed on Pbsn -96/-67 bp was eliminated 
by NF1 antibody (lane 3 vs. 2), but not reduced by control antibodies (lane 4-6). The 
complex formed on consensus NF1 binding site was also reduced (or supershifted) by 
NF1 antibody (lane 9 vs 8), but not an Oct1 antibody (lane 10). Same NF1 antibody has 
no effect on the complex formed with a control Oct1 binding site (lane 12 vs. 11), while 
Oct1 antibody produced a supershift (lane 13). (D) AP1 and C/EBP bind to Pbsn. The 
complexes formed by LNCaP and Pbsn -116/-87 bp (lane 2) were reduced by using a 
mutant -116/-87 bp probe (lane 3). The binding was also competed off by cold -116/-87 
bp oligonucleotides (lane 4-5), AP1 consensus (lane 6-7) and C/EBP consensus (lane 8--9) 
binding sites, but not by a control oligonucleotide (lane 10-11).      
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Figure 3-2 (continued). (E) EMSA shows that c-jun antibody (lane 3) and C/EBP 
antibody (lane 6) supershifted the complex formed by LNCaP and radiolabeled Pbsn -
116/-87 bp (lane 2). Other control antibodies (lane 4-5), including c-fos antibody (lane 4), 
had no effect. C-jun antibody also supershifted the complex formed on the consensus 
AP1 binding site (lane 9 vs 8). Same antibody had no effect on the complex formed on a 
mutant Pbsn -116/-87 probe. 
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Figure 3-3. SDS-PAGE fractionation of LNCaP nuclear extracts and molecular 
mapping of TS1-, TS2-interacting proteins. (A) LNCaP N.E. were fractionated into 9 
factions according to molecular weight. DNA binding activities to TS1 (lane 11-20) or 
TS2 (lane 1-10) were tested by EMSA, which revealed a similar binding pattern. Lane 1 
and 11 are controls using total LNCaP N.E. (B) Binding activities for both TS1 and TS2 
were calculated to be at 35-44 kDa, 45-52 kDa, 53-70 kDa and 90-115 kDa, based on the 
migration-molecular weight curve. 
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Figure 3-4. Identification of Foxa (HNF-3) motifs in Pbsn promoter (A) Location of 
Foxa motifs. Mutation study revealed two key cis-acting elements R1 and R2 (dashed 
lines). Each contains a potential Foxa binding motif (bold arrows). The direction of the 
arrow indicates the sense or the antisense strand that matched the consensus sequence. 
Two adjacent ARBSs (ARBS-1 and ARBS-2) are underlined. Sequences in italic indicate 
the nucleotide replacements in mutation assays. (B) LNCaP nuclear extracts were 
incubated with radiolabeled TTRs (consensus Foxa binding sequence), Pbsn -127/-102, 
or Pbsn -257/-232 probes. Strong complexes formed with TTRs (lane 2). Foxa1 or Foxa2 
antibody reduced the corresponding band (lanes 3 and 4). Four complexes, a, b, c and d, 
were formed with R2 (lane 7). Complexes b and c were specifically removed by Foxa1 or 
Foxa2 antibody (lanes 8 and 9), but not other mock antibodies (lanes 10–16).  
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 Figure 3-4 (continued). Molar excess (200-fold) of cold TTRs oligonucleotides 
completely competed off complexes b and c (lane 17), whereas 400- and 600-fold molar 
excess of TTRs also affected complex a (lanes 18 and 19). Three complexes, A, B, and C, 
were formed with R1 (lane 18). Complex B was specifically eliminated by Foxa1 (HNF-
3α) antibody (lane 19). (C) Western blot. Whole-cell lysates (20 µg) from HepG2, Hela, 
Cos-1, LNCaP, PC3, and DU145 cells were resolved on SDS-PAGE and probed with 
Foxa1 antibody. (D) A radiolabled oligonucleotide (ARBS2/R2, Table 2-1) containing 
both ARBS-2 and R2 was used in EMSA with 10 µg LNCaP nuclear extract. With the 
presence of an ARBS, two Foxa1 complexes (arrows) still formed with R2, because both 
complexes were reduced or removed by Foxa1 antibody (lane 1 vs. 2), or eliminated by 
mutating the Foxa1 motif in ARBS2/R2-M (lane 7, Table 2-1). Both complexes were not 
affected by 100-, 200-, and 500-fold molar excess of cold ARBS-2 site (lanes 4–6), 
whereas several other complexes (asterisk) were sensitive to the competition. (E) 
Southwestern bloting. Nuclear extracts from LNCaP and PC-3 cells were separated on 
SDS-PAGE, transblotted to nitrocellulose membranes, and probed with radiolabeled 
2xR2 (lanes 1 and 3), 2xmR2 (lanes 2 and 4) or 2xAR-con probes (lane 5). A Western 
blot using Foxa antibody was performed as a parallel control. Arrows indicate migration 
of proteins bound to the respective probes or antibody. 
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Figure 3-5. In vitro synthesized Foxa1 (HNF-3α) binds Pbsn promoter. (A) Wild-type 
Foxa1 and three truncated proteins ( N, FH, and C shown in panel D) were synthesized 
by in vitro TNT, and incubated with radiolabeled PB-127/-102 probe. In contrast to a 
nonspecific band (arrowhead) formed with the TNT blank control (lane 2), wild- type 
Foxa1 and Foxa1 C formed a strong complex (lanes 3 and 6), whereas N and FH 
(arrowhead) showed weak binding ability (lanes 4 and 5, overexposure). (B) The binding 
of Foxa1 with Pbsn -127/-102 was eliminated by an antibody raised against the Foxa1 C 
terminus (lane 3 vs. 2). The same antibody did not affect the complex formed by Foxa1
C, which has a deletion in the C terminus (lane 6 vs. 5). The Foxa1 binding was also 
affected by mutating the TRTTTGY motif (lane 4 vs. 2). (C) Weaker binding affinity was 
observed when Pbsn -257/-232 was used as a probe (lane 4 vs. 2).  
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Figure 3-7. Foxa1 (HNF-3 ) motifs are essential for maximum androgenic induction 
of Pbsn. (A) Wild-type PB promoter sequences containing boxed Foxa1 motifs were 
mutated (underlined lowercase characters) as indicated in M1–M3. (B) EMSA was 
conducted using 10 µg LNCaP cell extracts incubated with either wild-type PB-127/-102 
or mutant R2 probes (lanes 1–3). M1 disrupted the binding of three complexes (lane 2, a, 
b, and c), whereas only the higher-order complex “a” was eliminated by M2 (lane 3). 
Addition of Foxa1 antibody further removed complexes b and c (lane 4). (C) LNCaP 
cells were transiently transfected with luciferase reporter constructs (0.2 µg/well) 
containing either wild-type or mutant (M1–M3) PB promoters. Each well also received 
0.0125 µg of Renilla vector. Cells were treated with or without 10-8 M DHT for 24 h 
before harvest. Background activities of cell lysates with no DNA transfection were 
subtracted from the data obtained in the experimental group, before the normalization 
with Renilla activities. Results are presented as relative luciferase activity. Data shown 
here is a representative from at least six independent experiments in triplicate. Error bars 
indicate SD values. Asterisk indicates where P < 0.01 as compared with the androgen-
induced activity in wild-type (WT) reporter. (D) Probes (ARBS2/R2-M1, -M2, and 
ARBS1/R1-M3, Table 2-1) containing mutant Foxa1 motifs were used in EMSA to 
determine their interactions with a purified GST-AR-DBD protein.  
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Figure 3-8. Dominant negative Foxa1 (HNF-3 ) inhibits Pbsn promoter activity. (A) 
An empty vector as well as expression vectors corresponding to wild-type Foxa1, N141-
466, or C1-294 (0.2 µg per well) were cotransfected with a Pbsn luciferase reporter into 
LNCaP cells. Cells were treated with or without 10-8 M R1881 for 24 h followed by 
luciferase assays. (B) Different amounts of C1-294 (0.05 µg, 0.15 µg, or 0.25 µg per well) 
were cotransfected into LNCaP cells with Pbsn reporter. Luciferase activities were 
determined after 24 h incubation in the presence or absence of androgen. (C) In contrast 
to panel B, C1-294 (0.05 µg, 0.15 µg, or 0.25 µg per well) was cotransfected into LNCaP 
cells with a mutant Pbsn reporter (M1, in Fig. 3-7A). Error bars indicate SD values. 
Asterisk indicates P < 0.01 in comparison with androgen-induced activities in control 
wells, which were transfected with empty vector. (D) No significant change in AR 
protein level was detected by Western blot in cells transiently transfected with wild-type 
Foxa1, N141-466, or C1-294.  
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Figure 3-9. Identification of Foxa1 (HNF-3α) Binding Motifs in PSA Enhancer. (A) 
Two Foxa1 binding sequences (bold arrow) were identified in the PSA core enhancer (-
4.2/-3.9 kb) region. The first element (-4122/-4109), designated as PSA1, is adjacent to 
ARE III (underlined). The second one (-4028/-4005), designated as PSA2, is located in 
the middle of ARE IIIA and ARE IIIB (underlined). (B) EMSA. In vitro synthesized 
wild-type Foxa1 and mutant proteins ( N, FH, and C) were able to bind PSA1 (lanes 
3–6) as compared with the TNT blank control (lane 2). The Foxa1 binding was 
supershifted by the Foxa1 antibody (lane 3 vs. 7). (C) Concomitant DNA binding of AR 
and Foxa1. Radiolabeled oligonucleotide containing both ARE III and PSA1 was 
incubated with a constant amount (0.1 µg) of a purified GST AR-DBD protein. A slow 
migrating ternary complex (AR/Foxa1/DNA) (lanes 5–8) was formed as addition of 
increasing amounts (1, 2, 3, and 4 µl) of in vitro synthesized Foxa1, in contrast to Foxa1 
alone (lane 3) or AR alone (lane 4), indicating that Foxa1 and AR can occupy DNA 
concomitantly. The ternary complex was disrupted by addition of Foxa1 antibody (lane 
9). (D) EMSA using LNCaP nuclear extract shows the formation of Foxa1/PSA1 
complexes (lane 2), which were disrupted by Foxa1 antibody (lane 3). The probe PSA1 
(see Table 2-1 for sequence) contains binding sites for both AR and Foxa1. (E) In vitro 
synthesized wild-type Foxa1 also interacts with PSA2 (lane 4). 
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Figure 3-10. Mutations in forkhead motifs inhibited maximal androgen induction of 
PSA. (A) Two mutant PSA reporters (mPSA1-EP and mPSA2-EP) were generated by 
introducing point mutations to Foxa1 (HNF-3α) motifs in PSA1 and PSA2, individually. 
(B) LNCaP cells were transiently transfected with wild-type and mutant PSA-EP 
luciferase constructs. Luciferase activities were determined after 24 h incubation in the 
presence or absence of 10-8 M R1881. Three independent experiments were performed in 
triplicate. Background activity of untransfected cell lysate was subtracted from the results 
before normalization with Renilla activities. Error bars indicate SD values. Asterisk 
indicates where P < 0.01 in comparison with the androgen-induced activity in wild-type 
reporter. (C) Oligonucleotides containing mutant Foxa1 sites (mPSA1 and mPSA2, Table 
2-1) was used in EMSA to determine the Foxa1 binding. (D) An oligonucleotide (mPSA1, 
Table 2-1 for sequence) containing both ARE III and a mutant Foxa1 motif shows similar 
binding intensity with a purified GST AR-DBD protein in EMSA.  
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Figure 3-11. Foxa1 (HNF-3α) binds PSA Enhancer in vivo. (A) Schematic diagram of 
PSA gene 5'-upstream region. Six DNA fragments corresponding to the distal, ARE III, 
middle, ARE II, and ARE regions were amplified in ChIP assays using primers described 
previously. (B) LNCaP cells were initially grown in RPMI 1640 with 5% 
charcoal/dextran-treated fetal bovine serum for 3 d. Cells were then incubated for another 
48 h with or without 10-8 M DHT treatment. Western blot was performed to determine the 
expression levels of PSA and Foxa1. (C) Formaldehyde-cross-linked chromatins were 
sheared by sonication into an average size of 0.5–1.0 kb. (D) After an overnight IP with 
AR or Foxa1 antibodies, formaldehyde cross-linking was reversed, and DNA fragments 
were extracted, followed by PCR amplification (Materials and Methods).  
 110
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-12. Similar organization of forkhead and androgen response elements in 
prostate-specific gene enhancers. (A) A summary of Foxa1 (HNF-3α) binding motifs 
identified in prostate-specific enhancers. (B) Schematic diagram showing remarkable 
similarity in the organization of AR and Foxa1 binding motifs in different prostate-
specific gene regulatory regions.  
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CHAPTER IV 
 
FOXA1 (HNF-3α) PHYSICALLY INTERACTS WITH ANDROGEN RECEPTOR 
 
Introduction 
 Steroid receptors play a pivotal role in transcriptional control of numerous genes. 
In addition to acting via specific steroid response DNA elements, steroid receptors 
interact with many co-regulators as well as other DNA-binding transcription factors 
(Heinlein and Chang, 2002).  
 The cross-modulations between androgen and other pivotal signaling pathways 
through the direct interaction between AR and several sequence-specific transcription 
factors have been well-documented. Some of these AR-interacting proteins are essential 
mediators of other crucial intracellular signaling pathways. The overall effects of such 
cross-modulation from growth factors or cytokine signaling may result in altered 
transcriptional activity of AR, providing opportunities for tissue-specific or environment-
responsive gene expression.  
AP-1 and NFκB are two of the best characterized AR-interacting transcription 
factors which play key roles in affecting AR transcriptional activity. In addition, AR has 
also been found to be directly interacting with STAT3 and Smad3, both of which are 
signal transduction mediators. In addition, AR can also interact with tissue specific 
transcription factors such as the testis-specific factor SRY, and the prostate-enriched ets 
factor PDEF and the T cell factor 4 (Amir et al., 2003).  
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It has been reported that GR-mediated activation of multiple liver-specific genes 
requires Foxa2 (HNF-3β) (Espinas et al., 1995; Stafford et al., 2001; Wang et al., 1999; 
O'Brien et al., 1995; Wang et al., 1996; Christoffels et al., 1998). Recent studies showed 
that ER interacts with three forkhead transcription factors, FKHR, FKHRL1 and AFX 
(Schuur et al., 2001; Zhao et al., 2001). AR is a member of the steroid receptor family 
and shares many similarities with GR and ER in terms of structure and mechanism of 
function. The observation of close proximity of AR and Foxa1 (HNF-3α) binding sites in 
various gene promoters prompted us to examine if these two proteins can interact with 
each other. 
 
Results 
A. Foxa1 Precipitates with AR 
Co-Immunoprecipitation (Co-IP) was performed in an AR-Hela cell line (Huang 
et al., 1999), in which a flag-tagged full-length AR was stably integrated. Since Hela cells 
do not express Foxa1 (Fig. 3-4C), we transfected a Foxa1 mammalian expression vector 
(pcDNA3.1D/V5-Foxa1) and a control LacZ expression vector (pcDNA3.1D/V5-LacZ) 
into these cells. Western blot using anti-V5 confirmed the expression of V5-tagged LacZ 
and Foxa1 proteins in transfected cells (Fig. 4-1A, lanes 3, 4 vs. 1, 2). Cells were grown 
in medium with 10-8 M DHT. All cell lysates were immunoprecipitated with anti-flag 
M2 affinity gel in the presence of ethidium bromide (EB, 0-100 µg/ml), which was used 
to disrupt DNA/protein interactions (Lai and Herr, 1992). The gel was washed prior to 
Western blot analysis. As seen in Fig. 4-1B, flag-AR was detected in all AR-Hela 
precipitates (lanes 6-10) in contrast to normal Hela precipitate (lane 5). Only Foxa1 (lane 
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14-16) but not LacZ (lane 13) was detected in the AR-Hela precipitates, indicating that 
flag-AR specifically immunoprecipitates with Foxa1. Importantly, this interaction was 
resistant to the presence of EB (lanes 15 and 16), ruling out the possibility that it was 
mediated through DNA.  
B. Endogenous Foxa1 Physically Interacts with AR 
 Since the IP experiment in AR-Hela cells was performed in a condition where 
both Foxa1 and AR are overexpressed, the observation may not reflect a physical 
situation. Since LNCaP cells expressed both proteins, Co-IP was performed in LNCaP 
cells to examine this interaction in a physical circumstance where AR and Foxa1 proteins 
are expressed at endogenous levels. LNCaP cells were either grown in androgen-depleted 
medium for at least 3 days or grown in the presence of 10-8 M DHT. Cell lysates (1 mg 
per IP reaction) were immunoprecipitated with anti-AR-conjugated protein G-sepharose 
beads in the presence of EB. Similar IP were performed using Foxa1 antibody instead of 
anti-AR. Each reaction was performed in the presence of 1% NP-40 and 1 mg BSA to 
quench the non-specific binding. Fig. 4-1B unambiguously demonstrated a physical 
interaction of AR and Foxa1 in DHT-treated cells in contrast to androgen-depleted 
condition. This interaction was resistant to the presence of EB at a concentration of 100 
µg/ml, demonstrating a direct protein/protein interaction (Fig. 4-1B). These IP 
experiments strongly suggested that AR and Foxa1 are involved in the assembly of a 
multi-nucleoprotein complex. 
C. Responsible Domains for AR/Foxa1 Interaction 
In vitro GST pull-down assay was performed to confirm the AR/Foxa1 interaction 
as well as to determine the interacting regions. A full-length Foxa1 protein labeled with a 
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C-terminal V5 epitope was synthesized in vitro. Five GST-AR fusion proteins containing 
different AR subdomains (Fig. 4-2A) were purified as described before (Snoek et al., 
1996). Fig. 4-2B is a GST pull down experiment showing that the AR DBD/hinge region 
(524-649 amino acids) alone is sufficient to mediate the interaction with Foxa1. 
Experiments were repeated at least five times.  
In the experiments, the ARNT/DBD showed a weaker interaction with Foxa1 as 
compared with ARDBD/Hinge or ARDBD/LBD (Fig. 4-2B), suggesting AR N-terminal 
might have a negative effect on the interaction. Although the biological relevance of this 
effect is currently unknown, this effect was obviously not due to the lower activity of 
ARNT/DBD protein, since it bound to ARBS-1 sequence (on Pbsn promoter) with a 
similar extent as ARDBD/Hinge or ARDBD/LBD on a molar basis (Fig. 4-2C).  
In Fig. 4-2A and D, in vitro synthesized Foxa1 fragments were used to map the 
AR-interacting region(s) in Foxa1 protein. Most interestingly, the forkhead domain 
(amino acids 141-294) alone was sufficient to mediate a strong interaction with AR (Fig. 
4-2D, lanes 13, 22 and 31), whereas the N- or C- terminal domain alone did not bind with 
AR. Fig. 4-2E demonstrates that the interaction between ARDBD/Hinge and Foxa1 
forkhead domain was insensitive to the presence of EB (0-150 µg/ml), supporting a direct 
protein/protein interaction.  
The ligand effect on this interaction was also examined (data not shown) and the 
results suggested that, under these in vitro conditions, the interaction between 
ARDBD/LBD and Foxa1 could occur without ligand. This was not surprising since in 
vitro purified GST-ARDBD/LBD fragment may not act identically as in vivo wild type 
AR, in terms of protein folding. Although these in vitro binding experiments cannot 
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exactly reflect the physical conditions, they identified responsible regions for AR/Foxa1 
interaction. 
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Figure 4-1. Foxa1 (HNF-3 ) co-immunoprecipitates with AR. (A) AR-Hela cells, with 
stably integrated flag-AR, were transfected with an Foxa1 expression vector 
(pcDNA3.1D/V5-Foxa1) and a control LacZ expression vector (pcDNA3.1D/V5-LacZ). 
Western blot using anti-V5 antibody detected the V5-labeled LacZ (lane 3) and Foxa1 
(lane 4) proteins in transfected cells, but not in nontransfected cells (lanes 1 and 2). All 
cell lysates were immunoprecipitated by an anti-flag M2 affinity gel in the presence of 
EB. The gel was washed before Western blot analysis. Anti-flag detected flag-AR in all 
AR-Hela cell precipitates but not in normal Hela cells (lanes 5 vs. 6–10). Anti-V5 
detected Foxa1 (lanes 14–16) but not LacZ (lane 13) in AR-Hela precipitates. The 
AR/Foxa1 interaction was not affected in the presence of 25 µg/ml (lane 15) and 100 
µg/ml (lane 16) EB. (B) LNCaP cell lysates (1 mg per IP) from DHT-treated or untreated 
cells were immunoprecipitated with Foxa1 or AR antibody in the presence of EB (0–100 
µg/ml) as indicated. Western blot was performed using individual antibodies as indicated. 
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Figure 4-2. Mapping interaction domains by GST pull-down. (A) A schematic 
diagram showing a series of AR and Foxa1 (HNF-3 ) subdomains used in in vitro GST 
pull-down assays. The AR DBD/hinge region and the Foxa1 FH domain are highlighted 
in black. Two conserved Foxa1 C-terminal domains designated as region 2 and 3 are in 
striped boxes. (B) Five purified GST-AR fusion proteins (20 µg for each) were bound to 
glutathione agarose beads, followed by incubation with V5-labled Foxa1 protein 
synthesized in vitro. Western blot was performed to determine the Foxa1-interacting 
domain in AR. (C) The GST AR fusion proteins DBD/Hinge (50 ng), NT/DBD (250 ng), 
and DBD/LBD (150 ng) were used in EMSA to determine their DNA binding activities 
with ARBS-1 on a molar basis. (D) The expression of eight V5-labeled Foxa1 
subdomains as well as a LacZ protein was confirmed in Western blot (lanes 1–9). These 
proteins were in vitro synthesized and incubated with the GST-bound AR NT/DBD, 
DBD/Hinge, and DBD/LBD to determine the AR-interacting region in Foxa1. (E) The 
interaction of AR-DBD/Hinge and Foxa1 FH domain was resistant to the presence of 25–
150 µg/ml of EB. LBD, Ligand-binding domain; NT, N-terminal domain.  
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Figure 4-2 (continued). 
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CHAPTER V 
 
FOXA1 IS ESSENTIAL FOR REGULATED PROSTATIC DUCTAL 
MORPHOGENESIS AND EPITHELIAL CELL MATURATION 
 
Introduction 
The impetus for studying the development of the prostate gland stems from the 
increasing incidence of diseases that affect it. The prostate is an exocrine gland composed 
of extensively branched ductal networks which develop from the embryonic urogenital 
sinus (UGS), a derivative of the hindgut (Cunha et al., 1987). In mice, at around 
embryonic day 18 (E18), the endoderm-derived urogenital sinus epithelium (UGE) 
invades into the surrounding urogenital sinus mesenchyme (UGM), forming the earliest 
prostatic epithelial buds. This initial morphological event is dependent on systemic 
androgens produced by the fetal testis (Cunha et al., 1987). The subsequent outgrowth of 
prostatic buds gives rise to a number of solid epithelial cords, in which immature 
progenitor cells co-express numerous cytokeratins (Ck),  Ck5, Ck8, Ck14, Ck18, and 
other markers such as p63 (Wang et al., 2001). Prostate branching morphogenesis and 
cytodifferentiation occur postnatally (1-3 week) (Sugimura et al., 1986a). As the ducts 
branch and canalize, epithelial cells differentiate into two distinct cell populations, the 
luminal and basal cells, each expressing a subset of characteristic markers (Ck8 and Ck18 
for luminal cells, Ck5, Ck14 and p63 for basal cells) (Wang et al., 2001; Hayward et al., 
1996a).  Prior to puberty, the serum levels of androgens rise and the luminal cells begin 
to produce secretory proteins characteristic of the different prostatic lobes: the anterior 
prostate (AP), the ventral prostate (VP) and the dorsolateral prostate (DLP). By sexual 
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maturation (6 weeks), secretions increase substantially as the serum androgen levels peak 
(Cunha et al., 1987). 
Regulated interactions among key signaling pathways are prerequisite for organ 
development (Chuang and McMahon, 2003). Spontaneous and engineered gene 
inactivation in the mouse, combined with organ culture and tissue recombination, have 
highlighted the essential roles of androgenic signaling and epithelial-stromal interactions 
in directing prostatic development (Marker et al., 2003; Abate-Shen and Shen, 2000). In 
the absence of androgens or of androgen receptor (AR), the prostate does not develop 
(Bardin et al., 1973; Cunha et al., 1987). Tissue recombination experiments using Tfm 
mice provide direct evidence that the stromally-located AR is essential for eliciting many 
aspects of prostatic epithelial differentiation (Donjacour and Cunha, 1993). Thus, under 
normal conditions, the growth and differentiation of prostatic epithelium is controlled 
through androgen-regulated paracrine signaling from the mesenchyme (Cunha et al., 
1987). Conversely, reciprocal paracrine signaling from the epithelium also patterns 
stromal cell differentiation (Cunha et al., 1996). Recently, emerging evidence suggested 
that the epithelial-mesenchymal interaction during early prostatic morphogenesis 
involves several conserved families of molecules, including the Sonic hedgehog (Shh) 
(Podlasek et al., 1999a; Lamm et al., 2002; Wang et al., 2003; Freestone et al., 2003; 
Berman et al., 2004), the Wnt (Yang et al., 2002), the Bone Morphogenetic Protein 
(Lamm et al., 2001), the Fibroblast Growth Factors (Thomson and Cunha, 1999; 
Donjacour et al., 2003), the Notch-Delta membrane molecule (Wang et al., 2004; Shou et 
al., 2001), and the Nkx3.1 homeobox protein (Bhatia-Gaur et al., 1999; Schneider et al., 
2000; Tanaka et al., 2000).  
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The mechanism by which androgen and diverse signaling pathways are integrated 
during prostatic organogenesis is still under active investigation. For example, Shh 
signaling regulates prostatic ductal morphogenesis, while testosterone treatment of in 
vitro cultured mouse embryonic urogenital sinus (UGS) upregulated Shh activity 
(Podlasek et al., 1999a). However, androgen treatment of rat prostate at a postnatal stage 
did not affect Shh or Ptc1 expression while the addition of recombinant Shh to in vitro 
cultured prostates caused an expansion in the mesenchyme (Freestone et al., 2003).  
Treatment of the embryonic UGS with a neutralizing antibody (Podlasek et al., 1999a) or 
cyclopamine, a chemical blocker of Shh signaling, abrogated prostatic ductal budding 
(Lamm et al., 2002). Further, abnormal activation of Shh has been reported in various 
pathologic conditions including prostate cancer (Fan et al., 2004). 
Signaling interactions could occur through different levels. In prostatic epithelial 
cells, β-catenin is a key transcriptional effector of Wnt signaling which mediates the 
interaction with androgen signaling by directly interacting with the ligand binding 
domain of AR and enhancing gene transcription (Yang et al., 2002). T cell factor 4, the 
downstream nuclear effector of Wnt/β-catenin signaling, also directly binds to the AR 
DNA binding domain and represses androgen signaling (Amir et al., 2003).  Further 
evidence indicates that Wnt/β-catenin is required for endoderm formation (Logan et al., 
1999; Imai et al., 2000; Rocheleau et al., 1997b; Stainier, 2002)..  More recently, β-
catenin was shown to interact with Sox17 to upregulate endodermal genes, including two 
forkhead proteins, Foxa1 and Foxa2 (Sinner et al., 2004).  
Forkhead transcription factors play crucial roles in the development of various 
organs (Carlsson and Mahlapuu, 2002). The vertebrate endoderm expresses Foxa1, Foxa2, 
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and Foxa3, which are involved in the formation of the epithelial gut tube (Zaret, 1999; 
Zaret, 2002). A role for this class of genes in differentiation of the gut is a feature 
conserved in metazoan development: the Drosophila ortholog of Foxa, forkhead, is 
essential for the morphogenesis of the anterior digestive tract (Weigel and Jackle, 1990; 
Weigel et al., 1989); pha-4, the Foxa relative in C. elegans, specifies the cells of the 
pharynx (Gaudet and Mango, 2002; Kalb et al., 1998; Horner et al., 1998).  
The mouse prostatic epithelium is derived from the embryonic hindgut endoderm 
and expresses Foxa1 and Foxa2 (Peterson et al., 1997; Kopachik et al., 1998; Mirosevich 
et al., 2004). Foxa1 is expressed during development and throughout differentiation, 
while Foxa2 is expressed only in the early prostatic ductal budding (Mirosevich et al., 
2004). I have shown that Foxa1 functionally interacts with AR to enhance the 
transcription of multiple prostate-specific genes associated with secretory epithelial 
differentiation (Gao et al., 2003). However, the in vivo role of Foxa1 in earlier stages of 
prostatic development has not been established.  
Several lines of evidence suggest that the expression of some mammalian 
forkhead genes is dependent on the Shh signaling pathway. Examples include Foxa2 in 
the floorplate of the neural tube (Chiang et al., 1996; Hynes et al., 1997), and the 
pharyngeal endoderm (Yamagishi et al., 2003), Foxc2 and Foxd2 in the presomitic 
mesoderm (Furumoto et al., 1999; Wu et al., 1998), and Foxf1 in lung and foregut 
mesenchyme (Mahlapuu et al., 2001). Studies suggested that the time course of Shh 
expression in normal prostate coincides with the formation of the main prostatic ducts, 
and the expression is down-regulated at the conclusion of prostate ductal development 
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(Podlasek et al., 1999a). However, a detailed cell-specific distribution and correlation of 
these key signaling molecules within developing UGS is currently unknown. 
Transgenic mice with targeted gene inactivation have provided tremendous 
insights into the mechanisms that underlie organ development. Some genetically 
engineered mice, however, die at embryonic stages prior to prostatic development; hence 
functional assessments of such genes were prevented. Until now, only a few transcription 
factors have been reported to participate in prostatic development at the molecular level. 
Nkx3.1 homeobox gene loss-of-function mutant mice are viable, and display reduced 
prostate ductal branching as well as progressive epithelial hyperplasia (Bhatia-Gaur et al., 
1999; Schneider et al., 2000; Tanaka et al., 2000). Similarly, mice carrying single or 
compound mutations in a series of Hox genes (Hoxa13, Hoxb13 and Hoxd13) have 
impaired prostate branching morphogenesis (Podlasek et al., 1999b; Warot et al., 1997; 
Economides and Capecchi, 2003). In contrast, a basal epithelial nuclear protein, p63, is 
thought to be critical for prostatic induction, since p63-deficient mice do not form 
prostatic buds and die at birth (Signoretti et al., 2000). Because p63 is not expressed in 
mesenchymal cells, the absence of prostatic induction must not be directly caused by 
mesenchymal signaling, but rather by defects in the UGE progenitor cells. Although these 
data provided important insights into some aspects of prostate development; they cannot 
fully explain the molecular mechanisms that control prostatic specification and 
differentiation. 
In the mouse, Foxa1 is first expressed in the definitive endoderm at the late 
primitive streak stage (E7-8) and later in endoderm-derived tissues (Sasaki and Hogan, 
1993). Foxa1 homozygous mutant mice die perinatally due to impaired glucose 
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homeostasis (Kaestner et al., 1999; Shih et al., 1999). Prior to the expression of Foxa1, 
Foxa2 is expressed in the early primitive streak (E6.5), and later in the definitive 
endoderm, the notochord and the floor plate of the neural tube (Sasaki and Hogan, 1993). 
In contrast to Foxa1 deletion, homozygous inactivation of Foxa2 results in a more severe 
phenotype which includes defective foregut morphogenesis and absence of the notochord 
(Weinstein et al., 1994).  
Since Foxa1 interacts with AR to control genes associated with differentiation 
(Gao et al., 2003) and since Foxa2 expression correlated with early prostatic budding 
(Mirosevich et al., 2004), I hypothesized that Foxa1 and Foxa2 play essential but distinct 
roles in prostatic organogenesis. Here the impact of Foxa1 loss-of-function and 
haploinsufficiency on the development of mouse prostate was evaluated through two in 
vivo model systems: organ rescue and tissue recombination. Our findings established that 
Foxa1 regulates prostatic ductal morphogenesis, and controls epithelial cell organization, 
proliferation, and maturation. Altered epithelial-stromal patterning found in Foxa1-/- 
prostates is due at least in part to the hyperactivity of Shh and Foxa2, and the loss of 
Nkx3.1 signaling molecules in Foxa1-/- epithelial cells. Thus, through the identification 
of a cis-regulatory code, Foxa1 was revealed to be crucial for the prostatic organogenesis.  
 
Results 
A. Distribution of Foxa1, Foxa2, Shh, Ptc1, β-catenin and AR in embryonic UGS 
Embryonic UGS is a simple tubular structure containing a multilayered 
endoderm-derived epithelium and a surrounding undifferentiated mesenchyme. Prostatic 
morphogenesis is initiated at embryonic day 17-18 (E17-18) in the mouse, with the 
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epithelium budding into the surrounding urogenital sinus mesenchyme (UGM) (Cunha et 
al., 1987). Fig. 5-1A shows an E18 mouse UGS. The entire urogenital sinus epithelium 
(UGE) is immunopositive for Foxa1. As expected, no positive staining was observed in 
UGM. The same section was  stained for cytokeratin 14 (Ck14), a marker for basal 
epithelial cells (Fig. 5-1B). Both Ck14-positive and Ck14-negative epithelial cells 
express Foxa1 at similar levels (Fig. 5-1C). At the same time, prostatic sections from a 
six week old mouse were stained for Foxa1. Strong nuclear staining was observed in the 
mature glands (Fig. 5-1D), indicating that Foxa1 expression is elevated and maintained in 
all postnatal prostate epithelium.  
Foxa2 immunoreactivity in E18 UGS was highest in the peripheral layers of basal 
epithelial cells immediately adjacent to the surrounding mesenchymal cells (Fig. 5-1E). 
Epithelial cells localized proximal to the urethral lumen were either unstained or weakly 
stained for Foxa2 (Fig. 5-1E). Dual staining revealed that Shh was co-expressed with 
Foxa2 (Fig. 5-1F, G) in the basal precursor cells which subsequently give rise to the 
nascent prostatic buds. This observation is consistent with the ability of Shh to induce 
Foxa2 expression (Sasaki et al., 1997).  
To determine how Shh signal is transduced in embryonic UGS, we checked the 
expression of Patched1 (Ptc1), which is a transmembrane receptor for Shh and is a direct 
downstream target for Shh signaling. Fig. 5-1 H-J shows a double immunofluorescent 
staining for Shh and Ptc1 in an E21 mouse UGS. Expression of Shh was continuously 
detected in the UGE with strongest activity observed in the peripheral basal epithelial cell 
layer and in the newly formed prostatic epithelial buds (white arrow in Fig. 5-1I). Ptc1 
and Shh were co-expressed in these cells (Fig. 5-1H and J). In addition to the UGE 
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compartment, Ptc1 was also detected in a mesenchymal cell population close, but not 
immediately adjacent to the UGE (Fig. 5-1H). Approximately ten-cell layers separate this 
stromal Ptc1-expressing cell population and the epithelial cell source of Shh. Such an 
arrangement is within the effective range of Shh signaling (Ingham and McMahon, 2001). 
Analysis of serial sections illustrated that this Ptc1-positive stromal cell population also 
expressed smooth muscle α-actin (SMA) (Fig. 5-1K), an early differentiation marker for 
smooth muscle cells and a direct mesenchymal target of Shh signaling (Weaver et al., 
2003). Detection of Ptc1 in both UGE and UGM suggested that Shh can act in both a 
juxtacrine and a paracrine fashion in the UGS as in other organs such as the developing 
limb (Dillon et al., 2003).  
AR is the classical mediator of androgen signaling in the UGS. AR staining in an 
E21 UGS demonstrated that all UGS cells, including the basal epithelium (Fig. 5-1L), 
were AR-positive. However, the intensity of staining was stronger in UGM as compared 
to UGE (Fig. 5-1K-L). Fig 5-1M shows that in E21 UGS, a proportion of the UGE co-
expressed both the basal cell marker p63 and the luminal cell marker Ck8, indicating its 
immature status (Wang et al., 2001).  
Staining was also performed to detect the localization of β-catenin, which, in 
cooperation with Sox 17, can promote Foxa1 and Foxa2 (Sinner et al., 2004). Staining for 
β-catenin detected specific membrane-localized signals in both UGE and the adjacent 
mesenchymal cells surrounding the epithelium (Fig. 5-1N). However, the strongest 
expression was seen in the p63-expressing peripheral basal epithelial cells (Fig. 5-1O-P).  
Finally, using in situ hybridization, we show that Foxa1 continued to be expressed 
in the postnatal developing prostate (Fig. 5-1Q) and in adult glands (Fig. 5-1S). In 
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contrast, Foxa2 was strongly but transiently expressed only during prostatic induction 
(Fig. 5-1R), its expression decreased to undetectable levels in mature secretory glands 
(Fig. 5-1T). 
Collectively, these data establish the temporal and spatial expression of crucial 
developmental proteins at the epithelial-mesenchymal interface where key signaling 
interactions could orchestrate prostatic organogenesis.  
B. Foxa1 is essential for ductal morphogenesis 
Conventional Foxa1 knockout mice have been generated using a targeting vector 
which deletes Foxa1 DNA-binding domain and creates an in-frame fusion with the 
Escherichia coli lacZ gene (Shih et al., 1999). The neonatal Foxal-/- mice die soon after 
birth, therefore the impact of Foxa1 loss-of-function on prostate development cannot be 
fully assessed. To circumvent this problem, we used two in vivo experimental strategies, 
renal capsule organ rescue (Wang et al., 2000b) and tissue recombination (Cunha and 
Donjacour, 1987).  
Urogenital tracts were dissected from neonatal Foxa1 pups (n=64). Prostatic 
rudiments are visible in Foxa1-/- mice (n=13). Histologic analysis of postnatal day 1 (P1) 
prostates from control and Foxa1-/- mice did not show a detectable difference, indicating 
that prostatic induction occurs in Foxa1-/- mice. Viable prostate rudiments from these 
mice were rescued by renal capsule grafting to intact male athymic nude mice (Wang et 
al., 2000b). To ensure the integrity of the prostatic rudiments (asterisks in Fig. 5-2A), 
intact seminal vesicles, and a portion of the urethra were retained in the grafted tissue 
(region below the broken line in Fig. 5-2A). After 2-15 weeks, the host animals were 
sacrificed and prostates were removed from the graft site. Fig. 5-2B-D shows typical 
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examples of rescued organs developed in host renal capsule for 8 weeks. The Foxa1-/- 
prostates (asterisk in Fig. 5-2D) were consistently smaller and were solid while controls 
were enlarged and contained secretions (Fig. 5-2B, C). Rescued prostates and seminal 
vesicles were compared after fine dissections (lower panel in Fig. 5-2B-D). With the 
deletion of the Foxa1 allele, β-galactosidase expression occurs under control of the Foxa1 
promoter. Staining detected the lacZ transgene expression in Foxa1+/- and Foxa1-/- 
prostate epithelium, but the abnormal epithelial cell organization was pronounced seen in 
the null (Fig. 5-2F, G).  
Histological analysis of rescued prostates showed that, in contrast to controls, 
which developed a mature lumen lined with a monolayer of secretory luminal epithelium 
(Fig. 5-2I), age-matched null prostate developed solid epithelial cell cords with 
cribriform patterns (Fig. 5-2H). No normal-appearing lumen was observed in Foxa1-/- 
prostates (Fig. 5-2H). An identical phenotype was consistently observed in ventral, 
dorsolateral and anterior lobes of all rescued Foxa1-/- prostates (n=13).  
Since AR signaling is pivotal in directing prostate development, we determined if 
loss of Foxa1 affects AR expression. Immunohistochemistry detected uniform nuclear 
AR staining in Foxa1-/- and control prostates (Fig. 5-2J-M). The results are consistent 
between different lobes (VP in Fig. 5-2J, K; DLP in Fig. 5-2L, M). Notably, when 
extending the rescue period up to 15 weeks, Foxa1-/- prostates show continuous growth 
of epithelial cords with no significant normal ductal canalization or  luminal epithelial 
cell development (Fig. 5-2O) in contrast to control prostates (Fig. 5-2N). 
As a complementary approach, tissue recombination experiments were performed 
using Foxa1+/+ and Foxa1-/- bladder epithelium from neonatal mice combined with wild 
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type embryonic E18 rat (r) UGM. Fig. 5-2P shows that recombinants, generated from 
Foxa1+/+ and Foxa1-/- epithelium, developed in the nude mouse renal capsule. The size 
and the wet weight of Foxa1-/- recombinants (n=15) are significantly smaller than control 
recombinants (n=15) even though the same number of rUGM cells were used (Fig. 5-2P-
Q). Histological comparison revealed that the wild type inductive embryonic rUGM 
failed to elicit normal-appearing prostatic glandular morphogenesis in Foxa1-/- 
recombinants (Fig. 5-2R), as it did in age-matched wild type epithelium (Fig. 5-2S). 
Since wild type rUGM was used, the recombination experiments indicated that the 
abnormal growth in the null prostates is due to the loss of Foxa1 in the epithelium. 
C. Foxa1 regulates epithelial-stromal patterning and epithelial cell maturation 
To define this phenotype in Foxa1-/- prostates, we examined the distribution of 
distinct epithelial and stromal cell populations. Immunohistochemistry for the basal 
keratin Ck5 demonstrated that Foxa1-/- prostates contain a majority of basal epithelial 
cells (Fig. 5-3A). Under normal conditions in the mouse, mature prostate glands contain 
only a small proportion (around 10%, depending upon lobe) of basal cells as compared to 
luminal cells. Basal epithelial cells are normally organized into a discontinuous layer 
located between the luminal cells and the basement membrane (Fig. 5-3C). However, 
basal keratin-expressing cells become the predominant cell type in Foxa1-/- epithelium, 
and their location is extended into the epithelial cords (Fig. 5-3B). Staining tissue 
recombinants developed from Foxa1-/- (Fig. 5-3D) and control epithelium (Fig. 5-3E) 
revealed the same phenotype.  
Since the structural alterations in the null prostates were strongly reminiscent of 
primitive epithelial cords, we performed double staining for p63 and Ck8, a nuclear basal 
 130
and cytoplasmic luminal cell marker, respectively. In normal prostatic development, 
basal and luminal markers are divided into each corresponding cell types as solid 
epithelial cords differentiate into distinct epithelial cell lineages (Wang et al., 2001; 
Hayward et al., 1996a). This is clearly illustrated in Fig. 5-3G showing that nuclear p63 
(in green) and Ck8 (in red) were expressed by distinct epithelial cell populations in 
control samples. However, Foxa1-/- epithelium contained a large number of cells that co-
expressed both markers (arrow in Fig. 5-3F). Epithelial cells with this expression profile 
can only be detected in undifferentiated UGE of normal embryo and in the solid epithelial 
cords of early developing prostate (Wang et al., 2001) (Fig. 5-1P). These results strongly 
suggested that Foxa1-/- epithelium is arrested at an immature precursor status and never 
matures even with prolonged grafting. 
To better visualize cell types and morphology, dual staining was performed for 
AR and Ck14 on each prostatic lobe (Fig. 5-3H-M). In contrast to basal cells in Foxa1+/+ 
controls (Fig. 5-3I, K and M), Foxa1-/- basal cells were enlarged, expressed AR and 
formed a continuous layer surrounding the epithelial cords (Fig. 5-3H, J and L).  
Given that loss of Foxa1 led to a failure of the prostatic epithelium to mature it 
seems likely that stromal patterning, which itself is dependent upon epithelial 
differentiation (Cunha et al., 1996), would also be abnormal (Fig. 5-3N). 
Immunohistochemistry for SMA revealed an extensive expansion in the smooth muscle 
layer surrounding the Foxa1-/- epithelial cords (Fig. 5-3N, O), suggesting mesenchymal 
hypercellularity. Age-matched normal prostate glands showed a very slender layer of 
smooth muscle surrounding the ductal epithelium (Fig. 5-3P). Interestingly, tissue 
recombinants composed of Foxa1-/- epithelium and wild type UGM show a similar 
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expansion in smooth muscle cells (Fig. 5-3Q) in contrast to control recombinants (Fig. 5-
3R). These data suggest that the Foxa1-/- epithelium is capable of inducing abnormal 
mesenchymal proliferation and patterning, probably through altered epithelial-stromal 
signaling. To further determine the differentiation status of this smooth muscle layer, we 
examined the expression of γ-actin, which is a late marker of smooth muscle 
differentiation. Fig. 5-3S and T shows that smooth muscle cells in both control and null 
recombinants express γ-actin indicating that although altered paracrine signaling from 
Foxa1-/- epithelium elicited abnormal stromal patterning, nevertheless smooth muscle 
differentiation was complete.  
Importantly, we detected a haploinsufficient phenotype from the heterozygous 
DLP of sexually mature mice, with abnormal ductal structure (Fig. 5-4B) and increased 
basal epithelial cells (Fig. 5-4D). This milder but similar histological abnormality 
confirmed that the grafting studies accurately reflected the natural consequences of the 
loss of Foxa1. 
D. Foxa1 is essential for luminal cell determination 
As prostatic branching morphogenesis and ductal canalization occur, immature 
epithelium differentiates. Under the direct stimulation of androgens, luminal cells 
produce prostate-specific secretory proteins such as Pbsn (Kasper and Matusik, 2000). 
Transmission electron microscopy provides an unbiased way to identify secretory 
features at the ultrastructural level (Sahlen et al., 2002). Electron microscopy analysis of 
luminal epithelial cells from 12-week wild type ventral prostate show tall columnar 
shapes (Fig. 5-5A), enlarged Golgi complexes, and numerous dense secretory materials, 
the prostasomes (Sahlen et al., 2002), within apical vesicles or at luminal surfaces 
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(arrows in Fig. 5-5C). These ultrastructural features, which signify secretory activity, are 
almost completely absent in age-matched Foxa1-/- epithelial cells (Fig. 5-5B, D). 
We further analyzed the expression of prostate-specific luminal markers at both a 
protein and the mRNA level. Imaging Mass Spectrometry (IMS) employing MALDI-
TOF analysis of hundreds of 50 µm spots (approximately a five cell width) on frozen 
tissue sections was used to obtain a representative protein profile of low molecular 
weight proteins. IMS has been previously used for profiling mouse prostate secretory 
proteins (Chaurand et al., 2001; Chaurand et al., 2004). Fig. 5-5E shows protein profiles 
obtained from 4-week rescued ventral prostates of Foxa1+/+, Foxa1+/- and Foxa1-/- 
genotypes. Peaks at mass to charge (m/z) 18441 and 24781 (denoted by arrows), 
consistent with the molecular weight of Pbsn (18-kDa) and prostate spermine binding 
protein (Sbp, 25-kDa) (Chang et al., 1987), were detected in Foxa1+/+ and Foxa1+/- 
prostates, but absent in Foxa1-/- prostates. Similar profiles were obtained from 12-week 
rescued prostates, indicating no change in secretory profiles with prolonged grafting.  
Based upon these results, semi-quantitative RT-PCR was performed. Pbsn mRNA 
was completely undetectable while Sbp is dramatically decreased in Foxa1-/- prostates 
compared to controls (Fig 5-5F). We have reported the critical role for two forkhead 
response elements in directing Pbsn promoter activity (Gao et al., 2003). However, in this 
study, Sbp was identified as novel Foxa1 target. To investigate this finding we examined 
the Sbp promoter and identified two forkhead binding sites immediately flanked by two 
individual androgen response elements (Fig. 5-6A), a similar arrangement to that seen in 
other androgen-driven prostate-specific gene enhancers (Gao et al., 2003). These binding 
sites were experimentally confirmed by EMSA (Fig. 5-6B), strongly supporting the idea 
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that Foxa1 is essential for both the expression of a wide variety of secretory proteins in 
the prostate and for the differentiation of luminal cells.  
E. Activation of Shh and Foxa2 in Foxa1-/- prostate leads to epithelial 
hyperproliferation and stromal expansion 
 
The phenotype seen in Foxa1-/- prostates indicated altered epithelial-
mesenchymal interaction. To explore this defect at a mechanistic level, we examined the 
potential signaling pathways that may attribute to this abnormality. Given that Shh 
signaling is important in prostatic ductal morphogenesis, we first examined Shh and Ptc1 
expression by immunofluorescent staining of rescued Foxa1-/- prostates. Strong and 
focused Shh expression was detected in Foxa1-/- epithelial cell cords (Fig. 5-7A) and 
Shh-positive ductal epithelial buds were evident (Fig 5-7B). The same epithelial cell buds 
were positive for Ptc1 staining (Fig. 5-7C). Detection of epithelial Ptc1 in normal 
neonatal prostatic ductal tips has been reported recently (Pu et al., 2004). No focused 
staining for Shh and Ptc1 was observed in age-matched wild type prostates. By 
comparing the staining for SMA (top two arrows in Fig. 5-3N), which was performed on 
a serial section, we noted that the Shh-expressing epithelial cell buds (denoted by arrows 
in Fig. 5-7B) are surrounded by a thick smooth muscle layer. Since SMA is a 
mesenchymal target of Shh signaling, these data suggest that the localized Shh signal 
produced by Foxa1-/- epithelium may contribute to the altered epithelial-stromal 
interaction. 
We have shown that Foxa2 is transiently expressed in UGE and nascent prostatic 
epithelial buds (Fig. 5-1R), and that Foxa2 expression correlates with Shh (Fig. 5-1E-G). 
To examine Foxa2 expression in Foxa1-/- epithelium, immunohistochemistry was 
performed on serial sections, and Foxa2 nuclear staining was detected in most of the 
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Foxa1-/- epithelial cells (Fig. 5-7D). Strong Foxa2 expression was seen in epithelial buds 
where Shh was present (Fig. 5-7E). Foxa2 positive cells formed numerous microlumen 
with cribiform patterns (denoted by arrows in Fig. 5-7F). These changes are consistent 
with the epithelial hyperproliferation in Foxa1-/- prostate. A continuous expansion of 
Foxa2-expressing cells was observed in rescued Foxa1-/- prostates with extended rescue 
period of 15 weeks (Fig. 5-7G). Age-matched control prostates, consistent with previous 
reports (Kopachik et al., 1998; Mirosevich et al., 2004), show complete negative staining 
for Foxa2 (Fig. 5-7H). We confirmed these observations in tissue recombination 
experiments. The Foxa1-/- recombinants show many tiny epithelial buds that contain 
Foxa2-positive cells (arrows in Fig. 5-7I and J), suggesting Foxa2 expression closely 
correlates with epithelial cell proliferation and budding, a role consistent with its 
expression pattern during embryonic UGE proliferation (Fig. 5-1E).  
Nkx3.1 is a prostate-specific homeobox gene which has been reported as the 
earliest known marker for prostate development (Bhatia-Gaur et al., 1999). Nkx3.1-/- 
mice display progressive epithelial cell hyperplasia in the prostate (Bhatia-Gaur et al., 
1999; Schneider et al., 2000; Tanaka et al., 2000). The hyperproliferation in Foxa1-/- 
epithelium is more severe than in Nkx3.1-/-mice. Thus, we examined Nkx3.1 expression 
in Foxa1-/- prostates. Fig. 5-7K shows Nkx3.1 staining on a section adjacent to the area 
in Fig 5-7B, showing Shh staining. No nuclear staining was observed in the Foxa1-/- 
epithelial cells that express Shh and Foxa2, while strong nuclear staining was detected in 
rescued control prostates (Fig. 5-7L). These data suggest that Nkx3.1 may be a 
downstream target of Foxa1. 
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The cross talk between β-catenin and the androgen pathway have been well-
documented (Yang et al., 2002). Activation of β-catenin nuclear signaling has been 
implicated in abnormal prostate epithelial cell growth (Bierie et al., 2003; Cheshire and 
Isaacs, 2003). To determine whether nuclear translocation of β-catenin contributes to the 
epithelial cell disorganization, we examined β-catenin expression. Double 
immunofluorescent staining for β-catenin and p63 (Fig. 5-7M and N) did not suggest an 
increased nuclear level of β-catenin in the basal cells in Foxa1-/- prostate. Instead, β-
catenin signals are still appropriately localized to the cell membrane in both the null and 
control cells (Fig. 5-7N and O). 
Although Foxa1-/- epithelial cells generally showed a loss of cell polarity and 
organization (Fig. 5-7N vs. O), the epithelium did not develop into dysplasia or cancer 
even at prolonged rescue periods. Ki67 staining suggested an overall increase of 
proliferating cells in Foxa1-/- prostates (Fig. 5-8B), while the ratio of Ki67-positive cells 
to negative cells did not suggest a significant change when compared to controls (Fig. 5-
8A). Foxa1-/- epithelial cells also express normal levels of adhesion molecules such as 
the E-cadherin (Fig. 5-8C and D). These data suggest that the abnormal morphogenesis 
observed in Foxa1-/- prostate results from failure of the epithelium to differentiate and 
the altered epithelial-mesenchymal interaction.  
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Figure 5-1. Distribution of key developmental factors in prostatic morphogenesis. (A) 
E18 UGS shows Foxa1 expression (green) in the entire UGE (asterisk).  (B) Same section 
dual-stained for Ck14 (red) reveals a peripheral basal epithelial layer. (C) Triple 
immunofluorescence merged from A, B and DAPI nuclear counterstaining (blue). (D) 
Strong nuclear Foxa1 staining was detected in 6-week mature prostate. (E) E18 UGS 
expresses Foxa2 (nuclear signal in green) with strongest level in peripheral epithelial 
layer. Inset shows the entire UGS counterstained with DAPI. (F) Same section double-
stained for Shh reveals a distribution pattern that overlaps with Foxa2. The Shh (red) is 
localized at cell-membrane. (G) Merged image from E and F. (H) In E21 UGS, Ptc1 
(green) was detected in both epithelium (asterisk) and mesenchyme (short arrow). Ptc1 is 
also detected in nascent prostatic buds (long arrow). (I) Same E21 section shows 
exclusively epithelial staining for Shh (red). (J) Merged from H and I.  
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Figure 5-1 (continued). (K) E21 UGS double-stained for AR (green) and smooth muscle 
α-actin (SMA) (red). The SMA-expressing cells are the same cell population expressing 
Ptc1 (short arrow). (L) E21 UGS double-stained for AR (green) and Ck14 (red). Arrow 
depicts the budding epithelium. (M) E21 UGS double-stained for luminal Ck8 (red) and 
basal nuclear protein p63 (green). (N) E18 UGS shows β-catenin expression (red) in both 
epithelium and the adjacently surrounding mesenchyme, with strongest signal in the 
peripheral epithelium (arrowhead). (O) Same E18 section is double-stained for the basal 
nuclear protein p63. (P) Magnified image merged from N and O. (Q-R) In situ 
hybridization of Foxa1 and Foxa2 in neonatal prostatic rudiments. Inset magnifies the 
strongly positive epithelial buds. (S) Foxa1 is maintained in mature prostate gland. (T) In 
contrast, no Foxa2 transcript is detected in mature prostate gland. 
Q R
Foxa1                                 P1      Foxa2                                  P1
TS 
Foxa1                             10wk Foxa2                               10wk
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 Figure 5-2. Foxa1 regulates prostatic morphogenesis. (A) Upper panels are P1 urogenital 
organs in lateral and dorsal views. Asterisks indicate the prostatic rudiments. Broken lines 
indicate where the bladder (BL) was removed. The remaining tissues (lower panels) containing 
prostatic rudiments and seminal vesicles (SV) were grafted into the renal capsules of nude mice. 
(B-D) Upper panels show rescued tissue developed in host renal capsules with indicated 
genotypes. Foxa1-/- prostate (asterisk) is smaller than controls. SVs are depicted with dotted lines 
and show no comparable difference. Lower panels show SVs and prostates after dissection. (E-G) 
β-galactosidase staining for rescued prostates. (H-I) Histology of age-matched Foxa1-/- and 
control prostates. (J-K) AR staining of Foxa1-/- and control ventral prostates.  (L-M) AR Staining 
of Foxa1-/- and control dorsolateral prostates. (N-O) AR staining for control and Foxa1-/- 
prostates with extended rescue period up to 15 week. (P) Tissue recombinants derived from wild 
type (left) and Foxa1-/- (right) epithelium, combined with equal number of rat E18 urogenital 
mesenchymal cells. (Q) Foxa1-/- recombinants show significantly lower wet weight compared to 
controls (P<0.01). (R-S) Histology of age-matched Foxa1-/- and wild type tissue recombinants. 
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Figure 5-3. Foxa1 is critical for prostatic epithelial and stromal patterning. (A) Ck5 
staining in Foxa1-/- prostate. (B) High magnification shows basal epithelial cells (arrow) 
within the epithelial cords. (C) Less basal cells in control prostate. (D-E) Ck5 staining for 
Foxa1-/- and control tissue recombinants. (F) Foxa1-/- epithelial cells co-express both 
p63 (green) and Ck8 (red), indicating immature differentiation status. (G) Two markers 
are separated into distinct cell population in wild type epithelium. 
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Figure 5-3 (continued). (H-M) Different lobes of rescued Foxa1-/- and Foxa1+/+ 
prostates were double-stained for Ck14 (red) and AR (green). (N-P) SMA staining 
(arrows) suggested an expended smooth muscle cells in Foxa1-/- prostate (N-O), in 
comparison with wild type prostates (P). (Q-R) Tissue recombinants stained for SMA. (S-
T) Tissue recombinants stained for γ-actin. 
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 141
 
 
Foxa1+/+    Foxa1+/-   
A B
H
.E. 
C D
C
k14
HG 
Foxa1+/-
AR+Ck14AR+Ck14 
Figure 5-4. Foxa1 haploinsufficiency results in a minor phenotype in DLP. (A-D) 
Sexually mature dorsal prostate (H&E in Panel A,B, and basal cytokeratin 14 in Panel 
C,D) from wild type (Foxa1+/+) and heterozygous (Foxa1+/-). The dorsal heterozygous 
shows hyperproliferation and abnormal ductal development (B & D), indicating haploid 
insufficiency can result in a phenotype. Arrowheads point to basal cells which show 
hyperproliferation in the dorsal heterozygous (D) prostates. Arrows point to basal cells 
within the lumen. (G-H) Rescued Foxa1+/- dorsal prostate shows an increase in basal 
epithelial cells (arrow in H) and a mild phenotype of ductal morphogenesis (G). 
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Figure 5-5. Foxa1 regulates luminal cell determination. (A-D) Ultrastructural analysis 
of Foxa1-/- and control prostates. Magnifications: (A,B), 7403×; (C,D), 25309×. 
Asterisks indicate the lumen. In wild type cells (A and C), secretory materials are seen in 
apical vesicles (arrow) and at luminal surface (arrowhead). No secretion is seen in Foxa1-
/- cells (B and D). Bs, basement membrane. (E) MALDI-MS protein profiles of m/z 
range 3000-16000 obtained from rescued Foxa1+/+, +/- and -/- prostates. Continuous 
profiles were zoomed in at m/z range 16100-26000. Arrows denote peaks that are absent 
in Foxa1-/- but present in control prostates. (F) RT-PCR for Pbsn and Sbp. GAPDH 
serves as a loading control. 
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Figure 5-6. Androgen and forkhead response elements in Sbp promoter. (A) Two 
forkhead binding sites were found on the Sbp promoter, each immediately flanked by an 
ARE. (B) EMSA confirms these binding sites for Foxa1 and AR. Radiolabeled probes are 
indicated at bottom of each panel. Lane 1,4,6,9: probe only; lane 2,7: controls (no Foxa1 
templates added to the in vitro transcription/translation reaction); lane 3,8: probe plus in 
vitro sythesized Foxa1; lane 5,10: probe plus recombinant AR. Arrowheads and arrows 
denote Foxa1/DNA and AR/DNA complexes, respectively.  
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Figure 5-7. Activation of Shh and Foxa2 in Foxa1-/- prostates. (A) Strong and focused 
expression of Shh in Foxa1-/- prostates (arrows). (B) High magnification of two 
epithelial buds shows Shh activation. (C) Same section double-stained for Ptc1 shows co-
expression of Ptc1 in Foxa1-/- epithelium. (D) Nuclear Foxa2 staining is detected in 
Foxa1-/- prostates. (E) Strong Foxa2-expression in Foxa1-/- epithelial buds (arrows). (F) 
Foxa2-expressing cells form numerous microlumen with cribiform pattern, indicating 
hyperproliferation in the epithelium (arrows). (G) Continuous expansion of Foxa2-
positive cells in Foxa1-/- epithelium with extended rescue time up to 15 weeks. Arrows 
denote many tiny epithelial tips. (H) Foxa2 is not detected in age-matched wild type 
prostates. (I-J) Foxa2 staining in tissue recombinants generated from Foxa1-/- epithelium. 
(K-L) No nuclear staining of Nkx3.1 is detected in Foxa1-/- cells in contrast to strong 
nuclear immunoreactivity in control epithelium. Arrows in (K) denote the epithelial buds 
corresponding to the area shown in (B). (M) Foxa1-/- prostate stained for β-catenin (red) 
and counterstained with DAPI (blue). (N) Foxa1-/- prostate stained with β-catenin (red) 
and p63 (green) show that cell polarity was lost. (O) Control prostate stained with β-
catenin and p63 shows polarized epithelium that forms lumen. 
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Figure 5-8. Expression of proliferation marker and adhesion molecule in Foxa1-/- 
prostates. (A-B) Ki67 staining did not detect an increase in the epithelial proliferation 
rate of null prostate. Ki67 (red); Dapi (blue). (C-D) E-Cadherin staining illustrates 
abnormal epithelial patterning in 12 week rescued null prostate compared to control. 
Nuclei were counterstained with DAPI. (E-F) 1µm thin sections from 12 week rescued 
control and Foxa1-null ventral prostates were stained with toluidine blue. Note that the 
control glands show a monolayer of luminal cells while null prostates continue to show 
abnormal epithelial structure. 
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CHAPTER VI 
 
DISCUSSION 
 
 This study reported that an extracellular signal mediator, AR, and a tissue-
restricted forkhead protein, Foxa1, coordinately participate in the prostatic gene 
regulation and organ development. Foxa/HNF-3 proteins are a group of transcription 
factors that share remarkable sequence similarity over their DNA binding domain (DBD), 
termed a forkhead or winged-helix domain (Weigel and Jackle, 1990; Zaret, 1999; Lai et 
al., 1993; Kaufmann and Knochel, 1996). The Foxa proteins are involved in the 
differentiation of endoderm-derived tissues. This feature has been strikingly conserved 
among the metazoans (Zaret, 1999). The Drosophila homeotic protein fork head, which 
is equivalent to Foxa, was found to be essential for the development of the terminal 
region including the foregut and hindgut (Weigel and Jackle, 1990); the PHA-4 protein, 
which is a C. elegans Foxa equivalent protein, is also required for the formation of 
terminal gut structures in the worm (Gaudet and Mango, 2002). In mammals, Foxa1, 
Foxa2 and Foxa3 were originally discovered as liver-enriched factors, because of their 
ability to bind the transthyretin (TTR) gene promoter (Lai et al., 1991; Lai et al., 1990). 
In early embryo development stage, Foxa proteins are believed to provide developmental 
competence to numerous liver specific genes through their high affinity DNA elements. 
This mechanism is essential for the activation of these target genes in later stages (Zaret, 
1999; Zaret, 2002). The role that Foxa and some other developmental factors play in 
organ differentiation has been proposed as genetic potentiation (Zaret, 1999; Gualdi et al., 
1996; Zaret, 2002).  
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We observed strong nuclear staining of Foxa1 in both human and mouse prostate 
epithelial cells. The prostate epithelium, like the epithelium of other urogenital sinus 
derivatives (bladder and urethra), is derived from the endodermal layer of the embryo. In 
contrast, Wolffian duct derivatives (epididymis, ductus deferens, and seminal vesicle) are 
derived from the mesoderm (Thomson, 2001; Hayward, 2002). Understanding the role of 
Foxa1 in prostate may provide an insight into the differences in epithelial cell patterning 
and developmental programs among prostate and Wolffian-derived organs, which are all 
androgen-dependent (Cunha et al., 1987; Thomson, 2001). The cell-type dependent 
expression of Foxa1 and other endodermal factors could easily provide an explanation 
why a prostatic differentiation marker such as PSA can be instructively induced in human 
bladder epithelial cells under proper extracellular signals (Aboseif et al., 1999), while 
such differentiation, under the same signals, cannot occur in a mesoderm-derived context 
(Cunha et al., 1987). 
Using in vitro gel shift and mutation assays, functional Foxa1 sites were identified 
in both PSA and Pbsn gene regulatory regions. ChIP assay unambiguously demonstrated 
that Foxa1 binds to PSA enhancer in vivo. In our experiments, Foxa1 binding sites were 
further identified in other prostate specific gene promoters/enhancers. The binding site 
organization of forkhead and AR shows a striking similarity in these enhancers across 
different species, suggesting a functional relevance.  
The development of a complex eukaryote requires differential expression of over 
30,000 genes/proteins in precise spatial and temporal patterns (Carey, 1998). An 
organism uses transcriptional synergy to achieve such diversity, to maintain cell 
specificity, and to respond to the environment dynamically (Carey, 1998). A combinatory 
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use of a subgroup of general transcription factors, signal-dependent factors and cell-
specific factors could lead to large number of regulatory possibilities, ensuring that every 
gene is precisely controlled (Brivanlou and Darnell, Jr., 2002). In the prostate, AR is a 
signal-dependent nuclear receptor mediating extracellular signals, whereas Foxa1 is a 
cell-type limited “genetic potentiator” (Zaret, 1999). A synergy between these classes of 
factors has been suggested in other studies (Brivanlou and Darnell, Jr., 2002), and we 
show Foxa1 plus AR are involved in prostatic differentiation. In an in vitro DNA 
footprinting study, a prostate-specific protein was reported to bind a DNA sequence in 
Pbsn promoter (Patrikainen et al., 1999). Interestingly, this region overlaps the first 
forkhead binding site we discovered. Similarly, a gel shift experiment disclosed several 
cell-specific factor-binding elements in PSA core enhancer (Schuur ER et al., 1996). 
Among these elements, two of them completely cover the two Foxa1 motifs, while others 
overlap with binding sites for GATA proteins (Perez-Stable et al., 2000), which belong to 
another endodermal transcription factor family (Zaret, 1999). Consistently, the first 
forkhead element in PSA1 enhancer, which is adjacent to ARE Ш, was protected by a 
cell-specific protein in a previous DNA footprinting study (Farmer et al., 2001). 
Interestingly, the Pbsn promoter (-286/+28bp), the PSA enhancer (-4.2/-3.8 kb) and the 
hPAP enhancer (-1278/-779bp), where Foxa1 binding sites are located, have all been 
implicated in prostate-specific regulation (Zhang ZF et al., 2000; Pang et al., 1997; 
Schuur ER et al., 1996; Zelivianski et al., 2002). These observations strongly suggest that 
Foxa1 and AR may coordinately participate in the transcriptional regulation of other 
prostate epithelial cell specific genes. 
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X-ray crystallographic study revealed that the structure of HNF-3 forkhead 
domain resembles the globular domain of linker histone H1 (Clark et al., 1993). In vitro 
nucleosome assembly experiments further showed that Foxa1 is able to open compacted 
chromatin by displacing linker histone H1 in an ATP-independent manner (Cirillo et al., 
1998; Cirillo et al., 2002). This mechanism of Foxa1 is mediated through its high affinity 
DNA binding sites as well as the binding of its C-terminal to histones H3 and H4 (Cirillo 
et al., 2002). Transient transfection experiments were used to examine the role of Foxa1 
in prostatic gene regulation. Although transiently transfected DNA does not appear to 
assemble the same higher-order chromatin structure observed with genomic DNA, certain 
aspects of nucleosome-mediated regulation can be observed on transiently expressed 
DNA (Smith and Hager, 1997; Crowe et al., 1999). For example, studies by Crowe et al., 
demonstrated that Foxa1 relieves nucleosome-mediated transcription repression of a liver 
specific gene in transient transfection experiment (Crowe et al., 1999). In our study, 
mutations of these Foxa1 binding motifs significantly abolished Pbsn and PSA gene 
activities. Overexpression of a mutant Foxa1 protein (∆C1-294) suppressed Pbsn promoter 
activity in a dose-responsive and binding site-dependent manner. These results are 
consistent with the assumption that some level of nucleosome assembly occurs on the 
introduced plasmid. Also, these data are in agreement with previous studies showing that 
overproduction of mutant Foxa proteins, deleted in a similar region, suppressed multiple 
liver gene expressions (Vallet et al., 1995; Wang et al., 2000a).  
However, AR, which binds an ARE in a ligand-dependent manner, Foxa1 
occupies PSA enhancer in the absence of androgen. The DNA binding of Foxa1 seems 
not directly associated with PSA activation, which eventually requires the recruitment of 
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ligand-bound AR onto the multiple AREs. Thus, Foxa1, by itself, is not a strong 
transactivator. However, the occupancy of Foxa1 in the regulatory region may confer 
prostatic genes certain transcriptional potential, which is required for the later recruitment 
of additional factors as well as the activation by the rate-limiting activator, ligand-bound 
AR, during prostatic differentiation. 
Transcriptional regulation depends not only on the interactions between DNA-
binding proteins and their respective cis-regulatory elements but also on the interactions 
among these proteins and with other components of the transactivation machinery. In 
addition to their ability to interact with various type І or type П co-regulators, steroid 
receptors also form conplexes with other DNA binding proteins, resulting in the 
modulation of transcriptional activity (Heinlein and Chang, 2002). In the present work, 
AR was found to directly interact with Foxa1, since such an interaction was resistant to 
the presence of the DNA intercalator, ethidium bromide (Lai and Herr, 1992).  
In fact, AR has been found to interact with a number of DNA binding 
transcription factors including AP-1 (Sato et al., 1997), Smad3 (Kang et al., ; Kang et al., 
2002), NFκB (Palvimo et al., 1996), SRY (Yuan et al., 2001), PDEF (Oettgen et al., 2000) 
and other steroid receptors (Heinlein and Chang, 2002). The phenomenon of the 
interaction of AR and these distinct transcription factors was called cross-modulation, 
which was illustrated by well-documented AR interactions with AP-1 and NFκB (Sato et 
al., 1997; Palvimo et al., 1996). Such crosstalks between different signaling pathways 
may increase regulatory diversity and provide opportunities for cell-specific response. 
For example, a testis-expressed protein, SRY, interacts with AR and plays a role in germ 
cell development (Yuan et al., 2001); a newly discovered prostatic epithelium-specific Ets 
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transcription factor PDEF directly contacts AR and activates PSA gene expression. Here, 
the adjacent binding of Foxa1 and a direct contact with AR may establish an efficient 
molecular mechanism for ligand-bound AR to rapidly target correct gene sequences. 
Crystallographic study of Foxa3/DNA revealed a bend of DNA of about 13° upon Foxa3 
binding(Clark et al., 1993), which may provide favorable DNA conformation for adjacent 
factors, since chromatin-associated proteins such as high mobility group (HMG) box 
containing proteins have been well demonstrated for their ability to enhance DNA 
binding of steroid receptors by generating a sharp bend in DNA (Boonyaratanakornkit et 
al., 1998). A similar mechanism may apply to Foxa1 binding of DNA in the current 
model. It has been shown dynamically that the physical binding of GR to a glucocorticoid 
response element (GRE) was facilitated by the adjacent Foxa2 binding (Stafford et al., 
2001). This seems true for several other liver specific genes (Wang et al., 1996; Espinas 
et al., 1995). In addition, Foxa proteins cooperate with estrogen receptor (ER) to activate 
the vitellogenin B1 gene transcription (Robyr et al., 2000). Thus, cooperation between 
steroid receptors and Foxa proteins may be a general mechanism for the control of 
various tissue specific genes. 
Strong evidences suggest that Foxa1, like AP-1 (Sato et al., 1997), SRY (Yuan et 
al., 2001), T cell Factor 4 (Amir et al., 2003) and PDEF (Oettgen et al., 2000), is another 
AR-DNA binding domain (DBD)-interacting transcription factor. Even though the DBDs 
of steroid receptors appear to be mainly involved in DNA binding and homodimerization 
of receptor monomers, mounting evidence suggests that this domain also serves as an 
interaction interface for other proteins. Among these interacting partners are coactivators 
(Aarnisalo et al., 1998; Moilanen et al., 1998b; Moilanen et al., 1999; Moilanen et al., 
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1998a), factors of basal transcription machinery (Schwerk et al., 1995), and other 
transcription factors (Sato et al., 1997; Yuan et al., 2001; Oettgen et al., 2000). Most of 
these interactions are biologically relevant and result in transcriptional activation or 
repression.  
In the present work, immunoprecipitation experiments in LNCaP cells 
demonstrated the interaction of endogenous AR and Foxa1 occurs in the presence of 
androgen, suggesting the physical relevance of this interaction. In vitro DNA binding 
experiments showed that both proteins can adjacently and concomitantly bind respective 
cis-regulatory elements, which provided evidence that such AR/Foxa1 interaction does 
not inhibit the DNA binding of either protein, further suggesting that these interaction 
events are mediated through separate motifs in AR-DBD. The organized ARE and 
forkhead response elements in a number of different prostate-specific enhancers also 
suggested a fixed binding orientation (Fig. 6-1). Since winged-helix factors are 
asymmetric proteins, this binding site organization may facilitate the interaction between 
the fixed protein domains presented by each factor. A similar mechanism has been 
documented in a recent study, which shows that a closely linked REL and GATA binding 
sites are positioned in the same orientation within Drosophila immunity regulatory DNAs, 
and that this REL-GATA interaction plays a pervasive role in Drosophila immune 
response (Senger et al., 2004). The identification of AR/Foxa1 interaction may extend 
our understanding of the role of DBD in androgen action and provide a general insight 
into the regulatory mechanism between forkhead proteins and steroid receptors. 
In vertebrates, the endoderm gives rise to the epithelial cell lining of the 
respiratory and gastrointestinal tract, as well as to the lung, the liver, the thyroid, the 
 154
pancreas, and hindgut derivatives, including the bladder and prostate (Wells and Melton, 
1999; Cunha et al., 1987). Conserved molecular pathways that control endoderm 
development have been identified in recent studies (Abate-Shen and Shen, 2000). In 
addition to such generalized pathways, the prostate has its own specific regulatory 
mechanisms which include androgenic signaling. We propose that a regulated interaction 
of these conserved and specialized signaling pathways is essential for normal prostatic 
morphogenesis and differentiation.  
Foxa1 and Foxa2 are forkhead transcription factors that participate in liver and 
lung formation from foregut endoderm. Overexpressing these factors in embryonic stem 
cells elicited expression of genes that are associated with endodermal lineage (Levinson-
Dushnik and Benvenisty, 1997). We have shown that both factors are present in prostate 
epithelium during early prostatic morphogenesis, and have hypothesized that they play 
essential but distinct roles in prostate development.  
The presence of early prostatic structures in neonatal Foxa1-/- mice indicates that 
Foxa1 is not absolutely required for initial budding process. However the buds that are 
formed do not follow the normal pattern of development and differentiation. Rescued 
Foxa1-/- prostates and tissue recombinants generated from Foxa1-/- UGE, demonstrated 
an epithelial hyperplasia with suppressed lumen formation, as well as abnormal stromal 
proliferation. These solid epithelial cell cords that appear in the null prostate form 
cribriform patterns, similar to those frequently seen in prostatic intraepithelial neoplasia, 
indicating a role for Foxa1 in ductal morphogenesis, canalization and epithelial 
proliferation. A number of key signaling molecules such as the Shh play crucial role in 
controlling prostatic ductal morphogenesis, although differential effects on embryonic 
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ductal budding (Podlasek et al., 1999a; Lamm et al., 2002) and on postnatal growth 
(Freestone et al., 2003; Wang et al., 2003) were observed. Prostatic rudiments were 
induced in rescued Shh-/- mouse prostates suggesting that like Foxa1, Shh is not required 
for prostatic bud formation (Freestone et al., 2003; Berman et al., 2004). 
Shh expression and signaling is normally downregulated at the conclusion of 
prostatic ductal branching (Podlasek et al., 1999a). A similar temporal pattern is true for 
Foxa2, whose expression was shown in this study to be overlapping with Shh during 
prostatic induction. A temporal expression of these critical factors during prostate 
development is illustrated in Fig. 6-2. Shh modulates its own activity by inducing 
negative regulators such as Ptc1 and hedgehog-binding protein 1 (Chuang et al., 2003). 
Mis-activation of Shh signaling has been observed in a variety of diseases including the 
human prostate cancer (Fan et al., 2004). We found focused expression of both Shh and 
Foxa2 in Foxa1-/- prostatic epithelial cell cords. Continued expression of Shh was seen 
even in Foxa1-/- prostates grafted for fifteen weeks but it was not seen in the wild type 
controls. This continuous activation of Shh in Foxa1-/- cells could result from a defect in 
the negative feedback loop.  
The present work is supported by previous reports that Shh signaling has 
important mitogenic effects on the development of various tissues including the neural 
tube, lung, kidney, prostate and salivary gland (Bellusci et al., 1997a; Lamm et al., 2002; 
Yu et al., 2002; Jaskoll et al., 2004; Thibert et al., 2003). Shh is capable of eliciting 
mitogenic effects on both epithelium and stroma. Overexpressing Shh in the developing 
lung led to increased proliferation in both mesenchymal and epithelial cells (Bellusci et 
al., 1997a). In the prostate, Shh stimulation induced embryonic prostatic epithelial growth 
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(Podlasek et al., 1999a), as well as mesenchymal expansion in postnatal prostates 
(Freestone et al., 2003).  
Shh acts primarily through its transmembrane receptor Ptc1, a direct downstream 
target of Shh (Ingham and McMahon, 2001). We detected Ptc1 expression in both the 
epithelial and the mesenchymal cell compartments in embryonic UGS. In addition to the 
mesenchymal Ptc1 reported previously (Podlasek et al., 1999a; Berman et al., 2004), the 
detection of epithelial cell Ptc1 in embryonic prostatic buds is consistent with a recent 
observation made in embryonic salivary gland (Jaskoll et al., 2004). Epithelial cell Ptc1 
has also been detected in neonatal prostatic ductal tips (Pu et al., 2004). We observed 
Ptc1 expression in Foxa1-/- prostatic epithelial cords where focused activity of Shh was 
detected. Collectively, our data suggest that, in addition to a paracrine mechanism, Shh 
signaling may also act within the prostatic epithelium in a juxtacrine manner. This 
provides an explanation for the constant epithelial hyperproliferation in Foxa1-/- 
epithelium (Fig. 6-3). A similar model picturing Shh signal transduction in the epithelium 
of the embryonic salivary gland has recently been proposed (Jaskoll et al., 2004). 
In addition to the epithelial hyperplasia, there is a concomitant suppression of 
lumen formation in Foxa1-/- prostates. The genesis of the tubular structures in the 
prostate resembles the process in mammalian mammary gland or salivary gland, which 
involves cell proliferation and programmed cell death (Hogan and Kolodziej, 2002; Hogg 
et al., 1983). The defect observed in Foxa1-/- prostates could be due to a lack of cell 
death in the epithelium. Indeed, Shh has been shown to promote cell survival through 
binding to its receptor Ptc1, while Ptc1 acts as a proapoptotic factor in its unbound status 
and patterns neural tube by inducing selective cell death (Thibert et al., 2003; Guerrero 
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and Altaba, 2003). In the prostate, Shh signaling has also been shown to inhibit ductal 
canalization (Freestone et al., 2003), thus playing an opposing role to androgen, which 
promotes lumen formation as a part of the normal developmental process (Hayward et al., 
1996a). Our data is consistent with these previous studies.  
Foxa2 is fundamentally important for the formation of the mammalian node and 
notochord, while mis-expressed Foxa2 in the developing neural tube induces ectopic 
floor plate formation (Weinstein et al., 1994; Ang and Rossant, 1994). The Foxa2 
enhancer contains crucial Shh-responsive element (Sasaki et al., 1997), and Shh signaling 
has been shown to be critical for Foxa2 expression in other organs (Yamagishi et al., 
2003; Mahlapuu et al., 2001). Shh secreted from the notochord induced expression of 
Foxa2 in the floorplate of the neural tube; reciprocally Foxa2 maintained Shh expression 
in a positive feedback loop (Chiang et al., 1996; Hynes et al., 1997; Echelard et al., 1993a; 
Sasaki et al., 1997). Thus, the expression of Foxa2 in Foxa1-/- cells may be due to a 
continuous response to Shh signaling. Alternatively, Foxa1 may act as a negative 
regulator of Foxa2, whose gene regulatory region contains a functional forkhead binding 
element (Guo et al., 2002). Along these lines Foxd3 is capable of activating Foxa2 by 
binding to its enhancer; however, such transactivation can be abrogated by Oct-4, which 
binds and sequesters Foxd3 (Guo et al., 2002). We have shown an elevated nuclear Foxa1 
level during normal prostatic morphogenesis and maturation. We would therefore suggest 
that this increased nuclear Foxa1 might act as a competitor possibly by binding the same 
forkhead response element in Foxa2 enhancer, thus negatively modulating its expression.  
The expression of Nkx3.1 is initiated at prostatic budding, somewhat later than 
that of Foxa1 and Foxa2 (Bhatia-Gaur et al., 1999; Huang et al., 2004) (Fig. 6-2). The 
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level of Nkx3.1 expression is elevated during prostatic morphogenesis and is maintained 
in mature glands (Bhatia-Gaur et al., 1999), representing a reversed profile to Foxa2 
expression. Both the human and mouse Nkx3.1 gene 5’-upstream regions contain 
forkhead binding sites (unpublished observation). Nkx3.1 nuclear expression was not 
detected in Foxa1-/- cells, suggesting a potential mechanism whereby Foxa1 could 
positively regulate Nkx3.1. Given that Nkx3.1 has been proposed as a negative 
transcriptional regulator (Chen et al., 2002a), we speculate that upregulation of Nkx3.1 
by Foxa1 in normal prostate could serve as another mechanism for modulating early 
developmental molecules such as Foxa2 (Fig. 6-3). 
In embryonic UGS and Foxa1-/- prostates, the cell type-specific analysis of Shh 
and Foxa2 expression suggested that both factors are predominantly expressed in the 
basal keratin-expressing cell population. The basal cells are postulated to act as the 
transit/amplifying population in the prostate and are widely believed to be capable of 
acting as luminal cell precursors (Abate-Shen and Shen, 2000). The increased number of 
basal cells in Foxa1-/- prostates is consistent with the activated Shh signaling, which is 
critical in promoting precursor cell numbers in other tissues in the body (Ruiz et al., 2002; 
Machold et al., 2003). Consistent with this finding, we did not detect any mature luminal 
epithelial cells, in Foxa1-/- prostates, in terms of ultrastructural features or the expression 
of differentiation markers. These data suggested that under normal developmental 
process, Foxa1 promotes prostatic epithelial cell maturation through functional balancing 
the activities of Shh and Foxa2 (Fig. 6-3). 
Further, Foxa1-/- epithelium faithfully expressed AR, however the differentiated 
response was completely lost in the null prostates. In contrast, Tfm mice that lack a 
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functional AR have served as a unique model for studying the role of epithelial cell AR in 
prostatic differentiation. Urinary tract epithelium from Tfm mice can be instructively 
induced, by wild type embryonic UGM, to produce prostatic morphology (Cunha and 
Lung, 1978; Cunha and Chung, 1981). Although ductal/luminal structures developed in 
these Tfm recombinants, the luminal epithelium in those glands did not produce secretory 
proteins (Donjacour and Cunha, 1993). Morphologically, most of the ducts/lumena in 
Tfm recombinants was composed of low columnar or cuboidal luminal epithelium 
(Donjacour and Cunha, 1993). These observations demonstrated that epithelial cell AR is 
not necessary for prostatic induction but it is required for the final stage of luminal 
epithelial cell morphogenesis and the initiation of secretory activities (in other words, for 
the differentiated function of luminal cells to occur) (Donjacour and Cunha, 1993). The 
overall morphology of Foxa1-null prostates indicated that prostate development was 
defective at a stage of ductal canalization and cytodifferentiation, since the solid 
epithelial cords continue to grow with limited lumen formations. Epithelial cells inside 
the cords proliferated constantly but failed to organize into a normal luminal structure 
and secretory function was impaired in Foxa1-null prostates. These data suggests that 
although both epithelial AR and Foxa1 regulate differentiated function in prostate 
epithelial cells, Foxa1 plays an early role in regulating glandular morphogenesis, a 
process in which epithelial cell AR is not crucially involved. 
In conclusion, these data collectively supported the presence of a cis-regulatory 
code composed of androgen and forkhead response elements. Through phenotypic 
characterization of transgenic mouse prostates and functional analysis of prostatic-
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promoters, we documented the essential roles of Foxa1 in prostate development and 
function.     
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acaacaacaa caacaacaac aaacaaacaa acaaacccta
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ctgcgggtcaggacattttttttttaagatttatttatttatttattattttatttatatPSP-94
promoter  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-1. A diagram illustrates the AR-Foxa1 binding elements in various 
prostatic gene enhancers. Blue arrows are ARE. Green Arrows are forkhead response 
elements. The direction of the arrow indicates the sense or the antisense strand that 
matched the binding sequence. Binding sites framed by red boxes indicate a very similar 
binding orientation of the two proteins. Since winged-helix factors are asymmetric 
proteins, this binding site organization may facilitate the interaction between a fixed 
protein interface presented by each protein.     
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Figure 6-2. The temporal expression of key developmental factors in prostate 
development. Shh signaling, BMP4, FGF10, Foxa2 and androgen signaling (first peak at 
E17-18) are correlated with the prostatic induction and early morphogenesis. Sustained 
Foxa1 expression is throughout the entire developmental process, while the expression of 
Nkx3.1 signifies the prostatic epithelial determination. The details of the time course of 
prostatic morphogenesis and cytodifferentiation are described in the text. 
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Figure 6-3.  A proposed model for forkhead proteins in regulating prostatic 
organogenesis. (a) Embryonic UGS is composed of UGE (in green) and UGM (in red). 
(b) Shh produced by UGE, acts via Ptc1 receptors located in both epithelium and 
mesenchyme, positively regulating ductal epithelial budding and stromal proliferation.  
Shh signaling elicits morphogenetic effects through downstream targets including the 
epithelial Foxa2 and the mesenchymal Bmp4 and Fgf10 (Pu et al., 2004). In normal 
process, Foxa1 activates transcriptional inhibitors or differentiation modulators, such as 
Nkx3.1, and negatively modulates Shh and Foxa2 expression through a direct or indirect 
mechanism. (c) Decreased activity in Shh and Foxa2 leads to ductal canalization, while 
accumulated Foxa1 and Nkx3.1 induces a variety of genes associated with epithelial 
maturation. (d) Hyperactive Shh signaling in disease conditions or in Foxa1-/- prostates 
where Foxa1 or its balancing mechanism is abolished, abnormal signal induces mitogenic 
effects in both epithelium and stroma, leading to abnormal ductal patterning mimicking 
immature prostatic cords. 
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FUTURE DIRECTIONS 
A. Identify Foxa1 downstream targets in the mouse prostate. It is important to 
identify the downstream effectors or signaling pathways that mediate Foxa1 function 
in the prostatic epithelium. Nkx3.1 is a good candidate, whose enhancer (in both 
human and mouse) contains a number of forkhead response elements. More targets 
will be identified through cDNA microarray analysis by comparing rescued Foxa1-/- 
prostates and rescued age-matched wild type prostates. Candidate genes will be 
especially interesting if they show functional links to Shh or Foxa2 signaling 
molecules. 
B. Determine the role of Foxa2 in mouse prostate development. Foxa2 is only 
transiently expressed in prostatic epithelium during prostatic budding. However, 
Foxa1-/- prostate epithelium shows continuous Foxa2 expression. The role of Foxa2 
in prostate development is important for further study. Conditional Foxa2 allele will 
be disrupted in the mouse prostate epithelium using a cre-lox strategy. The phenotype 
of Foxa2-/- prostates can then be assessed.   
C. Identify the factor binding immediately next to Foxa1 on Pbsn promoter. Gel 
shifts and Southwester analysis indicated that there is at least one more protein 
directly bound to the Pbsn promoter sequence immediatedly downstream to Foxa1 
binding site (-121/-115 bp). The core binding sequence of this protein covers a 
palindromic sequence “GTATAC”, which may be a DNA target for POU domain 
transcription factors. Interaction between forkhead protein and POU transcription 
factor has been described recently (Guo et al., 2002). Binding site DNA affinity 
chromatography or yeast one hybrid system can be employed to identify this protein. 
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